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Abstract 
 
Objectives: This project was undertaken to investigate the potential of the human 
PLB-985 cell line to terminally differentiate, along the myeloid lineage into mature 
neutrophil-like granulocytes, and to identify the molecular properties of the 
differentiated PLB-985 cells in comparison with blood neutrophils, in order to establish 
their usefulness as model of neutrophil differentiation and functions.  
 
  
Methods: Human neutrophils were isolated from whole blood of healthy, consented, 
adult donors. The human PLB-985 cells were grown in routine culture media of RPMI 
1640 (+10mM L-glutamine). Exponentially growing PLB-985 cells were induced to 
differentiate into neutrophil-like cells in differentiation culture media of RPMI 1640 
(+10mM L-glutamine), supplemented with three differentiation and maturation-
inducing agents: ATRA, DMF and sodium pyruvate. Granulocytic differentiation was 
measured by cell morphology using light microscope, apoptosis was determined by 
morphology or flow cytometry, cell viability, cell cycle parameters, expression of cell 
surface receptors and phagocytosis were determined by flow cytometry, oxidative 
burst activity was measured using flow cytometry and luminol-enhanced 
chemiluminescence assay, and expression of apoptotic proteins was determined by 
western blotting.  
 
 
Results: A modified differentiation protocol and optimisation procedure has been 
established. Terminally-differentiated, neutrophil-like PLB-985 cells, have been 
consistently cultured, that resemble mature blood neutrophil morphology, evident by 
the acquisition of multi-lobed nucleus and granulated cytoplasm, and which had an 
appreciably extended lifespan. It was discovered that supplementing the 
differentiation medium with either G-CSF or GM-CSF both improved differentiation 
and delayed apoptosis of the differentiated cells. These cells underwent cell cycle 
arrest and progression into apoptosis and they resembled mature blood neutrophils 
in terms of cell cycle parameters and apoptotic morphology. The differentiation 
induced expression of anti-apoptotic proteins, Mcl-1 and Bcl-XL in these cells and their 
expression levels correlated with cell survival status, whilst Bcl-2 expression was lost. 
The differentiated PLB-985 cells also displayed phagocytosis and oxidative burst 
activity, expressed cell surface receptors for CD11b, CD14 and CD16 and expressed 
strong chemotactic transmigration towards chemoattractants. Finally, JAK inhibitors 
baricitinib and tofacitinib suppressed the growth, differentiation and viability of the 
differentiated cells, increased their progression into apoptosis, and down-regulate 
their responses to G-CSF and GM-CSF signalling. Hence, they may inhibit in vitro 
granulopoiesis, and may have anti-inflammatory activity. 
 
 
Conclusions: This study has indicated that under appropriate conditions, PLB-985 
cells can differentiate terminally into mature neutrophil-like phenotypes that resemble 
blood neutrophils morphologically and functionally, with an enhanced survival of the 
mature cells. These differentiated PLB-985 cells may therefore, provide an excellent 
neutrophil-model system for in vitro study of neutrophil differentiation and functions, 
such as apoptosis regulation. 
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Chapter 1: Introduction 
 
1.1 Background 
 
Neutrophils or polymorphonuclear leukocytes (PMNs) are key mediators of 
inflammation and defence against microbial infection. They are the most abundant 
white blood cells in human blood and the first leukocytes recruited to the site of 
infection or inflammation. Circulating blood neutrophils are generally-considered to 
be mature and terminally-differentiated. Therefore, they are short-lived, lack 
proliferation capacity and presently are impossible to transfect in vitro to express 
exogenous genes or proteins. These properties have made experimental 
manipulation of neutrophils ex vivo challenging, and hindered biochemical studies of 
their signal activation mechanisms and genetic makeup. In this regard, establishment 
of cell line models capable of differentiating along the myeloid lineage into mature 
neutrophil-like granulocytes, which exhibit similar morphological and functional 
properties to neutrophils are very important tools to enable the manipulation of key 
genes and proteins, and determine the effects of such modulations on function. 
 
The overall aim of this project was to develop culture conditions that optimised the 
induction of the human promyelocytic leukaemia PLB-985 cell line to terminally 
differentiate into mature, neutrophil-like granulocytes, using three differentiation and 
maturation inducing agents; ATRA, DMF and sodium pyruvate. PLB-985 is a recently-
established cell line that has been demonstrated to show greater levels of 
differentiation and can undergo both granulocyte and monocyte/macrophage 
differentiation in the presence of appropriate inducing agents. It is currently most 
commonly-used cell line model for neutrophil differentiation. Previous reports have 
shown the human PLB-985 cell line as having the potential to differentiate into 
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neutrophil-like cells under the influence of various chemical agents. However, the 
efficiency of differentiation reported was very low, and the differentiated cells only 
partly resembled mature neutrophils (Pivot-Pajot et al., 2010; Ashkenazi & Marks, 
2009; Hazan-Eitan et al., 2006; Hiran et al., 2001; Drayson et al., 2001; Martin et al., 
1990; Tucker et al., 1987; Souza et al., 1986; Breitman et al., 1980; Collins et al., 
1978). In addition, mature neutrophils constitutively undergo apoptosis (Edwards, 
1994; Edwards et al., 2004) and so the more efficient the differentiation of PLB-985 
cells into mature neutrophils, the greater the extent of apoptosis. This limits the 
usefulness of these cells as experimental models.   
 
The research focus of this thesis is specifically on the development of a modified 
differentiation protocol and optimisation procedures to obtain terminally-differentiated 
PLB-985 cells that functionally and morphologically resemble mature neutrophils, with 
prominent multiple lobed nuclei, granulated cytoplasm, and with appreciably 
extended lifespan. Subsequently this research aims to study the molecular and 
functional properties of the differentiated neutrophil-like PLB-985 cells, in order to 
establish their usefulness as models of neutrophil differentiation and function. 
 
 
1.2 Haematopoiesis 
 
Haematopoiesis is the process responsible for production of diverse types of blood 
cells from haematopoietic stem cells that reside in the bone marrow.  (Zhou & Zon, 
2001; Orkin, 2000). Blood consists of a number of morphologically and functionally 
distinct cell types, such as lymphoid cells consisting of  B-lymphocytes, T-
lymphocytes and NK (natural killer) cells; myeloid cells comprising different subsets 
of granulocytes (i.e. leukocytes or white blood cells: neutrophils, basophils and 
eosinophils) and monocytes (precursors of macrophages), macrophages, 
18 
 
erythrocytes (red blood cells), megakaryocytes, mast cells and dendritic cells (DCs) 
(Iwasaki & Akashi, 2007).  
 
Blood cells have diverse and specialised functions: granulocytes and monocytes play 
important roles in inflammatory responses and defence against infections. 
Neutrophils phagocytose micro-organisms such as bacteria and fungi, eosinophils 
help in destroying parasites, basophils secrete histamines, which upon interactions 
with cell surface receptors induce many responses such as, increased permeability, 
enhanced intra-capillary pressure and decreased blood pressure. Monocytes leave 
the bloodstream and enter tissue to mature into macrophages, and macrophages 
engulf large organisms and damaged cells. Erythrocytes distribute oxygen bound to 
haemoglobin to the tissues, while platelets help in blood clotting and repair of 
damaged vessels. B-lymphocytes produce antibodies, while CD8+ T-lymphocytes kill 
cells recognised as foreign to the body, including virus-infected and some cancer 
cells. CD4+ lymphocytes generate chemokines and cytokines that regulate all 
elements of the immune system (Domen et al., 2006).  
 
In spite of their differences in function, most mature blood cells are considered to be 
terminally-differentiated cells which do not divide and eventually die within days or 
weeks after release from the marrow (Edwards, 1994). Therefore, they must be 
continuously replenished throughout the lifespan. For example, to maintain normal 
haematopoiesis in an adult human, approximately  20 × 1010 erythrocytes and 16 × 
1010 leukocytes must be replenished by proliferation from more primitive cells each 
day (Bellantuono, 2004). Haematopoietic development is a well-regulated but 
dynamic process that begins during embryogenesis and continues in the bone 
marrow throughout adulthood, for sustained production of blood cells (McKercher et 
al., 1996; Edwards, 1994). 
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1.2.1 Haematopoietic stem cells and progenitor cells 
 
Haematopoiesis begins with pluripotent stem cells that undergo asymmetric cell 
division to self-renew and also to give rise to other cell lineages (Moss, 2016). Stem 
cells have the capacity for self-renewal and can differentiate into multiple cell types, 
depending on the physiological need (Kondo et al., 2003). They are categorized into 
two types: pluripotent stem cells which can differentiate into the cells of all three germ 
layers, namely; endoderm, ectoderm, and mesoderm, and the multipotent stem cells 
which are lineage-specific and more differentiated, such as neuronal stem cells, 
hepatic stem cells and hematopoietic stem cells (HSCs). Cells differentiate from stem 
cells via committed progenitors which are restricted in their developmental potential 
to a specific lineage. The establishment of the haematopoietic system during 
embryogenesis follows an ordered hierarchical sequence of developmental 
activations and specifications from the primitive stem cells, such as formation of 
hematopoietic stem cells, multipotent progenitors, committed precursors and finally, 
fully-differentiated, mature cells (Bellantuono, 2004). Although stem cells are rarely 
found in most tissues, each tissue has arisen from a specific stem cell. The principal 
function of stem cells in adult tissues is to repair and regenerate the tissue in which 
they reside (Reya et al.,  2001; Kondo et al., 2003).  
 
The continued production of blood cells directly depends on hematopoietic stem cells, 
which are the ultimate and only source of all blood cells. Under normal situations, 
these cells divide to produce progenitor cells, which, depending on the tissue, can 
undergo a few cell divisions and subsequent differentiation steps to generate a 
complex web of mature cells along specific pathways (Figure 1.1). These events 
result in continuous production of sufficient numbers of cells of all lineages (Joanna 
et al., 2001; Akashi et al., 2000). 
20 
 
 
 
Figure 1.1 Development of different mature blood cells from multipotent 
haematopoietic stem cells. Stem cells divide into two daughter cells, one retains 
the characteristics of the original cell for self-renewal, whilst the other one matures 
into committed haematopoietic precursors, that give rise to either common myeloid 
progenitors (CMP) or common lymphoid progenitors (CLP). CMP give rise to 
granulocytes (neutrophils, eosinophils and basophils), monocytes/macrophages, 
erythrocytes and megakaryocytes while CLP give rise to B- lymphocytes and  T- 
lymphocytes (Moss, 2016).  
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1.2.2 The lymphoid and myeloid lineages 
 
Traditionally, mature blood cells with specific functions are categorised into two 
different development lineages; the lymphoid lineage (B, T and NK cells) and the 
myeloid lineage (granulocytes and monocytes). It is believed that these two classes 
undergo separate differentiation pathways (Iwasaki & Akashi, 2007; Traver & Akashi, 
2004). Dendritic cells have a specific development program that is usually activated 
from either lymphoid or myeloid pathways (Manz et al., 2001). The earliest lineage-
decision that a developing haematopoietic stem cell or multipotent progenitor 
population must make is whether to develop into a lymphoid or myeloid lineage, and 
once done, that decision is irreversible (Kondo et al., 2003). The common lymphoid 
progenitor (CLP) is the first known lymphoid-restricted cell (Kondo et al., 1997), while 
the common myeloid progenitor (CMP) is the first known myeloid-restricted cell in the 
adult mouse bone marrow (Iwasaki & Akashi, 2007). These two progenitor 
populations represent the early branch points between myeloid and lymphoid 
lineages and interestingly, they have been shown to demonstrate a high level of 
lineage fidelity (restriction) in both in vitro and in vivo haematopoietic development 
studies (Akashi et al., 2000).   
 
During commitment to either the lymphoid or myeloid pathways, progenitor cells 
undergo proliferation and sequential differentiation, which are accompanied by a 
decrease of regeneration capability to produce specific mature cells (Bellantuono, 
2004). Each successive stage of development permanently loses the potential to 
become other specific cell types (Stuart, 2000).  
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1.2.3 The myeloid cells differentiation 
 
Activation of specific transcription factors plays key role at the separate differentiation 
branches in determining lineage commitment. A number of genes that prevent normal 
myeloid cells development but have no effect on lymphocytes development have 
been identified (Metcalf, 1988). These genes encode transcription factors which 
regulate the expression of many myeloid genes, such as those encoding receptors 
for macrophage-colony stimulating factor (M-CSF), granulocyte-colony stimulating 
factor (G-CSF) and granulocyte/macrophage-colony stimulating factor (GM-CSF) as 
well as those encoding granule components, such as lactoferrin and neutrophil 
gelatinase (Rosenbauer & Tenen, 2007). The proliferation and differentiation of 
precursor cells committed to neutrophilic-granulocytic lineage is regulated by colony 
stimulating factors (Shimoda et al., 1997). 
 
The gene encoding for Ets (E26 transformation-specific) family transcription factor 
PU-1, a product of oncogene SPI1 has been identified as the gene essential for the 
development of cells of the myeloid lineage (McKercher et al., 1996). Hence, 
formation of the early myeloid progenitors depends essentially on PU1. The PU.1 
protein is exclusively expressed in haematopoietic cells and it has been linked to 
regulation of many genes of the myeloid lineage, such as c-FMS (CSF-1R) which 
encodes the M-CSF receptor. It is expressed at high levels in mature myeloid cells 
and contrastingly, its expression is down-regulated during early erythroid and T-cell 
differentiation in a step-wise manner, thereby contributing to myeloid specification 
(Dash & Gilliland, 2001; McKercher et al., 1996). Deletion of SPI1 in mice leads to 
defective foetal and/or new-born haematopoiesis, including complete absence of 
macrophages and B-cells (Metcalf, 1988; McKercher et al., 1996). Soluble cytokines, 
such as G-CSF and M-CSF secreted by stromal cells also play important roles at later 
stages of myeloid cell maturation to maintain myelopoiesis (Barreda, et al., 2004).  
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Retinoic acid receptors (RARs) are another class of transcription factors essential for 
normal maturation of neutrophils. Retinoid X receptors (RXRs) form heterodimers 
with RARs. Retinoic acid binds to RAR-RXR dimers when it enters a cell. This allows 
the dimer to enter the nucleus and bind to specific sites within the promoter 
sequences on specific regions of DNA, and enable RAR to regulate gene expression 
(Lutz et al., 2002). 
 
 
1.2.4 Regulation of myeloid cells differentiation 
 
All myeloid cells have a relatively short lifespan and thus must be replaced with newly 
produced ones, from the differentiation of haematopoietic stem cells present in the 
bone marrow. Their normal number in the bloodstream is maintained by the balance 
between newly-produced cells recruitment into tissues or cell death by apoptosis, the 
latter via a well-regulated process whose disruption could result in one of the various 
types of leukaemia. A key regulator of haematopoietic cell numbers is growth factor 
removal, levels of which are tightly regulated in vivo, to ensure normal levels of 
erythrocytes and leukocytes. Several experiments have indicated that haematopoietic 
cells in culture undergo apoptosis when they are deprived of a specific growth factors 
essential for their survival (Kennedy & Deleo, 2009).  
 
 
1.2.5 Defects in myeloid cell differentiation: leukaemia 
 
Leukaemia arises because of excessive production of many types of mature or 
immature haematopoietic cells in the bone marrow and blood, due to defects in the 
processes that regulate their normal proliferation and differentiation. These defects 
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are believed to be the result of disruption in individual genes associated with the 
regulatory processes of growth and differentiation, first identified when the physical 
appearance of chromosomes (Karyotype) from cells of a patient with chronic myeloid 
leukaemia was compared with that of normal leukocytes. The leukemic cells 
appeared to have a deletion in chromosomes 21 and 22 (named after the city of their 
discovery as Philadelphia chromosome). Since then, many chromosomal deletions 
and translocations in many forms of leukaemia have been identified using cloning 
techniques and fluorescence in situ hybridization (FISH). These have also enabled 
researchers to identify the specific gene product affected by the disruptions (Iwasaki 
& Akashi, 2007; Dash & Gilliland, 2001). 
 
Myeloid leukaemias are classified as acute (AML) or chronic (CML) according to the 
duration of clinical symptoms, maturity of the affected cells and total leukocyte count 
(Kawamoto & Minato, 2004). The characteristic features of acute leukaemia are short 
duration symptoms, presence of several immature cells in the bone marrow and blood 
and high total leukocytes count. Chronic leukaemia is characterised by symptoms of 
long duration, many mature cells in the bone marrow and peripheral blood, and a low 
to highly raised total leukocytes count. Leukaemia can also be classified based on 
the morphology of predominant blood cells as myelocytic, monocytic and lymphocytic 
leukaemia (Lutz et al., 2002). 
 
Certain haematopoietic diseases are also associated with defective apoptosis. For 
example, myelodysplastic syndrome (MDS) is characterised by decreased number of 
both progenitor and mature cells in the early stages, due to increased apoptosis in 
progenitor cells. However, elevated numbers of immature haematopoietic cells is later 
observed, which perhaps is due to apoptosis resistance. Myelodysplastic syndrome 
usually progresses to become acute myeloid leukaemia (Kawamoto & Minato, 2004). 
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1.3 The production and maturation of neutrophils: granulopoiesis 
 
Neutrophils and other leukocytes of the immune system are produced from pluripotent 
stem cells present in the bone marrow during haematopoiesis. About 60% of all 
granulocyte precursors are committed to the production of neutrophils (Kennedy & 
Deleo, 2009). Granulocyte differentiation and maturation continues through series of 
steps that culminate in the formation of granules and exit of mature neutrophils from 
the bone marrow into the peripheral blood (Figure 1.2). This process of granulocyte 
formation takes ~6.5 days and is known as granulopoiesis  (Bainton et al., 1971).  
 
Following granulopoiesis, terminally-differentiated, mature neutrophils are then 
released into the bloodstream to circulate for ~10-12 h before migrating into tissues 
where they function for 1-2 days, then die by apoptosis and are cleared from the 
tissue by macrophages or other phagocytic cells (Savill et al.,  1989; Fliedner et al., 
1964). Infection may, however, prolong their lifespan to several days in an infected 
tissue (Edwards, 1994). Neutrophils constitute about 40-65% of total leukocytes in 
the circulation, and are found at concentrations of 3-5×106/mL blood (Pillay et al., 
2010).  Mature neutrophils also exist in the bone marrow, liver, lung and spleen as 
reservoirs (marginated pools), for rapid deployment during infection or inflammation 
(Summers et al., 2010). The daily turnover of neutrophils is approximately 5 ×1010 
cells per day in a normal healthy adult human but this number may increase during 
infection to 5- to 10-folds (Lieber et al., 2004). Granulocytes are phenotypically distinct 
from lymphocytes and other circulating leukocytes based on multiple features, such 
as the granulated cytoplasm, multilobed nucleus and specific cell surface markers 
(Futosi et al., 2013). 
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Figure 1.2 The stages of granulopoiesis. The early precursor myeloblast 
undergoes developmental and maturation stages to become a segmented mature 
neutrophil. During the granulopoiesis steps, neutrophils change their nuclear shape, 
undergo nuclear condensation, acquire granules in their cytoplasm and finally 
develop a segmented multi-lobular nucleus. 
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1.3.1 Neutrophil granules 
 
Neutrophil granules are classified into three different types based on their protein 
contents and regulation of mobilization: primary granules (azurophilic or peroxidase-
positive) contain myeloperoxidase (MPO), azurocidin and defensin; secondary 
granules (specific or peroxidase-negative) contain lactoferrin, gelatinase, ficolin 1 and 
cysteine-rich secretory protein 3 (CRSP3); tertiary granules (gelatinase) contain 
gelatinase B or matrix metalloproteinase 9 (MMP9)  (Nauseef, 2007; Borregaard & 
Cowland, 1997). The biosynthesis of primary granules decreases during granulocyte 
maturation, whereas formation of secondary granules predominate as neutrophils 
mature (Kennedy & Deleo, 2009). These granules have different functions relative to 
their various protein and enzyme contents. For example, primary granules contain 
many cytotoxic proteins and peptides for killing and digestion of phagocytosed 
microbes, secondary granules supply proteins, such as receptors and oxidase 
components to the membrane and tertiary granules supply proteases for basement 
membrane digestion to allow for neutrophil extravasation and transmigration (Segal, 
2005). 
 
In addition, mature neutrophils possess secretory vesicles containing some proteins 
and receptors required for adhesion, transendothelial migration and chemotaxis. 
When transported to the plasma membrane, these vesicles can either release their 
proteins extracellularly or their membranes can fuse with the plasma membrane so 
that their proteins are expressed on the cell surface, for example, β2-integrin for 
rolling and adhesion (Borregaard, 2010; Borregaard et al., 1990). 
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1.3.2 Neutrophil membrane receptors 
 
One of the remarkable features of neutrophils is the possession of different types of 
receptors on their plasma membranes which enable them to recognise and bind 
pathogens and other opsonised or un-opsonised particles. Neutrophil receptors can 
be divided into at least three groups (Hallett & Lloyds, 1995): (a) G-protein-coupled 
transmembrane receptors (GPCRs), including those for formylated peptides (FPRs) 
(Migeott et al., 2006), complement fragment 5a (C5a) (Chenoweth et al., 1978), 
platelet activating factor (PAF) (Lukashova et al., 2017) and interleukin-8 (IL-8) 
(Holmes et al., 1991), (b) single-transmembrane receptors activated through 
crosslinking or immobilisation, such as adhesion receptors (e.g. selectins and 
integrins) (Albelda & Buck, 1990) and immunoglobulin receptors (FcγRs) (Bruhns, 
2012) and (c) single-transmembrane receptors, such as receptors for growth-
regulating cytokines (e.g. GM-CSF, TNF-α) (Rose-John & Heinrich, 1994) and Toll-
like receptors (TLRs) (Parker et al., 2005). These membrane receptors have different 
structures and mediate diverse functions differently. For example, activation of any of 
these receptors prime neutrophil NADPH oxidase for subsequent activation. 
However, GPCRs and crosslinking receptors (group a & b) prime the oxidase at lower 
concentrations and also activate it at higher concentrations, whereas the growth-
regulating cytokine receptors (group c) prime but do not activate the oxidase, hence 
called ‘dedicated primers’ (Hallett & Lloyds, 1995).  
 
 
1.4 Mobilisation and recruitment of neutrophils 
 
Mobilisation of circulating neutrophils to the site of infection or inflammation 
constitutes a major event in the neutrophil functional responses and occurs very 
rapidly to attack and eliminate the invasive pathogen or mediate the process of 
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inflammation. Neutrophils are recruited through a series of controlled, exocytic events 
that change their functional status, converting them from ‘resting’ circulating cells to 
‘active’ killing cells at the infection or inflammatory locus (Lee et al., 2003). Neutrophils 
reversibly move from the free circulation into the marginated pools, in which 
neutrophils are stored in capillaries of certain tissues for rapid mobilisation upon 
infection or cellular stress, and are much greater in number than the free-circulating 
neutrophils at any given time (Summers et al., 2010). 
 
Neutrophils recognise chemoattractants including cytokines and chemokines (e.g. 
fMLP, LPS, GM-CSF, IL-8, TNF-α, INF-γ,) produced by host cells during infection or 
inflammation as ‘signals’ of microbial invasion and/or tissue injury or inflammation 
using their cell surface receptors. These molecules are released by microbes, injured 
host cells, macrophage engulfed-particles or following complement activation and 
recruit neutrophils to the site of infection or inflammation (Wright et al., 2010). Most 
of  these chemotactic factors can also ‘prime’ neutrophils for enhanced function 
(Kobayashi et al., 2005).  
 
 
1.4.1 Neutrophil priming 
 
Circulating, inactive neutrophils become primed when exposed to infection-
associated molecules, such as bacterial molecules (e.g. LPS and fMLP), cytokines 
(e.g. GM-CSF), leukotrienes, and activated complement proteins. Primed neutrophils 
are considered ‘ready to go’ but awaiting subsequent stimulation to trigger the 
functional response (Hallett & Lloyds, 1995). Priming induces gross morphological 
and cellular changes in neutrophils, including enhanced motility, polarisation and 
increased lifespan (thought to be mainly via stabilisation of the anti-apoptotic protein, 
Mcl-1). The increased lifespan provides neutrophils with sufficient time to enable them 
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perform their functions in infection or inflammation (Edwards et al., 2004). Priming 
also enhances the expression of cell surface receptors and adhesion molecules, by 
translocating intracellular stores on granule membranes to the plasma membrane 
(Edwards, 1994). During neutrophil priming, specific granules, gelatinase-containing 
granules and secretory vesicles fuse to the plasma membrane, thereby expressing 
increased number and/or affinity of surface receptors, and release of proteins to 
prepare the cells for transmigration (DeLeo et al., 1998).  
 
 
1.4.2 Neutrophil transmigration and chemotaxis 
 
Neutrophils exit peripheral blood circulation through the endothelial cells of the blood 
vessels to enter the sites of infection by a process called ‘extravasation’ (Futosi et al., 
2013). Selectins, a C-type lectin family of glycoprotein expressed on the surface of 
activated endothelial cells (E- and P-selectins), primed neutrophils (L-selectin) and 
platelets (P-selectin) initiate the extravasation process. E- and P-selectins on the 
endothelial cells become up-regulated and interact with L-selectin on the surface of 
neutrophils to facilitate rolling of neutrophils along the surface of the endothelium 
(Kennedy & Deleo, 2009). The neutrophils then roll slowly until they stop and become 
attached to the activated endothelial cells. This initial interaction is called ‘tethering’ 
(Borregaard, 2010).  
 
Following rolling, firm adhesion of neutrophils to the endothelial cells is promoted by 
leukocyte adhesion molecules (e.g. CD11b/18, Mac-1, CD54, and LFA-1) 
(Borregaard, 2010). The inflamed tissue releases chemokines, such as IL-8 into the 
luminal surface of endothelial cells, whereas the rolling neutrophils express 
chemokine receptors that bind these chemokines to increase the expression of 
adhesion molecules (β2-integrins) and L-selectin shedding. The adhesion molecules 
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then mediate a stronger adhesion of neutrophils to the endothelial cells by interacting 
with ICAM-1 and ICAM-2 on the endothelial cells (Diamond et al., 1990). Other 
molecules expressed by neutrophils, including Mac-1, LFA-1 and PECAM-1 open the 
tight junctions of the endothelium for subsequent transmigration (Phillipson et al., 
2006; Muller et al., 1993). Neutrophils then transmigrate through the endothelial cell 
gaps by ‘diapedesis’, a process that changes the morphology of neutrophils during 
chemotaxis (Wright et al., 2010; Sengeløv et al., 1993). Transmigration is mediated 
in part, by CD31 (PECAM-1) (Muller et al., 1993), CD44 (Khan et al., 2004), CD47 
(Cooper et al., 1995) and CD54 (Diamond et al., 1990). 
 
Neutrophils can transmigrate paracellularly (between endothelial cells) or 
intracellularly (through an endothelial cell), but they usually transmigrate 
paracellularly as this method is faster and more efficient (Figure 1.3). By the time 
neutrophils reach the site of infection, pathogens may have been opsonised by 
immunoglobulins, complement fragments or acute-phase reactant proteins. The 
opsonised particles can then be detected and engulfed by the neutrophils through  
opsono-phagocytosis, for destruction and elimination (Borregaard, 2010). 
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Figure 1.3 Transmigration and chemotaxis of neutrophils. Tethering interactions 
facilitate neutrophils rolling along the vascular endothelial wall mediated by selectins 
on endothelial cells and neutrophils. Host and/or pathogen derived chemotactic 
molecules, such as IL-8, TNF-α and LTB4 diffusing from the infection site into the 
bloodstream bind specific receptors on the neutrophil surface, thereby arresting the 
rolling and inducing firm adhesion to the endothelial cells, mediated by L-selectin and 
β2-integrin. Adhesion then leads to transmigration (para- and intra- cellularly) into the 
target tissue by diapedesis, mediated by LFA-1 and MAC-1 on the neutrophils as well 
as PECAM-1, ICAM-2 and CD99 on the endothelial cells. Once in the tissue, primed 
neutrophils migrate to the infection site by chemotaxis, where they recognise, bind 
and phagocytose the invading microbes (Rigby & DeLeo, 2012). 
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1.5 Microbicidal activity of neutrophils 
 
Neutrophils are endowed with the capacity to ingest and subsequently kill pathogens 
through a series of well-coordinated and tightly-regulated processes of opsono-
phagocytosis and oxidative burst, resulting from the enrichment of phagolysosomes 
with various cytotoxic molecules derived from cytoplasmic granules following 
degranulation (fusion of cytoplasmic granules with phagocytic vacuoles) (Lacy, 2006), 
production of reactive oxygen species (ROS) by the NADPH oxidase, hypohalous 
acids (e.g. HOCl) generated by the MPO-halide system, or generation of neutrophil 
extracellular traps (NETs), which entrap large pathogens that cannot be internalised 
by opsono-phagocytosis, such as fungi and protozoa and kill them extracellularly 
(Nakazawa et al., 2016).  
  
 
1.5.1 Neutrophil phagocytosis  
 
Phagocytosis is a phylogenetically conserved process by which leukocytes and other 
phagocytic cells engulf microbes and apoptotic or necrotic cell debris. Phagocytosis 
is critical to the microbicidal function of neutrophils, which along with macrophages 
comprise the professional phagocytes (Lee et al., 2003). Phagocytosis is also a 
fundamental aspect of tissue homeostasis and remodelling, where it is involved in the 
clearance of apoptotic bodies formed from the daily turnover of billions of cells 
(Flannagan et al., 2012). Neutrophils are the primary professional phagocytes 
recruited to the site of infection or inflammation and provide the first line of defence 
to the host against the invading microbes.  
 
Neutrophils initially ingest particles into a plasma membrane-derived vacuole, the 
phagosome, following protrusion of pseudopodia which is then followed by a complex 
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process of maturation to acquire its degradative properties (Greenberg & Grinstein, 
2002). The nascent phagosome itself is insufficient to mediate pathogen killing until 
the maturation process occurs, which transforms the phagosome into a potent, 
cytotoxic phagolysosome that is acidic, oxidising and hydrolase-rich (Figure 1.4). This 
transition involves influx and efflux of materials through the initial fusion of 
phagosomes to endosomes and subsequently to lysosomes, thereby acquiring 
protein recycling function of the endosome  and degradative function of the lysosome 
(Pitt et al., 1992). In neutrophils, azurophilic and specific granules fuse with the 
phagosome to generate the phagolysosome (Edwards, 1994).  
 
Special receptors on the plasma membrane of neutrophils must recognise and bind 
the target particles either directly via pattern-recognition receptors (PAMPs) or 
indirectly via opsonic receptors before uptake (Flannagan et al., 2012). Fcγ receptors 
on the neutrophil cell surface recognise and bind to IgG antibodies bound to bacteria 
(e.g. Staphylococcus aureus and Escherichia coli). The principal Fcγ receptors in a 
resting neutrophil are the low affinity receptors, FcγRIIIb (CD16) and FcγRIIA (CD32), 
whilst in the primed neutrophil, the high affinity receptor FcγRI (CD64) may become 
functional (van de Winkel & Capel, 1993). Complement receptors, CR1 and CR3 (β2-
integrin Mac-1 or CD11b/CD18) recognise complement fragments (C3a, C3bi and 
C5) (Neuman et al., 1990). 
 
Activation of these receptors triggers the neutrophil cell membrane to extend 
pseudopodia. Following the formation of pseudopodia, neutrophils undergo 
morphological changes from spherical to an amoeboid shape that eventually 
surrounds and entraps the particle to form a phagocytic vacoule, phagosome. Next, 
the phagolysosome is formed by fusion of neutrophil granules to the vacoule 
(Borregaard, 2010). These granules contain various anti-microbial proteins and 
peptides, such as myeloperoxidase, elastase, proteinases and hydrolases, plus the 
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assembled and activated NADPH oxidase which generates ROS that together, kill 
and degrade the internalised microbe (Borregaard & Cowland, 1997). Neutrophils, 
like macrophages can ingest both opsonised and non-opsonised particles (Lee et al., 
2003). Complement-opsonised particles are ingested by attachment and gentle 
sinking into the cell, in contrast to IgG-opsonised particles which are engulfed 
following extension of pseudopodia, initiated by ligation of Fcγ receptors (Kennedy & 
Deleo, 2009; Hed & Stendahl, 1982).  
 
Neutrophils can also undergo ‘frustrated’ phagocytosis under certain pathological 
conditions. Frustrated phagocytosis occurs when the neutrophil attaches to a large, 
non-phagocytable surface, such as the cartilage-pannus junction in rheumatoid 
arthritis. This is triggered by the binding of IgG on the joint surface to the Fcγ receptors 
and subsequent activation of the neutrophils. However, the activated neutrophils are 
unable to internalise the surface as they do for small microbes, thereby creating a 
microenvironment of incomplete phagosome on the cartilage-pannus junction of the 
joint. This results in neutrophils degranulating directly onto the cartilage releasing 
proteases and ROS which degrade it and cause joint damage (Mohr & Menninger, 
1980).  
 
 
1.5.2 Neutrophil oxidative burst activity 
 
The oxidative burst, otherwise called the respiratory burst, is a metabolic process that 
occurs during phagocytosis whereby phagocytes produce reactive oxygen 
intermediates (superoxide and hydrogen peroxide) that are either directly or indirectly 
toxic to the pathogens (Kim & Seoh, 2015). During phagocytosis, neutrophils increase 
their oxygen consumption due to the activities of the activated membrane-bound 
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NADPH oxidase, that results in the generation of reactive oxygen species  (Kennedy 
& Deleo, 2009).  
 
The multi-component NADPH oxidase complex is composed of at least 7 proteins 
that reside on the membrane and in the cytosol of the resting neutrophil. The enzyme 
complex becomes assembled and activated on the plasma membrane or within the 
phagosome. Upon activation, the cytosolic proteins translocate to the membrane 
where they associate with the membrane proteins to assemble the NADPH oxidase 
(Edwards, 1996). The assembled NADPH oxidase catalyses the formation of 
superoxide (O2-) by electron transfer from cytosolic NADPH onto extracellular (or 
intraphagosomal) molecular oxygen (O2) (Dahlgren & Karlsson, 1999). The reaction 
catalysed by this enzyme complex is shown below: 
 
                        NADPH + 2O2                  NADP+ + 2O-2      
 
The transfer of electrons from NADPH to oxygen is a multi-step process involving 
sequential transportation of electrons along several components of the oxidase. FAD 
and two hemes are part of the redox centre of the cytochrome b558 component of the 
oxidase, but NADPH cannot directly bind this protein until the enzyme is completely 
assembled during activation, after which electron transfer occurs (Roos et al., 2003). 
 
                        NADPH         FAD                2 Heme                2O2                 
 
Defects in bactericidal activity of neutrophils observed in chronic granulomatous 
disease (CGD) patients result from their inability to generate superoxide because one 
or more of the components of the oxidase are either absent or defective. However, 
superoxide has a low microbicidal potency, suggesting that it is perhaps, not the 
superoxide itself that kills microbes. Within the phagosome, the superoxide 
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spontaneously or enzymatically dismutates into hydrogen peroxide (H2O2), which 
then reacts with superoxide to generate hydroxyl radical (OH.) and singlet oxygen 
(O.), both highly reactive and toxic compounds (Kennedy & Deleo, 2009; Quinn et al., 
2006).  
 
                          .O2- + .O2- + 2H+                 H2O2 + O2                  
                          H2O2 + .O-2    .OH + OH- + 1O2   
           
Hydrogen peroxide may also, together with halide ions be used as a substrate by 
myeloperoxidase (MPO) released from azurophilic granules, to catalyse the formation 
of hypohalous acids, such as hypochlorous acid (HOCl), a very toxic compound for 
all microbes (Nauseef, 2007). NADPH oxidase and the MPO-halide systems are 
therefore, critical components of human neutrophil antimicrobial activity (Figure 1.4).  
 
                            H2O2 + Cl                  HOCl + H2O  
 
Hypochlorous acid is short-lived and can subsequently react with amines to form 
secondary chloramines, which are much more stable and as microbicidal as 
hypochlorous acid.  
 
                            R-NH2 + HOCl              R-HN-Cl + H2O 
 
Superoxide can also react with nitrous oxide (NO) generated by the inducible NO 
synthase to produce a very reactive nitrogen intermediate, peroxynitrite (Roos et al., 
2003).  
 
                            O2- + NO. + H+                 OH. + NO2 
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Figure 1.4 Neutrophil phagosome formation and generation of reactive 
oxidants. At the site of infection, primed neutrophils recognise and engulf the 
invading microbe leading to formation of the phagosome. Priming also facilitates 
assembly of the NADPH oxidase components at the membrane. This activates the 
oxidative burst and production of ROS (H2O2, O2-, HO-. and 1O2) through oxidation of 
NADPH generated during the increased activity of the hexose monophosphate (HMP) 
shunt. Hypochlorous acid (HOCl) production occurs via myeloperoxidase (MPO), as 
well as generation of other secondary ROS which together kill the engulfed microbes 
within the phagosome (Quinn et al., 2006). 
 
 
 
 
 
 
 
39 
 
It has also been recently suggested that singlet electron may be converted into other 
compounds similar to ozone (O3) in a reaction catalysed by neutrophils- or microbe-
bound antibodies. In this way, neutrophils kill a large array of microbes very efficiently 
(Babior et al., 2003; Roos et al., 2003).  
 
 
1.5.3 Neutrophil extracellular traps 
 
Neutrophils may generate web-like structures, called neutrophil extracellular traps 
(NETs) which entrap and kill large extracellular pathogens, such as fungi and 
protozoa that cannot be engulfed by opsono-phagocytosis. During NETs formation, 
the activated neutrophils release their DNA and associated histone (chromatin) which 
then interact with granule enzymes to form a mesh-like structure. NETs are therefore, 
comprised of large strands of the de-condensed DNA and nuclear histones 
(chromatin), proteins from primary granules (e.g. elastase, myeloperoxidase and 
cathepsin G), secondary granules (e.g. lactoferrin) and tertiary granules (e.g. 
gelatinase) (Thieblemont et al., 2016; Nakazawa et al., 2016). However, several 
cytoplasmic proteins, granule membrane protein (CD63) and cytoplasmic markers, 
such as  actin, tubulin and annexin 1 are absent from NETs (Brinkmann et al., 2004). 
NETs can be found in vivo in acute inflammations, such as dysentery and appendicitis 
(Brinkmann et al., 2004).   
 
NETs trap microbes, prevent them from spreading and allow for elevated levels of 
antimicrobial molecules to degrade virulence factors and kill the microbes. NETs also 
serve as a source of autoantigens (Brinkmann et al., 2004). The efficiency of NETs 
as a new microbicidal mechanism has not yet been clearly established and their in 
vivo role remains controversial (Menegazzi et al., 2012). However, the release of 
NETs has been reported to represent a new form of neutrophil death called NETosis, 
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which is distinct from either apoptosis or necrosis, and which provides way for the 
neutrophils to continue killing pathogens beyond the end of their lifespan (Fuchs et 
al., 2007). 
 
 
1.6 Control of neutrophil activity 
 
Neutrophils are highly potent and non-specific killing cells. They may contribute to 
inflammatory damage in diseases such as rheumatoid arthritis, where inappropriately 
activated neutrophils accumulate in the joints and release reactive oxygen species 
and granule proteins into the extracellular milieu, causing swelling, localised tissue 
damage, and joint destruction (Cross et al., 2005). It is therefore, necessary to prevent 
inappropriate activation of neutrophils as this can lead to tissue damage or persistent 
inflammation. Neutrophils exist in either quiescent (inactive), primed or active states 
(Hallett & Lloyds, 1995). In the circulation, neutrophils exist as inactive cells 
undergoing constitutive apoptosis after 6-18 h (Edwards et al., 2004). Control of 
neutrophil function is largely achieved, by a two-step activation mechanism plus auto-
regulatory processes, including spontaneous apoptosis. Neutrophils first become 
primed when exposed to infection-associated molecules and their full activation 
occurs once a pathogen is encountered. This two-step activation process normally 
prevents the risk of inappropriate activation. 
 
Following clearance of infection or inflammation, the effete neutrophils undergo a safe 
and non-inflammatory process of cell death by apoptosis and the apoptotic bodies 
are subsequently cleared by macrophages (Lagasse & Weissman, 1994). The 
presence of cytotoxic enzymes and ROS within neutrophils, make it imperative that 
these cells are disposed of in a controlled manner, otherwise they would cause 
inflammation or localised tissue damage if these toxic molecules were released 
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following necrosis. For example in chronic obstructive pulmonary disease (COPD), 
infiltration of neutrophils followed by necrosis (thought to be induced by Haemophilus 
influenza) results in tissue damage (Naylor et al., 2007). 
 
1.6.1 Apoptosis of human neutrophil 
 
Kerr, Wyllie and Currie first coined the term ‘apoptosis’ in 1972, to describe an orderly 
and programmed cell death, which occurs through a series of coordinated events that 
results in the cellular contents being packaged into discrete vesicles, and disposed of 
safely by macrophages, upon recognition of apoptotic signals expressed on the 
surface of the dying cell (Kerr, 2002; Kerr et al., 1972). Well-regulated apoptosis is 
essential to fundamental life processes, such as morphogenesis during embryonic 
development, tissue-homeostasis for safe removal of damaged or excessive cells and 
for the resolution of inflammation (Jacobson et al., 1997). Dysregulated or delayed 
apoptosis, which will abnormally prolong the survival of an aberrant cell, can lead to 
persistent inflammation or to the development of cancers (Derouet et al., 2006; Igney 
& Krammer, 2002). Furthermore, increased resistance to apoptosis can make cancer 
cells difficult to kill using conventional cytotoxic or radiologic therapies (Vousden, 
2001; Zangemeister-Wittke & Simon, 2001). On the other hand, excessive apoptosis 
leads to neurodegerative diseases, such as Alzheimer’s and multiple sclerosis (Rohn, 
2010).  The morphological changes observed in all cells undergoing apoptosis are 
identical, leading to the conclusion that apoptosis was evolutionary ‘conserved’ and 
genetically ‘programmed’ in every cell (Afford & Randhawa, 2000).  
 
Apoptosis enables an organism to remove old, damaged or unwanted cells through 
an orderly process of cellular death without inducing any undesirable inflammatory 
responses (Jacobson et al., 1997). The normal apoptotic process culminates in the 
activation of caspases, a family of cysteine proteases that act as effectors of the cell 
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death pathway and are responsible for the dismantling of the cell’s components, 
which are subsequently packaged into smaller apoptotic bodies for clearance by 
phagocytes (Thomas et al., 2010).  Upon their activation, caspases cleave specific 
proteins such as DNA-dependent protein kinase (DNA-PK), topoisomerases and 
some cell cycle regulators (Pucci et al., 2000). Caspases are also responsible for the 
morphological features observed in apoptotic cells, such as blebbed nuclear 
membrane structure, nuclear fragmentation, rounding and shrinking of the cell due to 
cytoplasmic and chromatin condensation. These features are exhibited when the cell 
reaches the final stages in the apoptotic pathway (Elmore, 2007; Vousden, 2001). 
 
Apoptosis is distinct to necrosis, which is a disordered cell death, usually arising from 
cellular trauma, caused by external factors, such as toxins or physical injury, resulting 
in the cellular contents released into the external milieu, causing inflammation and 
local tissue damage by cellular enzymes, such as lysozymes and proteases (Naylor 
et al., 2007). As described previously (section 1.6), when human neutrophils complete 
their lifespan or their roles in infection and inflammation, they undergo constitutive 
apoptosis. Apoptotic neutrophils are non-functional and express distinctive surface 
molecules (e.g. phosphotidylserine) that allow for their safe recognition and 
elimination by macrophages and other phagocytic cells. This safe removal prevents 
tissue damage that would otherwise occur by release of neutrophils destructive 
products into the surrounding tissues if their apoptosis is delayed or should they die 
by necrosis. 
 
1.6.2 Pathways of neutrophil apoptosis  
 
Neutrophil apoptosis can be triggered by two major pathways: the extrinsic pathway 
or ‘death receptor’ pathway, activated by the engagement of death ligands with death 
receptors on plasma membrane (Akgul & Edwards, 2003), and the intrinsic pathway 
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or ‘stress pathway’, regulated by the mitochondria and the Bcl-2 protein family 
members (Akgul et al., 2001; Hengartner, 2000). In some cells, the extrinsic pathway 
links with the intrinsic pathway via the activated BH-3 only protein tBid (truncated Bid) 
which can engage Bcl-2 homology proteins, and possibly Bax (Adams & Cory, 2007). 
 
1.6.2.1 The extrinsic apoptotic pathway 
 
The extrinsic pathway of apoptosis is activated when death ligands bind to their 
cognate death receptors on the cell surface, thereby mobilising apoptotic proteins and 
caspase cascades inside the cell (Rossi & Gaidano, 2003). The caspase cascade is 
activated by activation of an initiator caspase 8, through cleavage of its pro-form into 
the active form, which then directly activates executioner caspases, such as caspase 
3 and 7 and/or indirectly activates the intrinsic pathway through Bid cleavage, leading 
to formation of apoptosome, then triggering of apoptosis. This pathway can therefore, 
link to the intrinsic pathway via the cleaved Bid (tBid) (Fan, et al., 2005).  
 
The extrinsic pathway is regulated by both pro-apoptotic factors, such as Fas ligand 
(FasL), TNF-α and TRAIL that trigger cell death, as well as anti-apoptotic factors, 
such as GM-CSF, G-CSF and IFNs that prevent cell death (Akgul & Edwards, 2003). 
FasR (Apo-1/CD95) and TNFR1 that bind Fas ligand and TNF-α, respectively are the 
two most characterized neutrophil death receptors and both activate the caspase 
cascade. Several adaptor proteins are recruited during engagement with the death 
receptors that facilitate interaction with other proteins (including pro-apoptotic 
proteins). These include TNF-associated death domain-containing proteins (TRADD) 
and Fas-associated death domain-containing proteins (FADD) (Ashkenazi & Dixit, 
1998). For example, Fas clusters with FADD and pro-caspase-8 or DISC (death-
inducing signalling complex) to activate pro-caspase-8 and initiate the caspase 
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cascade (Peter & Krammer, 2003), whereas TNFR1 clusters with TRADD, FADD and 
pro-caspase-8 and other adaptor proteins to trigger apoptosis (Cabal-Hierro & Lazo, 
2012).  
 
 
1.6.2.2 The intrinsic apoptotic pathway 
 
The intrinsic pathway of neutrophil apoptosis is initiated by cellular stress at the inner 
mitochondrial membrane, such as growth factor removal, products of oncogenes and 
bacterial or viral infections, leading to activation of Bid. The active truncated Bid (tBid) 
induces the release of cytochrome c from the mitochondrial intermembrane space 
into the cytoplasm. Cytochrome c then associates with, and mobilises apoptotic 
protease-activating factor-1 (Apaf-1) and ATP to activate caspase 9 leading to 
formation of the apoptosome, which in turn activates executioner caspases (e.g. 
caspase 3 and 7) and triggers apoptosis (Kennedy & Deleo, 2009; Green & Reed, 
1998). Both the extrinsic and the intrinsic pathways therefore, finally activate 
executioner caspases 3 and 7 to induce neutrophil apoptosis, and Bid serves as a 
cross-link between the two pathways (Brenner & Mak, 2009).  
 
The B-cell lymphocytic-leukaemia proto-oncogene-2 (Bcl-2) protein family are the 
main regulators of the intrinsic apoptotic pathway. These proteins are divided into two 
groups namely; anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL, Mcl-1, A1, Bcl-w, Bcl-B, 
and XIAP) and pro-apoptotic proteins (e.g. Bax, Bak, Bid, Bik and Bim), according to 
their functional contribution in the regulation of apoptosis. The pro-apoptotic members 
promote cell death by inducing the mitochondrial outer membrane permeability 
(MOMP) and release of cytochrome c, which then stimulates caspase activation via 
the apoptosome formation (Kuwana & Newmeyer, 2003).  
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Figure 1.5 The pathways of apoptosis. The extrinsic pathway is initiated by binding 
of a death ligand to its receptor on the cell surface, resulting in recruitment of 
intracellular death and death engagement domains (DD) and subsequent activation 
of caspase-8 and caspase-3, leading to apoptosis. This pathway also engages the 
intrinsic pathway through cleavage of Bid to tBid by caspase-8. The intrinsic pathway 
is triggered by cellular stress at the mitochondrial membrane and is regulated by Bcl-
2 protein family. Anti-apoptotic proteins, Bcl-2 and/or Mcl-1 sequester Bax/Bak 
oligomerisation and aBH3 (activator BH3) proteins. Upon stress, iBH3 (inactivator 
BH3) antagonises the release of aBH3 from Bcl-2/Mcl-1. This results in 
oligomerisation of Bax/Bak leading to permeabilisation of mitochondrial outer 
membrane (MOMP). Cytochrome c leaks out of the mitochondria and combines with 
Apaf-1 and ATP resulting in apoptosome formation, followed by activation of caspase-
9, executioner caspase 3 and then triggering apoptosis (Adams & Cory, 2007).  
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The anti-apoptotic (pro-survival) Bcl-2 family proteins on the other hand, promote cell 
survival by keeping the mitochondrial membrane integrity intact, thereby protecting 
the release of cytochrome c from the intramitochondrial space (Brenner & Mak, 2009). 
 
1.6.3 The Bcl-2 family proteins 
 
The Bcl-2 protein family are the main regulators of the intrinsic apoptotic process and 
consists of about 20 members identified by having sequence homology to the 
eponymous Bcl-2 protein at one or more regions called BH (Bcl-2 homology) domains 
(Harada & Grant, 2003). The family is functionally divided into two groups namely; 
anti-apoptotic and pro-apoptotic members according to their functional contribution to 
the regulation of apoptosis. The balance between these two opposing groups of 
proteins determines the cell’s fate towards survival or apoptosis (Brenner & Mak, 
2009). When the activities of the pro-apoptotic proteins overcome those of the anti-
apoptotic proteins, the cell progresses towards apoptosis (Mollet et al., 2013).  
 
The two groups can be further sub-divided based on their BH domain structure. The 
anti-apoptotic members are multi-domain, containing three or four BH domains. For 
example, Bcl-2, Bcl-XL and Bcl-W contain four BH domains (BH1-4) while Mcl-1 and 
A1(Bfl-1) contain three BH domains (BH1-3), lacking a well-defined BH4 (Akgul et al., 
2000). The pro-apoptotic members are either multi-domain, containing three BH 
domains (e.g. Bax, Bak and Bok contain BH1-3 domains) or BH3-only (e.g. Bad, Bid, 
Bik, Bim, NOXA and PUMA contain only BH3 domain) (Akgul, 2009; Akgul et al., 
2000). Furthermore, the BH3-only pro-apoptotic members have also been classified 
based on the nature of their interactions with other members of the Bcl-2 family into 
iBH3 (inactivator BH3-only) comprising Bad and NOXA proteins, and aBH3 (activator 
BH3-only) comprising Bid, Bim and PUMA proteins (Cairrão & Domingos, 2010; 
Thomas et al., 2010). 
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Table 1.1 The main Bcl-2 family members with their BH domain contents and 
apoptotic functions. 
 
Anti-apoptotic (multi-domain) Pro-apoptotic 
 
BH1-4 
 
BH1-3 
Multi-domain 
(BH1-3) 
 
BH3-only 
iBH3 aBH3 
 
Bad 
 
NOXA 
 
Bid 
 
Bim 
 
PUMA 
 
 
 
Mature blood neutrophils express a range of pro-apoptotic members of the Bcl-2 
family proteins, which may partly explain their ability to undergo apoptosis 
spontaneously and rapidly, but Mcl-1 is the only anti-apoptotic Bcl-2 protein family 
member expressed in human neutrophils, that has been measured reliably at both 
the protein and mRNA levels, and whose levels correlate with the cell’s survival 
(Edwards et al., 2004). 
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Figure 1.6 The schematic representation of BH-domain structure. All Bcl-2 
protein family members contain a conserved BH (Bcl-2 homology) domain. Although 
these proteins share some degree of homology in their BH-domain structure, distinct 
structural differences exist between their BH domains that allow each member to 
carry out its specific function in the regulation of apoptosis. Most Bcl-2 members have 
a C-terminal TM  (transmembrane) domain for anchoring into intracellular membrane, 
whilst the BH4 domain is restricted to some anti-apoptotic members only (Thomas et 
al., 2010) (Figure not drawn to scale). 
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1.6.3.1 Myeloid cell leukemia-1 (Mcl-1) protein 
 
Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 protein 
family, expressed in both normal and malignant myeloid cells (Mollet et al., 2013). It 
is a major regulator of apoptosis in myeloid cells and its cellular levels are closely 
correlated with apoptosis (Dzhagalo et al., 2008). Mcl-1 is highly regulated by 
transcriptional, translational and post-translational modifications, such as 
phosphorylation and ubiquitination (Edwards et al., 2004).  
 
The MCL-1 gene was first identified as an early expressed gene during PMA-induced 
differentiation of the cell line, ML-1, and Mcl-1 protein was the second member of the 
Bcl-2 protein family to be discovered (Kozopas et al., 1993). Alignment algorithms 
have identified sequence similarities of Mcl-1 to other Bcl-2 proteins. The protein 
however, has some unusual properties not shared by other members of the Bcl-2 
family. The large N-terminal domain of Mcl-1 determines many of its unique 
properties, and contains many motifs that affect its rate of turnover, localization and 
phosphorylation status. These post-translational modifications provide the protein 
with the ability to respond rapidly and reversibly to environmental signals, and switch 
the cell’s fate from survival to apoptosis and vice versa (Lutz, 2000). 
 
 
1.7 The cell cycle 
 
The cell division cycle, simply known as the cell cycle, is a conserved process in 
multicellular organisms by which cells replicate themselves through a set of cyclic 
events, involving two major phases; S (DNA synthesis) and M (mitosis), leading to an 
accurate duplication of the cell without genetic abnormalities (MacLachlan et al., 
1995). Replication of the genome is required for the transmission of genetic 
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information from one cell generation to the next and this occurs during the S phase 
of the cycle. The genome is then segregated into the two new daughter cells (nuclear 
division) during the M phase. In a normal cell cycle, M-phase does not occur until the 
S-phase is complete and is always preceded by the S-phase. DNA 
synthesis/replication and mitosis are therefore, the two essential processes triggered 
during the cell cycle (Pucci et al., 2000).  
 
There are two preparatory gaps between S and M phases; Gap 1 or G1 prepares the 
cell for growth (growth phase 1) and separates the M phase from the S phase whilst 
Gap 2 or G2 prepares the cell for mitosis (growth phase 2) and occurs between the 
S and M phases. The cells grow and carryout all normal metabolic processes in 
growth phase 1. From G1, the cells that will undergo another division proceed to S 
phase, whereas those that cease division exit the cycle to enter a dormant state G0, 
which is a resting phase in which the cells stop growing and proliferating (Pucci et al., 
2000; Yen et al., 1985). Overall, the events leading to cell division involve two major 
stages: (1) Interphase, which comprises the G1, S and G2 phases, and (2) Mitosis, 
which consists of prophase, metaphase, anaphase and telophase. Mitosis is followed 
by cytokinesis (cytoplasmic division) resulting in division of cell into two viable and 
identical daughter cells (Norbury & Nurse, 1992).  
 
During haematopoiesis, cells undergo a limited number of divisions before they 
commit to differentiate towards a specific lineage. Once committed to a lineage, 
specific transcription factors are activated that result in changes (increases or 
decreases) in the expression of specific genes, which then change the molecular and 
phenotypic properties of the cell. These changes often limit proliferation, induce 
growth arrest and differentiation. The terminally-differentiated cells may then begin to 
die by apoptosis (Kim & Seoh, 2015).  
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Figure 1.7 The phases of cell cycle progression. The eukaryotic cell division cycle 
comprises the three stages of interphase; G1, S and G2 and the Mitosis (nuclear 
division). G1 and G2 are phases of continuous cell growth while S is the phase of 
DNA replication. An inactive cell exits the cycle and enters the dormant state G0. 
Cells undergo two phase transitions; G1/S (to enter DNA synthesis), G2/M (to enter 
mitosis) during the cycle. This figure is however, not relevant to neutrophils as they 
are terminally-differentiated cells that do not undergo cell division cycle. 
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Circulating blood neutrophils are mature, terminally-differentiated and non-dividing 
cells. They have lost the ability to undergo the cell cycle or DNA synthesis and die 
constitutively by apoptosis (Edwards, 1994). 
 
 
1.7.1 Regulation of cell cycle events 
 
Cell cycle regulation is an example of homeostatic mechanisms that maintain proper 
development and cellular functions in multicellular organisms. The orderliness and 
timing of cell cycle events are checked at the G1/S and G2/M boundaries. These 
checkpoints involve control systems that ensure proliferation proceeds only in the 
presence of appropriate signals, such as growth factors as well as ascertain the 
fidelity of the genetic information passed from one generation to the next. For 
example, the checkpoints can be activated by DNA damage or by mis-aligned 
chromosomes at the mitotic spindle, in which cases cell growth is arrested to allow 
for repairs, because mutations or aberrations in the DNA will compromise the normal 
cell cycle control systems and perhaps lead to the development of cancers. 
Progression through the cell cycle resumes only after the damage is repaired, 
otherwise the cell is eliminated by apoptosis (Pucci et al., 2000).  
 
The progression of the cell through the four phases of the cell cycle is regulated by 
activation and inactivation of members of the tyrosine/threonine family kinases called 
cyclin-dependent kinases (CDKs). CDK activity depends on the presence of 
activating sub-units of specific cyclins, whose abundance increases or decreases in 
the phases of the cell cycle where they are needed or not needed, respectively (Pucci 
et al., 2000) (Figure 1.8). CDKs can be divided into two groups based on their roles 
in cell cycle progression and genes transcription. The first group is involved in the 
regulation of cell cycle progression and includes CDK1, CDK2, CDK4 and CDK6.  
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CDK4 and CDK6 complex with cyclin D during the early G1 and their phosphorylation 
permits the transcription of genes required for entry into S phase. Once the cell is 
committed to enter into S phase, cyclin D-CDK activity is no longer required 
(Galaktionov et al., 1996). Activated CDK2 complexes with cyclin E or cyclin A during 
the G1-to-S transition and S phase progression, respectively (Ohtsubo et al., 1995). 
CDK1 complexes with either cyclin A or Cyclin B during the G2-to-M transition and M 
phase progression, respectively (see Figure 1.8) (Girard et al., 1991).  
 
The second group of CDKs is involved in regulation of transcription, and includes 
CDK7/cyclin H and CDK9/cyclin T complexes. These promote the initiation and 
prolongation of RNA transcripts through phosphorylation of RNA polymerase II 
(Palancade & Bensaude, 2003). CDK activity is stimulated by dephosphorylating their 
conserved threonine and tyrosine residues via CDK-activating kinase (CAK), while 
the activity is down-regulated by phosphorylation of these residues via CDC25 
phosphatases (Pucci et al., 2000; Galaktionov et al., 1996). 
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Figure 1.8 The cell cycle control checkpoints. The cell’s progression through each 
phase of the cell cycle is regulated by CDKs and their associated cyclins (shown in 
red boxes) at different checkpoints within the cycle that determine whether or not the 
cell is prepared to enter into the next phase (Norbury & Nurse, 1992). This figure is 
also, not relevant to neutrophils as they are terminally-differentiated cells that do not 
undergo cell cycle. 
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1.8 The JAK/STAT signalling pathway 
 
The Janus Associated Kinase-Signal Transducer and Activator of Transcription (JAK-
STAT) pathway is a principal signalling mechanism for a wide array of cytokines and 
growth factors in mammals (Imada & Leonard, 2000). Janus associated kinases are 
a family of tyrosine kinases that play important roles in both innate and adaptive 
immunity, as well as in haematopoiesis. JAK family kinases consist of four members, 
JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase 2). JAK1, JAK2 and TYK2 are 
expressed ubiquitously, but JAK3 is only expressed in haematopoietic cells  (Clark et 
al., 2014), and has been described as the key regulator of Bcl-2 and Bax proteins 
(Edwards, 1994).  
 
In addition, seven STAT proteins have been identified in mammalian cells, which are 
localised as clusters on different chromosomes; STAT1 and STAT4 on chromosome 
1, STAT2 and STAT6 on chromosome 10, and STAT3, STAT5a and STAT5b on 
chromosome 11 (Rawlings, 2004). Nearly 40 different cytokine receptors signal 
through combination of these four JAKs and seven STATs, indicating common 
features across the JAK-STAT signalling cascade (Murray, 2007). Following binding 
of a ligand (cytokine or growth factor) to its cognate receptor, JAKs are activated, 
which in turn activates STAT proteins by tyrosine phosphorylation, leading to a rapid 
signalling from the plasma membrane to the nucleus where the activated transcription 
factors modulate expression of the target genes (Vijayakrishnan et al., 2010; Imada 
& Leonard, 2000). In the nucleus, the activated STAT proteins bind to specific 
promoter DNA sequences and initiate the transcription of genes that regulate 
essential processes in haematopoiesis and immune development, such as cell 
proliferation, differentiation and apoptosis (Figure 1.9) (Kisseleva et al., 2002). 
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Figure 1.9 The JAK-STAT signalling pathway. In normal cells, the binding of ligand 
(cytokine or growth factor) to their receptors on the plasma membrane triggers 
receptor dimerisation and JAKs activation in the cytoplasm. The activated JAKs then 
phosphorylate the receptors to provide sites for recruitment and phosphorylation of 
STATs. The phosphorylated STATs then dimerise and translocate to the nucleus 
where they bind to the specific promoter sequences of the DNA to effect the 
transcription and expression of specific genes that regulate fundamental cellular 
processes (Rawlings, 2004). 
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Mutations that decrease or increase the activities of the JAK-STAT pathway 
negatively affect these processes, particularly mutations that constitutively activate or 
fail to regulate JAK-STAT signalling properly may result in inflammatory diseases and 
many forms of leukaemia (Rawlings, 2004). 
 
 
1.9 Differentiation of leukaemia cell lines into granulocytes-like cells 
 
The first demonstration of in vitro differentiation of leukaemia cell line into mature 
phenotype was in 1971, when Friend induced murine erythroid leukaemia (MEL) cells 
to differentiate into orthochromic erythroblasts in vitro, using dimethylsulfoxide 
(DMSO) (reviewed in Watanabe et al., 1988). Following this, several cell lines with 
the capacity to differentiate into mature neutrophil-like phenotypes along the 
granulocytic pathway have been established. These include: U-937 in 1974 
(Sundström & Nilsson, 1976, Harris & Ralph, 1985), K-562 in 1975 (Andersson et al., 
1979, Klein et al., 1976), HL-60 in 1977 (Collins, 1987), KG-1 in 1978 (Koeffler & 
Golde, 1978) and PLB-985 in 1985 (Tucker et al., 1987).  
 
Moreover, a wide range of chemical agents have been used to induce the in vitro 
differentiation of leukaemia cell lines into mature phenotypes, including 
dimethylsulfoxide (DMSO) (Shin & Demura, 2012), dibutyrylcyclic AMP (dbcAMP) 
(Hazan-Eitan et al., 2006), granulocyte colony-stimulating factor (G-CSF) (Kim & 
Seoh, 2015), phorbol myristate acetate (PMA) (Perkins et al., 1991), 1,25-dihydroxy 
vitamin D3 (Perkins et al., 1991), interferon-γ (Hazan-Eitan et al., 2006), 
hexamethylenebiacetamide (HMBA) (Zhang et al, 2000), ester 12-0-
tetradecanoylphorbol-13-acetate (TPA) (Delia et al., 1995), sodium pyruvate (Manz 
et al., 2001), retinoyl glucuronide (Zile et al., 1987), N,N-dimethylformamide (DMF) 
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(Katschinski et al., 1999) and all trans retinoic acid (ATRA) (Breitman et al., 1981; 
Breitman et al., 1980). 
 
1.9.1 Human promyelocytic leukaemia PLB-985 cell line 
 
The promyelocytic leukaemia cell line, PLB-985 is a sub-clone of the myeloid 
leukaemia cell line, HL-60. PLB-985 cell lines are less mature than the promyelocytes 
of the HL-60, thus they can be used to study earlier events involving commitments 
into granulocytes or monocyte/macrophage differentiation, that are not  afforded by 
HL-60 (Tucker et al., 1987). These cells have been established from the peripheral 
blood of 38-year-old patient (woman) with a refractory myeloblastic leukaemia and 
are myelomonoblast-like, phenotypically(Pivot-Pajot et al., 2010, Pedruzzi et al., 
2002, Tucker et al., 1987).  
 
Promyelocytic leukaemia (PML) is a subtype of acute myeloid leukaemia (AML) 
characterised by cells that have a reciprocal translocation between chromosomes 15 
and 17, which generates a fusion transcript joining the promyelocyte (PML) gene and 
retinoic acid receptor-α (RAR- α) gene (Rowley et al., 1977). The biologic and clinical 
features of the disease include leukopenia and life-threatening coagulopathy. The 
leukaemic promyelocytes, upon exposure to retinoic acid have the unique ability to 
undergo differentiation, and both differentiation and apoptosis when they are exposed 
to arsenic trioxide (Grignani et al., 1993). 
 
PLB-985 is a bipotential cell line that can undergo both granulocyte and 
monocyte/macrophage differentiation in the presence of appropriate inducing agents. 
It is a more recently-established cell line that has been demonstrated to show greater 
levels of differentiation and is described as the current ‘best’ model of neutrophil 
differentiation (Hauert et al, 2002, Tucker et al., 1987). The PLB-985 cell line has 
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been widely used to measure expression of NADPH oxidase and production of 
reactive oxygen species (ROS) (Boulven et al., 2006), but other functional processes 
such as degranulation and phagocytosis are less well characterized, or restricted to 
one type of differentiating agent (Trayner et al., 1998).  
 
Though varying degrees of PLB-985 differentiation have been reported, many 
features that are characteristics of mature neutrophils, such as polymorphic nucleus, 
are not always reported. Also, a major experimental limitation of these in vitro 
differentiation systems is that once differentiated, the neutrophil-like cells undergo 
apoptosis. Thus, new ways to delay apoptosis in differentiated PLB-985 cells would 
be of benefit as that would enhance the utility of the differentiation system, especially 
when trying to define the effects of knock-out or knock-in of genes on neutrophil 
function. In this project therefore, PLB-985 cells have been induced to differentiate in 
vitro, along the granulocytic pathway into neutrophil-like phenotypes and used as 
model to study neutrophil differentiation and functions. New experimental procedures 
that delay apoptosis of the differentiated cells have also been investigated. 
 
 
1.10 Summary 
 
Neutrophils are indispensable phagocytic cells of the immune system that circulate in 
the blood in a terminally-differentiated, inactive state undergoing constitutive 
apoptosis. They transform into active killing cells at the site of infection inflammation 
upon exposure to a variety of stimuli that trigger intracellular signal transduction 
pathways. Neutrophils also play pathological roles in the progression of autoimmune 
and inflammatory diseases, such as rheumatoid arthritis and systemic lupus 
erythematosus. A clear understanding of the molecular signalling processes of 
neutrophils in health and disease is necessary, but certain limitations, such as short 
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lifespan, lack of proliferation capacity and difficulty to transfect to express exogenous 
genes or proteins, have made the experimental manipulation of neutrophils ex vivo 
challenging, and hindered the biochemical studies of their signal activation 
mechanisms and genetic makeup. 
 
Therefore, establishment of validated myeloid cell lines capable of differentiating into 
mature neutrophil-like phenotypes, as well as acquire the molecular and functional 
properties of mature neutrophils would be beneficial in addressing these limitations. 
In that regards, this research project investigated the potential of human PLB-985 cell 
line towards granulocyte differentiation and has characterised the molecular 
properties of the differentiated cells, as model of neutrophil differentiation and 
functions. 
 
 
1.11 Research aim and objectives 
 
The aims of this thesis are to develop a modified differentiation protocol and new 
optimisation procedures to obtain terminally-differentiated PLB-985 cells that 
resemble mature neutrophils morphology with prominent multi-lobed nucleus and 
granulated cytoplasm, as well as with appreciably extended lifespan. It also aims to 
study the molecular and functional properties of the neutrophil-like differentiated PLB-
985 cells, in order to establish their usefulness as model of neutrophil differentiation 
and functions. 
 
The main objectives of the study were: 
 
1. To develop a modified differentiation protocol and new optimisation 
procedures to obtain differentiated PLB-985 cells, using a combination of 
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three differentiation- and maturation-inducing agents; ATRA, DMF and 
sodium pyruvate. 
2. To induce PLB-985 cells to terminally differentiate into mature neutrophil-like 
granulocytes, with prominent multi-lobed nucleus, granulated cytoplasm and 
appreciably extended lifespan. 
3. To characterise the molecular functional properties of the differentiated PLB-
985 cells, in order to establish their usefulness as model of neutrophil fuctions, 
such as apoptosis, chemotaxis, phagocytosis, oxidative burst activity, 
expression of cell surface markers and activation of intracellular signalling 
pathways. 
4. To determine the effects of small molecule JAK inhibitors, baricitinib and 
tofacitinib on the growth, differentiation and viability of the differentiated PLB-
985 cells. 
 
 
1.12 Hypothesis 
 
The main hypothesis tested in this project is that “The human myeloid cell line PLB-
985 can be induced to differentiate terminally into mature neutrophil-like phenotypes 
with an enhanced lifespan under appropriate conditions, and the differentiated PLB-
985 cells can acquire most of the functional properties of mature blood neutrophils”.  
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Chapter 2: Materials and Methods 
 
2.1 Materials 
 
The promyelocytic leukaemia PLB-985 cell line was generously provided by 
Professor S.W. Edwards, University of Liverpool. RPMI 1640 (+10mM L-glutamine), 
RPMI 1640 + HEPES (+10mM L-glutamine), foetal calf serum (FCS), 
penicillin/streptomycin and Annexin V-FITC were obtained from Invitrogen (Paisley, 
UK), polymorphprep was from AxisShield (Oslo, Norway), rapid Romanowsky stains 
were from HD Supplies (Aylesbury, Bucks), all trans retinoic acid (ATRA) (R2625), 
ficoll paque, N,N-dimethyl formamide (DMF), sodium pyruvate, polyclonal rabbit anti-
human Mcl-1 antibody, cycloheximide, tetramethylethylenediamine (TEMED), sheep 
HRP-linked anti-mouse IgG antibody and human pooled AB serum were from Sigma-
Aldrich (Dorset, UK), anti-Actin monoclonal mouse antibody (Ab3280) was from 
Abcam (Cambridge, UK), anti-Bcl-2 antibody (#2876), anti- Bcl-XL antibody (#2762), 
anti-Bax antibody (#2772), anti-Bak antibody (#3814), anti-biotin HRP-linked antibody 
and biotinylated molecular weight marker were from Cell Signalling (Hertfordshire, 
UK), Immobilin psq PVDF membrane, Immobilin western chemiluminescent HRP 
substrate and Guava viaCount reagents were from Millipore (Watford, UK), bis-
acrylamide was from Geneflow (Hertfordshire, UK), BCA protein assay reagents were 
from Thermo Scientific (Southend-on-sea, UK), FITC-conjugated anti-human CD11b 
antibody (#130-091-240) was from Miltenyl Biotech, perCP-conjugated anti-human 
CD14 antibody (#FAB3832C) was from R&D Systems (Minneapolis, USA), 
monoclonal mouse anti-human Mcl-1 antibody and FITC-conjugated anti-human 
CD16 antibody (#555406) were from BD Bioscience (Oxford, England), FITC-
conjugated isotype antibody control (#Sc-2855) was from Santa Cruz Biotechnology 
(Texas, USA), JAK inhibitotrs; baricitinib (#S2851) and tofacitinib (#S5001) were from 
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Selleckchem (Houston, USA), non-fat dry milk was from Home Bargains (Liverpool, 
UK), western blot equipment was from Bio-Rad (Hertfordshire, UK), all other reagents 
were from Sigma-Aldrich (Dorset, UK), all laboratory plastic ware were from Nunc 
(Denmark) and Greiner Bio-one (Germany).  
 
 
2.2 Isolation of human blood neutrophils 
 
Whole blood was collected from healthy donors by venupuncture, into heparinised 
tubes, under sterile conditions. Ethical approval was obtained for this study from the 
University of Liverpool Committee on Research Ethics (CORE). All participants gave 
written, informed consent. Polymorphonuclear leukocytes were separated by 
centrifugation using Ficoll-paque according to manufacturer’s instructions. Cells were 
re-suspended in RPMI-1640 + HEPES (10mM L-glutamine) media and then 
contaminating erythrocytes removed by hypotonic lysis using ammonium chloride 
buffer (155 mM NH4Cl, 13.4 mM KHCO3, 96.7 μM EDTA, PH 7.6), in a 1:9 cell media 
to lysis solution ratio, for 3 min followed by centrifugation at 1,000 g for 5 min. Cells 
were counted using a Multisizer3 cell counter (Beckman Coulter) following a 1:1000 
dilution with Isoton II and the suspension volume adjusted to give a final concentration 
of 5 ×106 cells/mL using RPMI-1640 + HEPES (10mM L-glutamine) medium. Cell 
purity was assessed by cytospining (20 μL (1×105 cells) in 200 μL PBS (+EDTA) at 
500 g for 5 min in a Shandon3 cytocentrifuge, and routinely found to be ˃95%, as 
determined by morphological examination under a light microscope, after rapid 
Romanowsky staining of cytospin slides. Cell Viability measured by Guava viaCount 
was also routinely ˃95%. Cells were usually incubated at 37oC with gentle agitation, 
where incubations for ≥ 5 h, cells supplemented with 10% (v/v) human AB serum. 
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2.3 Culture and differentiation of PLB-985 cells  
 
The human myeloid leukaemia PLB-985 cell line was cultured in RPMI-1640 (+10mM 
L-glutamine) medium (supplemented with 10% (v/v) foetal calf serum and 1% (v/v) 
penicillin/streptomycin) and incubated at 37oC in a humidified atmosphere of 5% CO2. 
Cell cultures were passaged every 2 - 3 days or as indicated in the text. For induction 
of differentiation into granulocytes, the RPMI-1640 (+10mM L-glutamine) medium 
was supplemented with 0.5% (v/v) foetal calf serum, 1% (v/v) penicillin/streptomycin, 
1% (v/v) sodium pyruvate, 0.5% (v/v) N,N-dimethylformamide (DMF) and 1µM All-
trans retinoic acid (ATRA). Normally, the culture was passaged and re-suspended in 
fresh medium on days 2 and 4. The exponentially-growing PLB-985 cells were 
seeded at a starting density of 2×105/mL in separate culture flasks labelled dPLB-985 
(differentiation-induced) and PLB-985 (non-induced) cells for a total of 6/7-day 
incubation period. 
 
For use in experiments, cells were harvested and analysed each day or on selected 
days, depending on the experimental design. Cells were centrifuged at 1,000 g for 3 
min and the supernatant discarded. Cells were re-suspended in fresh media, counted 
using a Multisizer3 cell counter (Beckman Coulter) and the suspension volume 
adjusted with media to give a final concentration of 1×106/mL. Cells were then plated 
under different experimental conditions as described in the text.  
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Table 2.1 Compositions of the culture media 
 
Ingredients Routine medium Differentiation 
medium 
 
RPMI 1640 + 10mM L-glutamine. 
Fetal calf serum (FCS) 
Penicillin/Streptomycin 
Sodium pyruvate 
N, N-dimethylformamide (DMF) 
All-trans retinoic acid (ATRA) 
 
500 mL 
10% (v/v) 
1% (v/v) 
- 
- 
- 
 
500 mL 
0.5% (v/v) 
1% (v/v) 
1% (v/v) 
0.5% (v/v) 
1µM 
 
 
 
 
2.4 Morphological analysis of PLB-985 cells differentiation  
 
Following culture of PLB-985 cells in the presence and absence of differentiation-
inducing agents, 20 μL of cells at a concentration of 1×106 /mL were diluted with 180 
μL PBS (+EDTA), slides prepared in a Shandon3 cytospin and cytocentrifuged at 500 
× g for 5 min to fix the cells on the slides. The slides were air-dried, stained with rapid 
Romanowsky stain and cell morphology analysed under a light microscope. Large 
rounded nucleus with well-defined nucleoli and agranular cytoplasm were observed 
in non-differentiated PLB-985 cells while the differentiated cells appeared with 
segmented, multi-lobed nucleus and granulated cytoplasm.  
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2.5 Morphological analysis of neutrophil and dPLB-985 cells apoptosis  
 
Following appropriate incubations, cytospin slides were prepared as described 
(section 2.4) and stained with rapid Romanowsky stain, before they were examined 
microscopically for neutrophils or differentiated PLB-985 cells morphology. Viable 
neutrophils and dPLB-985 cells exhibited indented, convoluted and segmented 
nuclei, decreased nucleoli and granulated cytoplasm, whilst both apoptotic 
neutrophils and dPLB-985 cells appeared smaller with dense cytoplasm, condensed 
chromatin and round, compact nuclei. 
 
 
2.6 Priming of isolated neutrophils and dPLB-985 cells 
 
Neutrophils at a final concentration of 5 x 106 /mL or PLB-985 cells at 1×106 /mL were 
primed by incubation with either G-CSF (10 ng/mL) or GM-CSF (5 ng/mL) at 37ºC for 
30 min with gentle agitation. This was followed by subsequent incubations according 
to various experimental designs. 
 
 
2.7 Preparation of whole-cell lysates  
 
Following culture and incubation of cells with the various treatments described in the 
text, for the indicated length of time, aliquots of 5×106 cells (neutrophils) or 1×106 cells 
(PLB-985) were pelleted by centrifugation at 1,000 g for 3 min, the supernatant 
discarded and cells re-suspended in 1mL of phosphate-buffered saline (PBS) to 
remove all traces of media. Cells were pelleted once again at 1,000 g for 3 min and 
supernatant discarded.  
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For PLB-985, cells were then re-suspended in 100 µL of boiling Laemmli lysis buffer 
(minus dithiothreitol and bromophenol blue) for 4-5 min with occasional vortexing. The 
cell lysates were then used for analysis or stored at -20oC. For neutrophils, the PBS 
washing step was omitted and cells were re-suspended in 100 µL of boiling normal 
Laemmli lysis buffer (plus DTT and bromophenol blue), for 4-5 min with occasional 
vortexing. The cell lysates were then used for analysis or stored at -20oC. 
 
 
2.8 Bichinconinic acid (BCA) assay 
 
For PLB-985 whole-cell lysates (protein extracts), the bichinconinic acid assay was 
performed as per manufacturer’s instructions, to ensure all samples had equal total 
protein concentrations. The protein concentrations were measured using a 
spectrophotometer at an absorbance of 562 nm.  Following determination of protein 
levels, samples were diluted with Laemmli buffer, 10% (v/v) dithiothreitol (DTT) and 
1% bromophenol blue (0.01% w/v) added to make the final volumes of the samples. 
Prepared samples were used directly for analysis or stored at -20oC. 
  
 
2.9 Electrophoresis and Western blotting 
 
Cell lysates were separated by SDS-PAGE using 1.5 mm thick resolving gels (12% 
(v/v) polyacrylamide, 370 mM Tris-HCl, pH 8.8, 1% (w/v) SDS, 1% (w/v) APS, 0.1% 
(v/v) TEMED). The APS and TEMED were added last to prevent polymerisation 
before casting. Following casting of resolving gels, water-saturated t-amyl alcohol or 
isopropanol was overlaid to ensure a levelled top surface of the gels. After 
polymerisation, the overlaid alcohol was discarded and gel’s surface washed with 
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deionised water. Stacking gels (4.5% (v/v) polyacrylamide, 122 mM Tris-HCl, pH 6.7, 
1% (w/v) SDS, 1% (w/v) APS, 0.1% (v/v) TEMED) were then cast onto the surface of 
resolving gels and a 10 or 15 wells casting comb inserted. After full polymerisation of 
the gels, samples of protein extracts were boiled for 5 min, centrifuged briefly and 15-
20 µL were loaded per well. 10 µL prestained marker was loaded in lane 1 and 5 µL 
of biotinylated marker was loaded in the last lane. Gels were electrophoresed for 45-
60 min at 200V using SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) 
SDS).  
 
Following separation, the stacking gel was removed and the resolving gel was 
allowed to equilibrate for 5 min in a transfer buffer (20% (v/v) methanol, 95mM glycine, 
12.5 mM Tris). Polyvinylidene difluoride (PVDF) membrane was immersed in 
methanol for 30 sec and washed in transfer buffer. The gel and PVDF membrane 
were then assembled into a sandwich cassette for transfer. Proteins were transferred 
to PVDF membrane by electrophoresis at 100V for 1 h.  
 
After protein transfer, membranes were briefly stained with ponceau S stain (0.1% 
(w/v) ponceau S in 5% (v/v) acetic acid) to confirm successful transfer, which was 
then removed with wash buffer (TBS (10 mM Tris, 150 mM NaCl, pH 8.0), 0.1% (v/v) 
Tween 20). Membranes were subsequently incubated for 1 h in a blocking buffer (TBS 
(10 mM Tris, 150 mM NaCl, pH 8.0), 0.1% (v/v) Tween 20) containing 5% (w/v) non-
fat dry milk) at room temperature with gentle agitation to block non-specific antibody 
binding. Membranes were then washed 2×30 sec in wash buffer to remove the 
blocking buffer. Membranes were then incubated in antibody buffer (containing either 
5% (w/v) non-fat dry milk or 5% (w/v) BSA in wash buffer), with specific primary 
antibody at an appropriate concentration (according to the manufacturer’s 
instructions), overnight at 4oC with gentle agitation. Membranes were washed 
thoroughly (3×5 min) with wash buffer to remove primary antibody, and then 
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incubated with specific horseradish-peroxidase (HRP)-conjugated secondary 
antibody in antibody buffer for 1 h, at room temperature on an orbital shaker. The 
membranes were once again washed with wash buffer (3×5 min) to remove the 
secondary antibody. Membranes were then treated with excess ECL detection 
reagents, incubated at room temperature for 5 min, dried, prepared in cassettes and 
exposed to photosensitive hyperfilm for 1-20 min depending on the signal intensity. 
The hyperfilms were then developed to detect the protein bands. 
 
Following development of the blot, membranes were stripped for 15-30 min in a 
stripping buffer (50 mM Glycine and 150 nM NaCl, pH 2.5) and 0.1% (v/v) tween 20) 
before use for re-probing.  The membranes were blocked in 5% non-fat dry milk (in 
wash buffer) at room temperature for 1 h, and then re-probed for other proteins of 
interest or for Actin to confirm equal protein loading in each lane. Table 2.2 
summarises the antibodies used in western blotting analysis. 
 
 
2.10 Densitometry 
 
The intensity of the signals formed by the protein bands on x-ray hyperfilm following 
treatment with ECL reagents was quantified using a Scanner and AQM Advance 6 
software by kinetic imaging, and the results were displayed graphically. 
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Table 2.2 Antibodies used for western blotting. 
Protein of 
interest 
Antibody 
buffer 
Primary 
antibody 
(Dilution) 
Secondary 
antibody 
(Dilution) 
Molecular 
weight (KDa) 
Mcl-1 
Non-fat dry 
milk 
Rabbit anti-
human Mcl-1 
(1:10,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000)) 
40 
Mcl-1 BSA 
Mouse anti-
human Mcl-1 
(1:1,000) 
HRP-linked 
sheep anti-
mouse IgG 
(1:10,000) 
40 
Bcl-2 BSA 
Rabbit anti-
human Bcl-2 
(1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
26 
Bcl-XL BSA 
Rabbit anti-
human Bcl-XL 
(1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
30 
Bak 
Non-fat dry 
milk 
Rabbit anti-
human Bak 
(1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
25 
Bax BSA 
Rabbit anti-
human Bak 
(1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
20 
Phospho-
STAT3 
BSA 
Rabbit anti-
human Phospho-
STAT3 (1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
79, 86 
STAT3 BSA 
Rabbit anti-
human STAT3 
(1:1,000) 
HRP-linked 
donkey anti-
rabbit IgG 
(1:10,000) 
79, 86 
β-Actin 
Non-fat dry 
milk 
Mouse anti-actin 
(1:20,000) 
Sheep anti-
mouse HRP-
linked (1:10,000) 
42 
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2.11 PI-labelling and complement-mediated opsonisation of S. aureus 
 
To assay phagocytosis of S aureus by neutrophils and dPLB-985 cells, 1×1010/mL 
live S aureus were suspended in PBS and heat-inactivated by incubation in a water 
bath at 60oC for 30 min. The heat-killed cells were then centrifuged at 2,000 ×g for 10 
min and the supernatant discarded. The cells were then washed ×3 in PBS. The cells 
were re-suspended in PBS, stained with 120mM propidium iodide and then placed on 
an orbital shaker at 4oC in the dark for 2 h. The PI-stained cells were then centrifuged 
at 2,000 g for 10 min, supernatant discarded and cells washed ×3 with HBSS (+0.1% 
gelatin). Human AB serum was denatured by incubation in water bath at 55 oC for 45 
mins to inactivate the pathways (classical and alternative) of complement cascade. 
The heat-killed, PI-labelled S. aureus (SAPI) was then complement-opsonised by 
suspension in 30% (v/v) human AB serum (in PBS) and placed on an orbital shaker 
at 37oC with gentle agitation for 1 h. The opsonised SAPI were then washed ×3 and 
re-suspended with PBS to a final concentration of 1×109/mL cells and stored at 4oC. 
 
 
2.12 Complement-opsonisation of polystyrene latex beads 
 
For analysis of phagocytosis of latex beads by neutrophils and differentiated PLB-985 
cells, 40µL of 10% suspension of 1.1 µm diameter non-fluorescent and amine-
modified fluorescent polystyrene latex beads were re-suspended in 500 µL PBS and 
centrifuged at 5,000 ×g for 30 s. The supernatant was discarded and bead particles 
re-suspended in 500 µL. This was repeated ×2 to wash the beads. Following third 
wash, the beads were complement-opsonised by suspension in 190 µL PBS and 
addition of 10 µL heat-denatured human AB serum. These were mixed gently and 
incubated at room temperature for 2 h. The opsonised latex beads were then washed 
72 
 
×3 with PBS to remove unbound serum, and finally re-suspended in PBS to a final 
concentration of 1×109/mL bead particles. 
 
 
2.13 Luminol-enhanced chemiluminescence assay of oxidative burst activity 
 
The oxidative burst activity of neutrophils and differentiated PLB-985 cells was 
analysed by quantification of reactive oxygen species (ROS) produced in a luminol-
enhanced chemiluminescence assay. Luminol readily diffuses through the cell 
membranes and rapidly becomes oxidised by free-radicals generated during the 
oxidative burst. The molecule then releases energy in the form of light, which was 
used to measure the total (intracellular and extracellular) oxidants generation. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Luminol-enhanced chemiluminescence reaction. Reactive oxygen 
species (ROS) produced during oxidative burst activity oxidise the luminol into an 
electrochemically excited 3-aminophthalate intermediate, which emits energy in the 
form of photons of light as it returns to its ground state, measured as the total 
generated ROS using luminometer.  
 
 
Luminol 
Hydrogen 
peroxide 
Singlet dianion 
(excited state) 
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The chemotactic peptide, fMLP was used to stimulate receptor-dependent activation 
of the oxidative burst from the cells after incubation with GM-CSF, while receptor- 
independent activation was stimulated by PMA.  Neutrophils (5×106 /mL) or dPLB-
985 cells (2.5×106 /mL) were incubated in the absence and presence of G-CSF 
(10ng/mL) or GM-CSF (5 ng/mL) (for priming), at 37oC for 45 min. Following 
incubations, 40 μL of cells was pipetted into wells in a white, low adhesion 96-well 
plate (as neutrophils produce a non-specific respiratory burst when adhered to TC 
plates) containing 100 μL HBSS media and 60 μL incubation mixture (158.8 μL HBSS 
media, 1 μL luminol (10 μM final concentration), and 1µM fMLP or 0.1µg/mL PMA 
final concentrations per well. Cells were pipetted as quickly as possible with PMA 
added first as its reaction is slow (5-10 min) followed by fMLP whose activation is very 
rapid (2-4 min). Both wells with unstimulated cells (no fMLP or PMA) and those with 
no cells (media alone) were also included to observe the differences in the 
background. The tubes and plates were wrapped in a thin foil during preparations 
because of the sensitivity of luminol to light. Chemiluminescence was measured as 
photon emission using a luminometer, and the total generated ROS was measured 
using a FLUOstar Omega plate reader from BMG Labtech set at 37oC, 20% O2, and 
5% CO2. 
 
 
2.14 Flow cytometry 
 
Flow cytometry analysis was performed with a Millipore ‘Guava EasyCyte plus’ flow 
cytometer. The technique measures single cells in a population of cells and quantifies 
them according to their light scattering properties or their surface or internal 
fluorescence following staining with fluorescent dyes or labelled antibodies. The 
method involves passage of cell suspensions through a single wavelength laser 
beam. The passage of cells scatters the laser-light which is then quantified by two 
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detectors; the parallel detector which measures the forward scatter (FSC) indicative 
of cell size and the perpendicular detector, which analyses the side scatter (SSC) 
indicative of cell granulation. Alternatively, fluorophores on cells stained with labelled 
antibodies become excited by the laser beam and emit fluorescence which is 
measured as the cell’s expression of a particular component. Samples were analysed 
in a 96-well plate. The distributions of fluorescence represent 5,000 gated events 
analysed per sample. 
 
2.14.1 Flow cytometry analysis of cell viability 
 
The Guava viaCount assay was used to measure cell viability. The Guava viaCount 
reagent contains two DNA binding dyes: nuclear and viability dyes. The assay 
distinguishes viable and dead/apoptotic cells based on differential permeability of the 
two dyes. The nuclear dye is cell-permeable and stains DNA in all cells and the 
viability dye is cell-impermeable and only stains DNA and RNA in dying cells with a 
permeabilised cell membrane. Following appropriate incubations in culture media, 25 
μL of cells (neutrophils at 5×106 /mL and PLB-985 at 1 ×106 /mL) was pipetted into 
relevant wells in a 96-well plate, containing 225 μL of ViaCount reagent (1:10 dilution) 
and incubated for 5 min at room temperature. The cell viability was then analysed 
using Guava ViaCount software on flow cytometer. 5,000 gated events were analysed 
per sample. 
 
2.14.2 Flow cytometry analysis of neutrophil apoptosis 
 
The phospholipid bilayer of the plasma membrane contains phosphatidylserine 
groups which in healthy cells, are restricted to the cytoplasmic side of the membrane, 
but when the cells enter apoptosis, these became delocalised and appear on the cell 
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surface. Phagocytes recognise and remove apoptotic cells in vivo by these cell 
surface phosphatidylserine groups. A cellular protein Annexin V, whose function is 
unknown, binds the phosphatidylserine groups on the cell surface (Crowley et al., 
2016). Therefore, FITC-conjugated Annexin V binds the cell surface 
phosphatidylserine groups of apoptotic cells and produces fluorescence which is 
measured as an indicator of an early stage apoptosis. Late-stage apoptosis/necrosis 
on the other hand, is determined using propidium iodide (PI) as an indicator. 
Propidium iodide is impermeable to the plasma membrane and is therefore, 
prevented entry into viable cells. However, apoptosis renders the plasma membrane 
permeable thus, allowing propidium iodide to enter the cell and bind to DNA, leading 
to an enhanced fluorescence (Rieger et al., 2011). Usually, an 18 h incubation of 
neutrophils resulted in 60-70% apoptosis in cells not treated with any apoptosis 
delaying-agent. 
 
1mL of cells at 106 /mL in RPMI + 10% human AB serum was incubated per well in a 
24-well plate, for 0, 2, 4, 6 h and overnight at 37oC in a humidified atmosphere of 5% 
CO2. 1 μL G-CSF (10 ng/mL) or GM-CSF (5 ng/mL) was used as a positive control 
for delayed apoptosis. Following incubation, samples were gently pipetted up and 
down wells several times to re-suspend the cells and then 25 μL was removed to a 
96 wells plate. To stain the cells, 25 μL HBSS containing 0.5 μL Annexin V was added 
to each well and incubated for 15 min at room temperature in the dark. This was 
followed by the addition of 200 μL HBSS containing 1 μg/mL propidium iodide. The 
samples were then analysed immediately on the flow cytometer, and 5,000 gated 
events were analysed per sample.  
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2.14.3 Flow cytometry analysis of cell cycle and DNA staining 
 
The cell cycle parameters of neutrophils and PLB-985 cells were analysed by flow 
cytometry, using univariate approach that measures total cellular DNA content and 
reveals the distribution of cells in three major phases of the cell cycle (G1, S and 
G2/M), after staining permeabilised, fixed cells with propidium iodide. It also allows 
detection of apoptotic cells in the dormant phase (G0) with fractional DNA content. 
Propidium iodide binds DNA and produces fluorescence which is proportional to the 
DNA concentration per cell, and which varies as the cells progress through the cell 
cycle.  
 
200 µL of cells at 106 /mL were pipetted into a small microfuge tube after appropriate 
incubations as described in the text, and centrifuged at 1,000 g for 3 min. The 
supernatant was discarded, the pellet flicked and washed by re-suspension in 200 µL 
PBS (+EDTA) and centrifuged at 1,000 g for 3 min. The supernatant was discarded 
and the pellet flicked and re-suspended in 200 µL ice-cold, 70% ethanol and kept at 
4oC for at least 1 h or overnight (when fluorescence was not to be measured 
immediately) to fix the cells. Triton-X/RNase/PI staining buffer (1 mg/mL PI in PBS 
and 1 mg/mL Ribonuclease A in 1% Triton/PBS combined in 1:9 ratio) was prepared 
just prior to analysis and kept in the dark as PI is light sensitive. The fixed cells were 
centrifuged at 1,000 g for 3 min, supernatant aspirated, pellet re-suspended in 200 
µL PBS (+EDTA) and centrifuged at 1,000 g for 3 min to remove the ethanol before 
staining. The supernatant was aspirated and the pellet re-suspended in 200 µL PBS 
(+EDTA). 200 µL of fixed (ethanol-free) cells was then transferred into wells in 96-
well plate containing 25 µL of the staining buffer. The cells were analysed immediately 
using the flow cytometer, and 5,000 gated events were analysed per sample. 
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Figure 2.2 Typical flow cytometer trace of DNA distribution profile indicating 
cell cycle parameters. The non-synchronously growing PLB-985 cells were 
permeabilised, fixed and stained with propidium iodide. The PI binding intensity 
increases as the cell progresses through the cell cycle and the amount of PI 
fluorescence is proportional to the increasing DNA concentration. 
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2.14.4 Flow cytometry analysis of cell surface receptors expression 
 
To study the expression of cell surface receptors (CD11b, CD14, and CD16) on the 
surface of neutrophils and differentiated PLB-985 cells, 10 μL of cells (neutrophils at 
5x106/mL and PLB-985 cells at 2.5x106/mL) were pipetted into a small microfuge 
tube, diluted with 200 µL PBS (+BSA) and centrifuged at 900 g for 3 min. The 
supernatant was discarded, tubes flicked and the pellet re-suspended in 10 µL PBS 
(+BSA). Appropriate (saturating) antibody volumes optimized for flow cytometry (as 
supplied by the manufacturers) were added as described in Table 2.3 and mixed by 
votexing. Cells were incubated for 30 min at 4oC in the dark. 200 µL PBS (+BSA) was 
then added and centrifuged at 900 g for 3 min. Supernatant was discarded and cells 
fixed by addition of 100 µL PBS (+BSA) and an equal volume of 4% 
paraformaldehyde (PFA) at room temperature, in the dark for 15 min. Fixed cells were 
then centrifuged at 900 g for 3 min, supernatant discarded and pellet re-suspended 
in 200 µL PBS (+BSA). Cells were then analysed for expression of the surface 
antigens using the flow cytometer or stored overnight in the fridge (in the dark) if the 
analysis was not to be done immediately. 
 
2.14.5 Permeabilisation of cells and intracellular CD16 staining 
 
For intracellular CD16 staining, cells were permeabilised using 0.1% saponin (in PBS) 
prior to staining. Following fixation with 4% PFA and washing, cells were suspended 
in 200 µL PBS (+ 0.1% saponin) and incubated at 4oC for 15 min, centrifuged at 900 
g for 3 min, and supernatant discarded. Cells were then re-suspended in 10 µL PBS 
(+ 0.1% saponin) and 2 µL CD16 added and incubated at 4oC for 30 min. Cells were 
then washed to remove excess/unbound antibody by suspension in 200 µL PBS 
(+BSA), centrifuged at 900 g for 3 min, supernatant discarded and pellet re-
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suspended in 200 µL PBS (+BSA). Expression of intracellular CD16 was analysed by 
flow cytometry. 
 
 
Table 2.3 Conjugated antibodies used in flow cytometry 
Antibody Neutrophil 
concentration 
dPLB-985 cells 
concentration  
Antibody 
volume 
CD11b-FITC 
CD11b-PE 
CD14-PerCP 
5 x 106 in 10 μL 2.5 x 104 in 10 μL 5 μL 
CD16-FITC 5 x 106 in 10 μL 2.5 x 104 in 10 μL 1 μL 
 
 
 
2.14.6 Flow cytometry analysis of phagocytosis 
 
Neutrophils or PLB-985 cells at 1×106/mL were incubated at 37oC in the presence or 
absence of priming agents; G-CSF (10ng/mL) or GM-CSF (5 ng/mL) for 30 min. 
Complement-opsonised SAPI or latex beads at 1:10 (cell to particle ratios) were 
added to the incubation mixture with gentle agitation on an orbital shaker in a 5% CO2 
incubator at 37oC for a further 30 min. Unstained or unstimulated cells were included 
to gate for negative fluorescence. The samples were centrifuged at 1,000 x g for 3 
min, the supernatant discarded and cells re-suspended in 1mL HBSS or PBS. 200 µL 
of the cell suspension was then pipetted into wells in a 96-well microtitre plate. The 
phagocytosis of SAPI or latex beads by neutrophils and dPLB-985 cells was 
measured by flow cytometry, analysing 5,000 gated events per well. 
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2.14.7 Flow cytometry analysis of oxidative burst activity 
 
Neutrophils or PLB-985 cells at 1×106/mL were incubated at 37oC in the presence or 
absence of priming agents; G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, 
followed by addition of DHR 123 (5µM) for 15 min, as a ROS detection probe. 
Oxidative burst activity was then stimulated by addition of fMLP (1µM) for 5 min, and 
PMA (0.1µg/mL) or latex beads at 1:10 (cell to particle ratios) for 15 min, including 
samples containing DHR 123 alone, as well as unstimulated cells to gate for negative 
fluorescence. The samples were then centrifuged at 1,000 x g for 3 min, the 
supernatant discarded and cells re-suspended in 200 µL HBSS or PBS and oxidative 
burst activity of neutrophils or differentiated PLB-985 cells was measured immediately 
by flow cytometry. The distributions of fluorescence represented 5,000 gated events 
analysed per sample. 
 
 
2.15 Transmigration and chemotaxis assay 
 
Millipore hanging cell culture plate inserts were used to measure the transmigration 
of neutrophils and differentiated PLB-985 cells. 24-well tissue culture plates were 
coated with poly-hema (2-hydroxymethyl methacrylate) at a concentration of 12 
mg/mL in ethanol to prevent cells adhering to the plates following transmigration, and 
used for the assay. The plates were incubated at 37oC, 5% CO2, overnight or until the 
ethanol evaporated. 800 µL RPMI 1640 (+10mM L-glutamine) media without and with 
chemoattractants; fMLP (10-8M), IL-8 (0.1µg/mL), zymosan A (1µg/mL) or casein (0.5 
mg/mL) were added into the relevant wells. The hanging inserts fitted with a 3 µm 
pore sized filters at their bases were suspended in the media and left for at least 10 
min at room temperature to equilibrate. 
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1x106 neutrophils or 4×105 dPLB-985 cells in 200 µL media were added into the 
hanging inserts and incubated at 37oC, 5% CO2 for 90 min. The hanging inserts were 
then removed from the wells and the cells that transmigrated into each well were 
counted using Multisizer 3 cell coulter counter (Beckman Coulter) following a 1:1000 
dilution with Isoton II. The number of migrated cells was expressed as a percentage 
of total number of cells added originally. 
 
 
2.16 Statistical analysis 
 
Statistical analysis was performed using IBM SPSS v20 software. Student’s t-test 
(independent and paired) or one-way analysis of variance (ANOVA) were used to 
analyse the data following testing for normality. Differences were considered 
significant within 5% confidence interval (p≤0.05) and the values were denoted by *. 
Error bars displayed in graphs signify the mean ± SEM where repeat experiments 
were performed. Some error bars are however, undetectable or appear extremely 
small due to low error in the affected data sets. 
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Chapter 3: Differentiation of PLB-985 cell line into mature 
neutrophil-like granulocytes 
    
3.1 Introduction 
 
In 1971, Friend induced the murine erythroid leukaemia (MEL) cells to differentiate 
into orthochromic erythroblasts in vitro using dimethylsulfoxide (DMSO). This was the 
first demonstration of in vitro differentiation of leukaemia cell lines (reviewed in 
Watanabe et al., 1988). Following this, wide range of chemical agents have been 
demonstrated to induce in vitro differentiation of leukaemia cell lines into more mature 
phenotypes which include hexamethylenebiacetamide (HMBA), ester 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Ji-wang et al., 2000), N,N-
dimethylformamide (DMF) (Katschinski et al., 1999), retinoyl glucuronide (Zile et al., 
1987) and all trans retinoic acid (ATRA) (Trayner et al., 1998). Likewise, many cell 
lines with the capacity to differentiate along the granulocytic pathway have also been 
established, such as U-937 in 1974 (Sundström & Nilsson, 1976, Harris & Ralph, 
1985), K-562 in 1975 (Andersson et al., 1979, Klein et al., 1976), HL-60 in 1977 
(Collins, 1987), KG-1 in 1978 (Koeffler & Golde, 1978) and PLB-985 in 1985 (Tucker 
et al., 1987).  
 
Phenotypically, the human promyelocytic leukaemia PLB-985 cell lines are 
myelomonoblast-like cells, and upon exposure to appropriate inducing agents, they 
can be induced to differentiate into more mature granulocytes or 
monocytes/macrophages depending on the inducing-agent (Shin & Demura, 2012). 
Chemical agents, such as dimethylsulfoxide (DMSO) (Shin & Demura, 2012), 
dimethylformamide (DMF) (Katschinski et al., 1999), dibutyrylcyclic AMP (dbcAMP) 
(Hazan-Eitan et al., 2006) and granulocyte colony-stimulating factor (G-CSF) (Kim & 
83 
 
Seoh, 2015) have been described to induce PLB-985 cell line to differentiate through 
the granulocytic pathway into mature neutrophil-like cells. These cells have also been 
induced to differentiate into monocytes/macrophages after incubation with phorbol 
myristate acetate (PMA) (Perkins et al., 1991), 1,25-dihydroxy vitamin D3 (Perkins et 
al., 1991) and interferon-y (Hazan-Eitan et al., 2006). In the present study, mixture of 
all-trans retinoic acid (ATRA), N, N-dimethylformamide (DMF) and sodium pyruvate 
was used to induce differentiation of PLB-985 cells into mature neutrophil-like 
granulocytes. 
 
Retinoic acid (RA) is one of the most potent differentiation-agents that induces in vitro 
differentiation of leukaemia cell lines. The use of retinoic acid to induce in vitro 
differentiation can be traced back to 1978 when Collins et al., used two isomers of 
retinoic acid; all-trans retinoic acid (ATRA) and 13-cis retinoic acid to induce the 
human promyelocytic leukaemia HL-60 cell line to differentiate into mature neutrophil-
like cells (Dong et al., 2003, Collins et al., 1978). Retinoic acid had been shown to 
induce both morphological and functional differentiation of cultured HL-60 cells, in 
contrast to DMSO which induced only their morphological differentiation (Martin et al., 
1990). Terminal differentiation of leukaemia cell lines induced with ATRA was found 
to be followed by a spontaneous apoptosis (Degos & Wang, 2001). 
 
N, N-dimethylformamide (DMF) is another chemical agent with differentiation and 
anti-tumour activity. DMF and its metabolite N-methylformamide (NMF) are capable 
of inducing in vitro differentiation of leukaemia cell lines into mature phenotypes (van 
Dongen et al., 1989). It has been used to induce erythroleukaemia cells to 
differentiate into erythocyte-like cells (Scher et al., 1973) and has been demonstrated 
to stimulate differentiation of HL-60 into mature granulocytes (Collins et al., 1978).  
Katschinkski et al. (1999) reported induction of PLB-985 cells into granulocytic 
differentiation using dimethylformamide (Katschinski et al., 1999).  
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Sodium pyruvate is a metabolite that serves as an additional carbon or energy source 
and also a free-radical scavenger that eliminates hydrogen peroxide generated in the 
culture media, thereby substantially protecting the cells against reactive oxygen 
intermediates induced toxicity (Giandomenico et al., 1997). As an anti-oxidant, 
pyruvate also stabilizes ATRA by protecting it from being oxidised. It has been 
reported to be effective in protecting the human neuroblastoma cell line SK-N-MC 
against hydrogen peroxide induced apoptosis through inhibition of caspase 3 activity 
(Jagtap et al., 2003). It has also been shown to promote in vitro nuclear maturation of 
bovine oocytes (Geshi et al., 2000). 
 
In this Chapter, PLB-985 cells were cultured in the presence of three differentiation- 
and maturation-inducing agents namely; all trans retinoic acid (ATRA), N, N-
dimethyformamide (DMF) and sodium pyruvate in order to induce their full 
differentiation into mature neutrophil-like cells. 
 
Therefore, the aims of this Chapter were to: 
 
1. Optimise the culture conditions that induce immature promyelocytic leukaemia 
PLB-985 cell lines to terminally-differentiate into mature neutrophil-like 
granulocytes. 
2. Determine the time course of differentiation of PLB-985 cells into mature 
neutrophil-like cells. 
3. Identify whether the terminally-differentiated PLB-985 cells resemble mature 
blood neutrophils phenotypically. 
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3.2 Methods 
 
PLB-985 cells were cultured with a starting density of 2×105/mL. ATRA (1µM), DMF 
(0.5% (v/v)) and sodium pyruvate (1% (v/v)) were added to the media to induce 
differentiation. The initial experiments carried out were to establish a protocol for 
successful induction of differentiation of PLB-985 cells into neutrophil-like 
phenotypes. In preliminary experiments, cells were cultured in unchanged media for 
6-7 days (in control- and differentiation-media) and their growth rate measured by cell 
counts. Subsequently, cells were re-suspended in fresh differentiation media after 
day 2 and 4 of culture, in order to enhance their proliferation, differentiation and 
survival. To determine if the experimental conditions could be further modified for 
maximum differentiation and survival, proinflammatory cytokines, G-CSF or GM-CSF 
and Toll-like receptors (TLRs) agonists (LPS, MALP-2, Pam3CSK4 and R848) were 
also added to the cell cultures during the media changes at days 2 and 4, and their 
effects in stimulating proliferation, differentiation and survival of granulocytes were 
measured. 
 
 
3.3 Results 
 
3.3.1 Growth and differentiation of PLB-985 cells 
 
In initial experiments PLB-985 cells were cultured in the absence and presence of 
differentiating agents (as described in Methods), and total cell counts were measured 
using Multisizer3 cell counter, as well as numbers of differentiated and apoptotic cells 
by microscopy and flow cytometry during culture for up to 6/7 days. The routine media 
for the growth and maintenance of PLB-985 cells is RPMI-1640 medium, 
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supplemented with 10mM L-glutamine, 10% (v/v) foetal calf serum (FCS) and 1% 
(v/v) penicillin/streptomycin (P/S). Initial experiments aimed at inducing differentiation 
used this medium except that it contained only 0.5% (v/v) foetal calf serum, and was 
supplemented with 1µM All-trans retinoic acid (ATRA), 0.5% (v/v) N, N-
dimethylformamide (DMF) and 1% (v/v) sodium pyruvate. The routine medium 
(designated as PLB-985) was therefore used in parallel with this modified 
differentiation medium (designated as dPLB-985) and cells were cultured in both 
media for a period of 7 days. Each day, samples were removed for cell counts, 
number of viable cells and number of differentiated cells measurements.  
 
The modified differentiation medium successfully induced the differentiation of PLB-
985 cells into neutrophil-like phenotypes. However, several experimental conditions 
have been employed to optimise the differentiation efficiency and prolong the survival 
of the differentiated cells, described in the proceeding sections. 
 
 
3.3.1.1 Differentiation conditions 1 
 
The PLB-985 cells cultured under the two conditions (PLB-985 and dPLB-985) both 
showed an exponential growth pattern with a doubling time of approximately 24 h 
(Figure 3.1) during first few days of the culture (days 1-3).  Thereafter, the proliferation 
rate declined as the cells aged in the culture. By day 3, the cell number was lower in 
the dPLB-985 cultures due to the loss of proliferation capacity caused by ATRA 
(Degos & Wang, 2001), DMF (Van Dongen et al., 1989) and sodium pyruvate (Long 
& Halliwell, 2009). The numbers of cells in both PLB-985 and dPLB-985 cultures were 
counted using a Multisizer3 cell counter daily or on selected days during the culture 
period, while the cell morphology was examined by light microscopy after preparation 
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of cytospin slides and Romanowsky staining. These parameters were used to confirm 
proliferation and morphological changes associated with differentiation. However, as 
the cell culture period extended beyond 3 days, the rate of cell proliferation declined 
and this was most marked for the dPLB-985 cells (Figure 3.1). In both cell cultures 
numbers declines by day 6 and 7 (Figure 3.1) 
 
At time points throughout this culture, samples were removed for analysis of cell 
morphology by Romanowsky staining of cytospin slides and light microscopic 
examination to determine cell viability and morphology. Differentiation was initially 
assessed by morphological criteria and compared to the morphology of mature, blood 
neutrophils (Figure 3.2). These cells are characterised by their relatively small cell 
size (~ 8-12 µm diameter) compared to non-differentiated PLB-985 cells, multi-lobular 
nucleus and granulated cytoplasm. These parameters were used to confirm the 
morphological changes associated with differentiation of PLB-985 cells. 
 
PLB-985 cells cultured in non-differentiation medium (PLB-985) had a round, diffuse 
nucleus that occupied a large proportion of the cytoplasm. This nucleus was generally 
rounded in morphology (Figure 3.3A) and no morphological features of differentiation 
were observed at any time points during the 7-day culture. When PLB-985 cells were 
cultured in differentiation medium (dPLB-985), they began to show signs of 
differentiation, such as indentations and convolutions in the nuclear membrane after 
day 2 of differentiation, and by day 5-6, many cells had acquired morphological 
features of a mature neutrophil, such as decreased cell size, segmentation of the 
nuclei into 3-5 lobes, disappearance or decreased appearance of nucleoli and 
granulation of the cytoplasm (Figure 3.3B). However, some cells showed 
morphological features of changes in nuclear morphology, but the nucleus could not 
be termed multi-lobed (Figure 3.3B (i)). Instead, these cells resembled band cells (not 
fully-matured neutrophils) and hence in this thesis, such cells are defined as “partially 
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differentiated”. Some cells showed clearly-defined multi-lobed nuclei (Figure 3.3B 
(ii)), and hence these were defined as “differentiated cells”. Some cells, however, 
showed few, if any signs of differentiation as assessed by nuclear morphology (Figure 
3.3B (iii)) and were termed “non-differentiated cells”.  
 
These morphological changes that indicate differentiation towards neutrophils had 
occurred were evident from day 3 in culture and by day 4, >70% of the cells (Table 
3.1) showed signs of differentiation, with ~ 60% having a fully-defined multi-lobed 
nucleus that is a defining characteristic of mature neutrophil-like cells. After day 5, a 
mixture of different cell populations was observed, resulting from various stages of 
differentiation undergone by the cells (Figure 3.3B). These include undifferentiated 
cells (6%), band cells (14%), differentiated cells (60%) and apoptotic/dead cells 
(20%). 
 
However, after day 4 of culture in dPLB-985, there were cells clearly identified in 
cytoslide spins that showed signs of apoptosis (Figure 3.3B (iv)), and these increased 
in number over the following days (Table 3.1). These were defined as small, round 
cells with a highly-condensed, round nucleus. Few, if any apoptotic cells were 
observed in the undifferentiated cultures at any time points. This suggested that after 
the PLB-985 cells had differentiated into mature neutrophils, they underwent 
apoptosis. This rapid transition into apoptosis is a characteristic of mature blood 
neutrophils, which after isolation and culture in vitro for 18-24 h (in the absence of any 
anti-apoptotic agent), approximately 60-70% will become apoptotic (Derouet et al., 
2004). Therefore, this culture and differentiation protocol was modified with the aims 
of trying to (a) increase the percentage of fully-differentiated cells and (b) to decrease 
the rate of apoptosis once the cells had differentiated into mature cells. 
Representative cytospin slide images of dPLB-985 cells cultured in differentiation 
condition 1 for each day over 7 days period are shown in Figure 3.4. 
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Figure 3.1 Growth of PLB-985 cells in the absence and presence of 
differentiation-inducing agents. Exponentially growing PLB-985 cells at a starting 
density of 2×105/mL were cultured in separate flasks designated PLB-985 (non-
differentiating) and dPLB-985 (differentiation-induced) cells. The media was kept 
unchanged for 7 days and cell number counted on days 0, 3, 5, 6 and 7 using a 
Multisizer 3 coulter counter, following 1:1000 dilution with Isoton II.  The cells had a 
doubling time of 24 h initially, but after day 3, the growth rate decreased, owing to 
neutrients depletion and perhaps death by apoptosis, particularly in dPLB culture. 
Data are expressed as mean of total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 
(paired, two-tailed student’s t-test). 
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Figure 3.2 Morphology of blood neutrophils and dPLB-985 cells. Freshly-isolated 
blood neutrophils (A) and neutrophil-like differentiated PLB-985 cells at day 5 of 
culture (B) were prepared, cytocentrifuged, stained with rapid Romanowsky stain and 
viewed under a light microscope. The prominent multi-lobed nuclei and granulated 
cytoplasms were evident in both cell types. 
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Figure 3.3 Morphological changes during differentiation of PLB-985 cells. PLB-
985 cells were cultured in the absence (A) and presence (B) of differentiation inducing 
agents. Cells samples were removed on day 5, cytospin slides prepared, stained with 
Romanowsky stain and viewed under the light microscope. In B, insets show (i) a 
partially differentiated (band) cell, (ii) fully differentiated cells, (iii) non-differentiated 
cells and (iv) apoptotic/dead cells. 
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Table 3.1 Percent proportions of dPLB-985 cells after day 3-6 of induction. 
Cells Differentiation Status Day 3 Day 5 Day 6 
Differentiated (%) 44.41 ± 4.07 65.89 ± 5.17 59.33 ± 4.39 
Partially differentiated (%) 24.74 ± 4.32 13.35 ± 2.04 10.94 ± 4.24 
Non-differentiated (%) 31.44 ± 3.54 8.41 ± 4.16 6.21 ± 3.36 
Apoptotic (%) 4.41 ± 1.36 12.35 ± 3.61 23.52 ± 4.43 
Total 100 100 100 
 
Proportions of differentiation of PLB-985 cells counted manually by morphological 
examination of cells from representative cytospin slides viewed under the light 
microscope, after day 3 of culture when cells began to exhibit vividly clear features. 
Counts expressed as percentages of the total number of cells (± SD, n=3).  
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Figure 3.4 Representative cytospin slides images of dPLB-985 cells morphology. dPLB-985 cells were cultured in the presence of 
differentiation-inducing agents for 7 days and cell samples were removed, cytospin slides prepared, stained with Romanowsky stain and 
viewed under the light microscope daily. Typical large, non-lobular nuclei, frequent nucleoli and agranular cytoplasm were evident on 
day 0-1. After day 2 of induction, cells began to show signs of differentiation, such as indentations in the nucleus, decrease in number 
of nucleoli, and appearance of granules in the cytoplasm. By days 4-7, the cells had acquired multi-lobular nuclear morphology. Some 
cells exhibiting apoptotic morphologies were also evident from day 4.
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3.3.1.2 Differentiation conditions 2 
 
The previous differentiation conditions successfully induced differentiation of PLB-
985 cells into mature neutrophil like phenotypes, but improvements in these culture 
conditions were then explored in order to increase the efficiency of differentiation of 
PLB-985 cells and to enhance the survival of the differentiated cells. To achieve these 
goals, several variations in the above differentiation protocol were explored. First, the 
differentiation culture medium was changed twice (at day 2 and 4) during the 7-day 
culture period. The rationale behind this approach was that, in the absence of a 
medium change over 7 days of culture, nutrient depletion and changes in pH of the 
media, as well as accumulation of excretory waste products, may contribute to 
decreased growth, impairment of differentiation and acceleration of apoptosis. 
 
3.3.1.2.1 Effect of media changes on differentiation and viability of dPLB-985 
cells 
 
The effects of differentiation media changes on days 2 and 4 of the culture period, on 
the percentage of differentiated PLB-985 cells are shown in Figure 3.5A. As can be 
seen, changing the culture medium in this way resulted in a significantly increased 
percentage of differentiated cells, compared to cells that were cultured for 7 days 
continuously in unchanged medium. In these experiments, cell viability was also 
measured using the Viacount assay (see Chapter 2, methods), which measures 
changes in the permeability of the plasma membrane. In the absence of changes in 
the culture medium at days 2 and 4, the viability of the differentiated cells, which was 
close to 100% over the first two days of culture, gradually decreased to around 20% 
by day 5 and then remained at around this level up to day 7 (Figure 3.5B). However, 
in differentiated cultures in which the media was replaced with fresh media at days 2 
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and 4, there was a statistically-significant (p<0.01, n=3) increase in the viability from 
day 4 onwards, compared to cells without media changes. By day 6, ~60% of the cells 
were viable after the media changes, whereas only ~20% were viable in the absence 
of these media changes. 
  
Superimposed plots for percentages of differentiation and viability of the cells cultured 
under these two different conditions is shown in Figure 3.6. Representative cytospin 
slide images showing these changes in morphology from day 3-6 in cultures without 
the media changes (NMC) and with the media changes at days 2 and 4 (MC- D2, D4) 
are shown in Figure 3.7. 
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Figure 3.5 Effect of media changes on differentiation and viability of dPLB-985 
cells. PLB-985 cells were cultured in differentiation media for 7 days, without (NMC) 
and with media changes on days 2 and 4 (MC). The number of differentiated cells 
was counted manually from representative cytospin slides viewed under the light 
microscope and the viability was measured using the viaCount assay on the flow 
cytometer. (A) Shows the number of differentiated PLB-985 cells and (B) shows 
dPLB-985 cells viability. Arrows indicate times of media changes and data are 
expressed as percentage of total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, 
two-tailed student’s t-test). 
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Figure 3.6 Superimposed plots of differentiation versus viability of dPLB-985 
cells.  PLB-985 cells were cultured in differentiation media for 7 days, without (A) and 
with (B) media changes on days 2 and 4. The number of differentiated cells was 
counted manually from representative cytospin slides viewed under the light 
microscope and the viability was measured using the viaCount assay on the flow 
cytometer. Arrows indicate times of media changes and data was expressed as 
percentage of total cells. Most of the differentiated cells in (A) died after day 4 of 
culture due to spontaneous apoptosis. 
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Figure 3.7 Representative cytospin slides images of dPLB-985 cells cultured without and with media changes. PLB-985 cells 
were cultured in differentiation media for 6 days, without and with media changes on days 2 and 4. Cells samples were removed on days 
3-6, cytospin slides prepared, stained with Romanowsky stain and viewed under the light microscope. Cells in upper panel (NMC) were 
cultured in unchanged differentiation media throughout the 6 days period, while cells in the lower panel (MC- D2, D4) were passaged 
and re-incubated in fresh differentiation media on days 2 and 4 of culture.
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3.3.1.3 Differentiation conditions 3 
 
Another set of experiments was then performed using the improved differentiation 
conditions described above (changing the medium at days 2 and 4), but 
supplementing the differentiation media with agents known to promote granulopoiesis 
and/or delay apoptosis in mature blood neutrophils. Hence, the pro-inflammatory 
cytokines and granulocyte maturation agents, G-CSF and GM-CSF (Parker et al., 
2005, Biethahn et al., 1999, Edwards et al., 1989) were added to the differentiation 
culture following media changes, to test their effects on differentiation and viability of 
the differentiated PLB-985 cells.  
 
3.3.1.3.1 Effects of G-CSF and GM-CSF on differentiation and viability of dPLB-
985 cells 
 
The cytokines G-CSF or GM-CSF, were added to the differentiating PLB-985 cells at 
the time of media replacements on days 2 and 4 of culture. The number of 
differentiated cells was counted manually from representative cytospin slides viewed 
under a light microscope, while the viability was measured using viaCount assay on 
the flow cytometer. As shown in Figure 3.8, these two cytokines further increased the 
number of differentiated cells, and also prolonged their survival period (Figure 3.9). 
By days 5, 6 and 7, G-CSF significantly (p≤0.05, n=3) increased the proportion of 
differentiated cells from 70.5% ± 0.38, 67.8% ± 0.88 and 59.9% ± 2.49 (with media 
replacements only) to 79.4% ± 1.87, 73.7% ± 1.14 and 65.6% ± 0.79 respectively 
(Figure 3.8A). GM-CSF also significantly increased (p≤0.05, n=3) the proportion of 
differentiated cells to 81.7% ± 1.12, 77.4% ± 1.23 and 68.9% ± 2.56, respectively 
(Figure 3.8B). Interestingly, more dramatic effects on improvements in cell viability 
were observed in the presence of these cytokines. For example, cell viabilities were 
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increased significantly (p≤0.01, n=3) by G-CSF from 60.0% ± 1.59, 41.5% ± 1.19 and 
38.2% ± 0.79 (with media change only) to 81.7% ± 2.38, 71.8% ± 1.02 and 66.8% ± 
0.94 at days 5,6 and 7 respectively (Figure 3.9A). GM-CSF also significantly 
increased viability (p≤0.01, n=3) to 78.7% ± 1.28, 73.9% ± 2.07 and 68.1% ± 4.50 
respectively (Figure 3.9B). 
 
In conclusion, these cytokines significantly enhanced the differentiation of PLB-985 
cells as well as greatly extended the survival of the differentiated cells. The 
relationships between differentiation and cell viability in the presence of G-CSF and 
GM-CSF are shown in Figure 3.10A and B, respectively. Representative cytospin 
slides images of cells incubated with G-CSF or GM-CSF are shown in Figure 3.11. 
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Figure 3.8 Effects of G-CSF and GM-CSF on differentiation of PLB-985 cells. 
Differentiating PLB-985 cells were incubated without (NC) and with addition of 
cytokines G-CSF, 10ng/mL (A) or GM-CSF, 5ng/mL (B) after day 2 and 4 following 
media changes. The number of differentiated cells was counted manually from 
morphological examination of representative cytospin slides viewed under the light 
microscope. Arrows indicate times of media changes and cytokine supplementation 
(after day 2 and 4). Data are expressed as percentages of total cells. (± SEM, n=3), 
* = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 3.9 Effects of G-CSF and GM-CSF on viability of dPLB-985 cells. 
Differentiating PLB-985 cells were incubated without (NC) and with addition of 
cytokines G-CSF, 10ng/mL (A) or GM-CSF, 5ng/mL (B) after day 2 and 4 following 
media changes. The cells viability was measured using the viaCount assay on the 
flow cytometer. Arrows indicate times of media changes and cytokine 
supplementation (after day 2 and 4). Data are expressed as percentages of total cells. 
(± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 3.10 Superimposed plots for effects of cytokines on differentiation and 
viability of dPLB-985 cells. PLB-985 cells were incubated in differentiation media 
for 7 days, with media changes and addition of cytokines G-CSF, 10ng/mL (A) or GM-
CSF, 5ng/mL (B) after day 2 and 4. The number of differentiated cells was counted 
manually from representative cytospin slides viewed under the light microscope and 
the cell viability was measured using the viaCount assay on the flow cytometer. 
Arrows indicate times of media changes and cytokines supplementation (after day 2 
and 4). Approximately 80% of the cells are differentiated and viable up to day 7 in 
both cultures due to apoptosis-delaying effects of the two cytokines. Data are 
expressed as percentages of total cells. 
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Figure 3.11 Representative cytospin slides images of dPLB-985 cells cultured with media changes and cytokines addition. PLB-
985 cells were cultured for 6 days, with differentiation media changes and addition of cytokines G-CSF, 10ng/mL (upper panel) or GM-
CSF, 5ng/mL (lower panel) after day 2 and 4. Cells samples were removed on days 3-6, cytospin slides prepared, stained with 
Romanowsky stain and morphology viewed under the light microscope. 
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3.3.1.4 Differentiation conditions 4 
 
Another set of experiments was again carried out attempting to further improve the 
differentiation conditions, by supplementing the differentiation media with Toll-like 
receptor (TLR) agonists, as some TLR-agonists have also been reported to induce 
myeloid cells differentiation and maturation, as well as promote neutrophil survival by 
delaying apoptosis (Kennedy & Deleo, 2009; Parker et al., 2005; Sabroe et al., 2002). 
The following selected TLR-agonists were therefore added to the differentiation 
culture during the media changes on days 2 and 4: TLR1/2 agonist Pam3CSK4, 
TLR2/6 agonist MALP-2, TLR4/10 agonist LPS and TLR7/8 agonist R-848, to 
determine their effects on differentiation and survival of the differentiated PLB-985 
cells. The concentrations used were those reported to optimally delay neutrophil 
apoptosis. 
 
3.3.1.4.1 Effect of TLR-agonists on differentiation and viability of PLB-985 cells 
 
The TLR-agonists; Pam3CSK4 (200ng/mL), MALP-2 (200ng/mL), LPS (200ng/mL) 
and R-848 (5µM) were added to the differentiating PLB-985 cells at the time of 
differentiation media replacements on days 2 and 4 of culture. The number of 
differentiated cells was counted manually from morphology of representative cytospin 
slides viewed under a light microscope, while the viability was measured using 
viaCount assay on the flow cytometer. As shown in Figure 3.12, LPS and R848 
significantly (p≤0.05 or 0.01, n=3) increased the number of differentiated PLB-985 
cells, compared to the numbers of differentiated cells obtained after media changes 
alone on days 3-6, as well as prolonged the survival of differentiated cells by day 6-7 
(p≤0.01, n=3) (Figure 3.13). MALP-2 and Pam3CSK4, on the other hand, showed no 
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significant effects on differentiation (Figure 3.14) or viability (Figure 3.15) of the 
differentiated PLB-985 cells. 
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Figure 3.12 Effects of LPS and R848 on differentiation of PLB-985 cells. 
Differentiating PLB-985 cells were incubated without (NA) and with addition of TLR-
agonists LPS, 200ng/mL (A) or R-848, 5µM (B) on days 2 and 4 after media changes. 
The number of differentiated cells was counted manually from representative cytospin 
slides viewed under a light microscope. Arrows indicate times of differentiation media 
changes and LPS or R848 addition. Data are expressed as percentages of total cells. 
(± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 3.13 Effects of LPS and R848 on viability of dPLB-985 cells. Differentiating 
PLB-985 cells were incubated without (NA) and with addition of TLR-agonists LPS, 
200ng/mL (A) or R-848, 5µM (B) on days 2 and 4 after media changes. The cell 
viability was measured using the viaCount assay on the flow cytometer. Arrows 
indicate times of media changes and LPS or R848 addition. Data are expressed as 
percentages of total cells. (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed 
student’s t-test).  
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Figure 3.14 Effects of MALP-2 and Pam3CSK4 on differentiation of PLB-985 
cells. Differentiating PLB-985 cells were incubated without (NA) and with addition of 
TLR-agonists MALP-2, 200ng/mL (A) or Pam3CSK4, 5µM (B) on days 2 and 4 after 
media changes. The number of differentiated cells was counted manually from 
representative cytospin slides viewed under a light microscope. Arrows indicate times 
of media changes and MALP-2 or Pam3CSK4 addition. Data are expressed as 
percentages of total cells. (± SEM, n=3). 
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Figure 3.15 Effects of MALP-2 and Pam3CSK4 on viability of dPLB-985 cells. 
Differentiating PLB-985 cells were incubated without (NA) and with addition of TLR-
agonists MALP-2, 200ng/mL (A) or Pam3CSK4, 5µM (B) on days 2 and 4 after media 
changes. The cell viability was measured using the viaCount assay on the flow 
cytometer. Arrows indicate times of media changes and MALP-2 or Pam3CSK4 
addition. Data are expressed as percentages of total cells.  
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Figure 3.16 Flowchart of procedures for optimisation of differentiation of PLB-
985 cells. Exponentially growing PLB-985 cells were initially seeded in differentiation 
medium. The cells were then passaged, re-suspended in fresh differentiation media, 
and supplemented with cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) on days 2 
and 4 of culture. Each day cells were harvested and re-suspended in fresh 
differentiation medium, with and without addition of G-CSF or GM-CSF for 30 min, for 
priming effect before analysis of function. Therefore, up to day 2 in culture, cells will 
only have been exposed to G-CSF or GM-CSF for 30 min (priming effect). From day 
3 onwards, cells were cultured with G-CSF or GM-CSF. This protocol describes the 
experimental conditions for optimal differentiation efficiency and was used in 
subsequent experiments in this thesis, henceforth referred to as the “optimised 
differentiation conditions”. 
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3.4 Discussion and conclusions 
 
The human promyelocytic leukaemia PLB-985 cell line can undergo both granulocyte 
and monocyte/macrophage differentiation in the presence of appropriate inducing 
agents. Phenotypically, these are myelomonoblast-like cells, and upon exposure to 
the appropriate inducing agents, they can be stimulated to differentiate into mature 
granulocytes or monocytes/macrophages (Shin & Demura, 2012). The aims of this 
Chapter were to optimise the culture conditions to induce PLB-985 cells to 
differentiate into mature neutrophil-like granulocytes using ATRA, DMF and sodium 
pyruvate, in order to establish their usefulness as model of neutrophil differentiation.  
 
The assessment of differentiation in this Chapter was mainly based on morphological 
properties. Standard morphologic/staining criteria categorizes myeloid cells as 
immature; comprising blasts, promyelocytes and promonocytes, or as mature; 
comprising myelocytes, metamyelocytes, bands and segmented neutrophils 
(Chomienne et al., 1990). The non-differentiated PLB-985 cells are characterised as 
being at the promyelocytic stage, but the combined effects of ATRA, DMF and sodium 
pyruvate have successfully transformed them along the myeloid lineage into 
myelocytes, metamyelocytes, band neutrophils and lastly, segmented neutrophils, 
the final cells in the myeloid lineage. This pattern of differentiation is analogous to that 
seen in neutrophil differentiation and maturation during granulopoiesis (see Figure 
1.2) (Iwasaki & Akashi, 2007, Lieber et al., 2004).  
 
The differentiated PLB-985 cells exhibited other morphological features of mature 
neutrophils, including reduced cell size, indented, convoluted and segmented nuclei, 
decreased number or absence of nucleoli and granulated cytoplasm (Collins et al., 
1978). After 3-4 days of induction, metamyelocytes and band neutrophils were the 
predominant cells in the culture in differentiation medium, whilst after 5-7 days in 
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culture, segmented neutrophils predominated. In contrast, PLB-985 cells cultured in 
the absence of differentiation-inducing agents remained in their promyelocytic form, 
exhibiting large rounded nuclei containing 2-4 nucleoli each, with a dispersed 
chromatin, agranular cytoplasm and relatively high nuclear/cytoplasmic ratio.  
 
Interestingly, alongside the progressive increase in proportion of cells showing 
mature neutrophil morphology, there was a parallel increase in the proportion of cells 
showing morphological features of apoptosis, such as condensation of chromatin and 
fragmentation of nuclei (Elmore, 2007). Indeed, these apoptotic cells appeared in 
appreciable numbers only, when or after the differentiated PLB-985 cells with mature 
neutrophil morphology predominated in the culture, usually after day 5-7 of culture. 
Apoptosis is a non-pathological, programmed cell death that is constitutively activated 
as neutrophils age in culture in vitro (Edwards et al., 2004). Thus, the differentiated 
PLB-985 cells have acquired one of the most definitive features of mature neutrophils, 
namely rapid progression into apoptosis. These observations indicate that 
differentiated PLB-985 cells may be a good cell line model for the in vitro study of 
neutrophil differentiation and functions, such as the underlying mechanisms of 
neutrophil apoptosis.  
 
The measurement of PLB-985 cells growth rate following induction of differentiation 
demonstrated that differentiation significantly decreased the rate of cell growth due to 
the loss of proliferation capacity caused by ATRA (Degos & Wang, 2001) and DMF 
(van Dongen et al., 1989). Therefore, as the cells began to differentiate, their 
proliferation capacity declined and when they became terminally differentiated, they 
ceased to divide and then underwent spontaneous apoptosis, thus behaving like 
mature neutrophils. Immunohistochemical studies and electron microscopy have 
provided evidence that induction of differentiation in leukaemia cell lines is closely 
associated with inhibition of their proliferation capability (van Dongen et al., 1989). 
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Therefore, the new differentiation protocol described in this Chapter has proved 
effective in stimulating PLB-985 cells to differentiate into mature neutrophil-like 
phenotypes with a typical multi-lobed nucleus and granulated cytoplasm.  
 
The effects of differentiation media changes on days 2 and 4 of culture demonstrated 
that the proportion of differentiated cells increased significantly as a result of fresh 
media replacements during the culture period. Most likely, these media changes 
replenished the nutrient supply to the differentiating cells, maintained the appropriate 
pH and removed the accumulated metabolic waste products. Media changes also 
slightly increased the viability of the differentiated cells. There was however, a drastic 
decrease in the number of viable cells that was evident after day 4 of culture, which 
is likely attributed to the spontaneous apoptosis within around 24 h of differentiation. 
 
Another significant finding in this study was the importance of cytokines G-CSF and 
GM-CSF supplementation in promoting both the efficiency of differentiation and 
extension of viability of the differentiated PLB-985 cells. These observations correlate 
with previous reported studies on the effects of G-CSF and GM-CSF on proliferation, 
differentiation and survival of granulocytes and macrophages (Begley et al., 1987). 
The induction of HL-60 cells to terminally differentiate into mature granulocytes 
through exposure to the two colony-stimulating factors has been reported (Souza et 
al., 1986). G-CSF has been demonstrated to induce the formation of neutrophil-like 
granulocyte colonies in semi-solid agar (Nicola et al., 1983), and to stimulate terminal 
differentiation, as well as inhibit the self-renewal capacity of murine myelomonocytic 
leukaemia cells in vitro (Burgess & Metcalf, 1980). In a similar way, GM-CSF has also 
been reported to promote proliferation and function of myelomonocytic cells, increase 
the number of blood neutrophils by delaying apoptosis and stimulate neutrophil 
functions, such as reactive oxygen production, by priming (Edwards et al., 1989).  
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Mature neutrophil undergoes spontaneous apoptosis and are therefore short-lived 
cells (Edwards, 1994). However, neutrophil apoptosis can be delayed and their 
lifespan considerably extended by exposure to the cytokines, such as GM-CSF, which 
acts by increasing their levels of survival protein Mcl-1 (Moulding et al., 1998). Mcl-1 
is an anti-apoptotic member of Bcl-2 family proteins with a very high turnover rate, 
and whose cellular levels correlate with neutrophil survival status (Moulding et al., 
1998). It has been demonstrated that GM-CSF increases cellular levels of Mcl-1 by 
increasing its stability and decreasing its turnover rate that normally occurs via the 
proteasome (Thomas et al., 2010, Derouet et al., 2004, Edwards et al., 2004). 
 
Selective activation of Toll-like receptors has been reported to promote neutrophil 
survival by delaying constitutive apoptosis (Parker et al., 2005). Among the four TLRs-
agonists added to the differentiation culture in this study, only LPS (TLR-4/10) and 
R848 (TLR-7/8) significantly increased the number of differentiated cells above those 
with no agonist (media changes only). These agents also extended the survival of the 
differentiated cells by day 6-7, but their effects were lower than those of G-CSF and 
GM-CSF. Ligation of TLR 4 to LPS is described as a principal survival signal in 
granulocytes (Sabroe et al., 2002).  
 
In contrast, MALP-2 (TLR-2/6) and Pam3CSK4 (TLR-1/2) did not show any significant 
effects on differentiation or viability of differentiated PLB-985 cells above that obtained 
with media replacements only. TLRs 2, 4 and 6 have been shown to directly regulate 
neutrophil apoptosis with TLR 4 being strongly linked to cell survival than TLR 2 or 
TLR 6 (Kennedy & Deleo, 2009). Recognition of specific molecular patterns in the 
microbial components (PAMPs) by TLRs is an important mechanism by which the 
innate immune system senses pathogen invasion, and the subsequent activation of 
Toll-like receptors induces the expression of specific genes which leads to stimulation 
of innate immunity (Akira & Takeda, 2004).  
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The percent differentiation, appearance of the multi-lobed nucleus and granulation of 
the cytoplasm described in this Chapter, are far better than those reported in 
publications using similar experimental system (Pivot-Pajot et al., 2010, Ashkenazi & 
Marks, 2009, Hazan-Eitan et al., 2006, Hiran et al., 2001, Drayson et al., 2001, Martin 
et al., 1990, Tucker et al., 1987, Souza et al., 1986, Breitman et al., 1980, Collins et 
al., 1978). Furthermore, apart from demonstrating this high efficiency of PLB-985 cell 
differentiation into mature neutrophil-like phenotypes, the optimised procedures used 
in this Chapter have also greatly extended the lifespan of the differentiated PLB-985 
cells. To the best of my knowledge, these culture modifications and the resulted 
enhancement of differentiation and survival of the differentiated cells have not been 
previously reported.  
 
To this end therefore, the new differentiation protocol described in section 2.3 of this 
thesis and the optimisation procedures involving media changes and cytokines G-
CSF or GM-CSF supplementation on days 2 and 4 described in Figure 3.16, were 
considered as the optimised differentiation protocol and used in subsequent 
experiments. Henceforth, referred in this thesis as the “optimised differentiation 
conditions”. 
 
In conclusion, while previous reports have described the human promyelocytic 
leukaemia cell line PLB-985 as having the potential to differentiate into neutrophil-like 
cells under the influence of various chemical agents, the efficiency of differentiation 
reported was very low. Furthermore, the differentiated cells only partly resembled 
mature neutrophils in terms of well-defined polymorphic nucleus. The results of the 
experiments described in this Chapter have confirmed and greatly extended these 
findings, and have also developed a new differentiation protocol and optimisation 
procedures to obtain terminally-differentiated PLB-985 cells that mostly resemble 
mature neutrophils, with prominent segmented, multi-lobular nucleus, granulated 
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cytoplasm and appreciably extended lifespan. Research in the following Chapters 
therefore, aimed to define the molecular properties of these differentiated neutrophil-
like cells. 
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Chapter 4: Effect of differentiation of PLB-985 on cell cycle 
progression and apoptosis  
 
4.1 Introduction 
 
Tissue homeostasis is essential for the proper development of multicellular 
organisms, and it is maintained through a balance between cell proliferation and cell 
death. Unregulated cell proliferation, if not compensated for by an appropriate cell 
death response, may result in pathological conditions, such as neoplasia (Pucci  et 
al., 2000). Apoptosis governs the normal turnover of cells irrespective of their type or 
tissue location, and therefore, in normal development damaged and unwanted 
excessive cells are non-pathologically killed and removed through apoptosis  
(Kennedy & Deleo, 2009).  
 
The cell cycle is a conserved process in multicellular organisms by which cells 
replicate themselves through a set of cyclic events, comprising two major phases; 
DNA synthesis (S) and mitosis (M),  leading to an accurate duplication of the cell 
without genetic abnormalities (MacLachlan et al., 1995). Replication of the genome 
is required for the transmission of genetic information from one cell generation to the 
next and this occurs during the S (synthesis) phase of the cycle. The genome is then 
segregated to two new daughter cells during the M (mitosis) phase (see Figure 1.7). 
There are two preparatory gaps between these two phases; Gap 1 or Growth phase 
1 (G1) separates the M phase from the S phase and Gap 2 or growth phase 2 (G2) 
occurs between the S and M phases. Cells exit the cycle from G1 and enter a dormant 
state G0 when they undergo differentiation. The orderliness and timing of these 
events are checked at the G1/S and G2/M boundaries (see Figure 1.8) (Pucci et al., 
2000; Yen et al., 1985).  
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Apoptosis on the other hand, is an evolutionary conserved, essential physiological 
process of cell death, through which eukaryotes remove defective or unwanted cells, 
without provoking an inflammatory response, and which occurs during normal 
development, turnover and certain pathological conditions (Fotedar et al., 1996, 
Earnshaw, 1995). Indeed, dysregulated apoptosis may lead to disorders, such as 
cancer and autoimmune diseases (Bursch et al., 2000). As described in section 1.6.2, 
apoptosis can be triggered through two pathways: extrinsic and/or intrinsic (see 
Figure 1.5), and the Bcl-2 protein family are the main regulators of the intrinsic 
apoptotic pathway. The Bcl-2 protein family can be divided into two groups namely, 
anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL and Mcl-1) and pro-apoptotic proteins (e.g. 
Bak, Bax and Bid), according to their functional contribution in the regulation of 
apoptosis (see Table 1.1). Mature blood neutrophils express a range of pro-apoptotic 
members of the Bcl-2 family proteins, including Bax and Bak which may partly explain 
their ability to undergo apoptosis spontaneously and rapidly (Edwards et al., 2004, 
Moulding et al., 2001). 
  
Several lines of evidence suggest that cell cycle and apoptosis are interconnected to 
some extent. This is supported by the fact that regulation of cell cycle progression 
may trigger or prevent programmed cell death, depending on the context of the cell. 
Tumour suppressor genes, such as cyclin-dependent kinases (Cdks), c-Myc and the 
dominant oncogenes p53 and RB, are important links between the cell cycle and 
apoptosis. These genes are involved in proliferative pathways and are not part of 
cell’s apoptotic machinery, but there is strong evidence which indicates that they may 
trigger progression into apoptosis (Bursch et al., 2000). Cell cycle arrest and/or DNA 
damage induces apoptosis in tumour cells (reviewed in Evan & Vousden, 2001). 
Furthermore, there are several morphological characteristics that are common to cells 
undergoing mitosis and apoptosis, which may indicate a connection between the two 
processes. Cells become rounded, shrunk, lose substrate attachment, have 
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condensed chromatin and blebs appear on their membrane during both processes 
(Nagata, 2000, Monczak et al., 1997).  
 
Although the cell cycle and apoptosis share many morphological features, critical 
differences exist between them. For example, apoptotic cells exhibit DNA 
degradation, which gives rise to DNA fragments in multiples of 180bp and cross-
linkage of membrane proteins. These processes make the plasma membrane more 
rigid (Nagata, 2000). In addition, apoptotic cells are subsequently phagocytosed by 
macrophages or adjacent endo- or epi-thelial cells (Brenner & Mak, 2009). 
Contrastingly, during mitosis cells exhibit DNA segregation, followed by cytokinesis 
resulting in cell division into two viable and identical daughter cells (Bursch et al., 
2000, Pucci et al., 2000). Hence, there is little or no evidence, to indicate that cell 
cycle and programmed cell death share common molecular mechanisms (Fotedar et 
al., 1996). Circulating blood neutrophils are mature, terminally-differentiated, non-
dividing cells that have lost the ability to undergo the cell cycle or DNA replication and 
die constitutively by apoptosis (Edwards, 1994).  
 
As presented in Chapter 3, differentiation of PLB-985 cells significantly decreases 
their rate of proliferation due to the effects of ATRA and DMF, which inhibit DNA 
replication and cell proliferation following induction of differentiation (Degos & Wang, 
2001; van Dongen et al., 1989). There was also, a progressive increase in the number 
of cells exhibiting apoptotic morphologies, in parallel with an increase in the number 
of cells exhibiting mature neutrophil morphology, especially after day 5 of induction, 
when differentiated cells predominated in the culture. This finding correlated with the 
observation reported by Degos & Wang that leukaemia cell lines induced to 
differentiate terminally to granulocytes in response to ATRA, subsequently underwent 
spontaneous apoptosis (Degos & Wang, 2001).  
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It was therefore necessary to determine the rate of apoptosis of terminally-
differentiated PLB-985 cells and isolated blood neutrophils, as mature neutrophils 
have a very short half-life due to their ability to undergo spontaneous apoptosis 
(Edwards, 1994). Taken altogether, these data suggest a connection between 
differentiation, growth arrest and apoptosis which will be investigated further in this 
Chapter. 
 
The aims of the studies described in this Chapter are therefore to: 
 
1. Measure cell cycle parameters in differentiation-induced and non-induced 
PLB-985 cells and mature blood neutrophils. 
2. Determine the effects of differentiation of PLB-985 cells on apoptosis.  
3. Investigate the relationship between cell cycle progression and 
programmed cell death in differentiated PLB-985 cells. 
4. Determine whether differentiated PLB-985 cells resemble isolated blood 
neutrophils in their cell cycle parameters and expression of proteins that 
regulate apoptosis. 
 
 
4.2 Methods 
 
All methods used in this Chapter are described in detail in Chapter 2. Cell cycle 
progression was analysed using the flow cytometer. For analysis of cell cycle 
parameters, cells were fixed with ethanol, and then stained with propidium iodide, 
which binds DNA and produces fluorescence that is proportional to the DNA 
concentration per cell, and which varies as the cell progresses through the cycle. The 
assay reveals the distribution of viable cells in three major phases of the cell cycle: 
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G1, S and G2. It also allows detection of apoptotic cells in the quiescent phase G0, 
with a decreased DNA content. Flow cytometry was used to analyse apoptosis.  
 
Expression of the Bcl-2 family of apoptotic proteins was determined by western blot 
analysis, performed with a range of human anti-Bcl-2 protein family antibodies. This 
approach was used to detect the expression levels of anti-apoptotic members of the 
Bcl-2 protein family, such as Mcl-1, Bcl-XL and Bcl-2; as well as pro-apoptotic 
members, such as Bax and Bak. Morphological examination of apoptosis in 
differentiated PLB-985 cells and isolated blood neutrophil was performed under a light 
microscope, after preparation of cytospin slides and Romanowsky staining. 
 
 
4.3 Results 
 
4.3.1 Effects of differentiation of PLB-985 cells on cell cycle kinetics 
 
PLB-985 cells were cultured in the absence (PLB-985) and presence (dPLB-985) of 
differentiation-inducing agents, with unchanged media for 6-days period. The cells 
were prepared, stained with propidium iodide and cell cycle kinetics were analysed 
on days 1, 3, 5 and 6 using the flow cytometer. As shown in Figure 4.1, on day 1 most 
of the cells were found accumulated in G1 (PLB: 43.81% ± 3.38%, dPLB: 49.73% ± 
4.14%), followed by G2 (PLB: 27.97% ± 8.48%, dPLB: 26.75% ± 1.30%) phases. 
Differentiation of PLB-985 cells induced cell cycle arrest after 3 days of culture, as 
indicated by increases (p≤0.05, n=3) in the number of cells in G0, suggesting G0 
arrest/apoptosis.  
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In parallel, the numbers of cells in S phase progressively decreased after day 3-6 of 
culture, whereas the percentage of cells in G2 phase increased, suggesting blockage 
of DNA replication and inhibition of normal cell cycle progression. These changes 
paralleled those reported in Chapter 3 and are indicative of cells in differentiation 
medium first undergoing cell cycle arrest as they mature into neutrophils that lack 
proliferative activity, and then subsequently undergoing apoptosis. Representative 
flow cytometer traces are shown in Figures 4.3 and 4.4. Figure 4.3 shows dot plots of 
DNA staining from which the cell cycle parameters (Figure 4.4) were calculated. 
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Figure 4.1 Effect of differentiation of PLB-985 cells on cell cycle parameters. 
Differentiation-induced (dPLB-985) and non-induced (PLB-985) cells were cultured 
for 6 days with unchanged culture media. Cells were prepared, stained with propidium 
iodide and cell cycle kinetics were analysed on days 1, 3, 5 and 6 using the flow 
cytometer. After days 3-6 of culture, there was significant, progressive increase in 
number of cells that accumulated in G0 and decreased number of cells in S and G2 
phases in dPLB-985. Data are expressed as percentages of total cells (± SEM, n=3), 
* = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.2 Proportions of PLB-985 and dPLB-985 cells in the different phases 
of cell cycle. Differentiation-induced (dPLB-985) and non-induced (PLB-985) cells 
were cultured for 6 d with unchanged culture media. Cells were prepared, PI stained 
and cell cycle parameters were analysed on days 1, 3, 5 and 6 using the flow 
cytometer. Most of the cells were in G1 phase but after days 3-6 of culture there was 
a significant increase in the number of cells in G0 and decrease in the number of cells 
in S and G2 phases. These cell cycle parameters were calculated from the DNA 
distribution profiles shown in Figure 4.3. Data are expressed as percentages of total 
cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.3 Representative flow cytometer histogram traces for cell cycle 
progression of PLB-985 and dPLB-985 cells. Cells were cultured for 6 d with 
unchanged culture media. Cells were prepared, stained with propidium iodide and 
cell cycle kinetics were analysed on days 1, 3, 5 and 6 using the flow cytometer. After 
days 3-6 of culture there was increased accumulation of cells in G0 and decreased 
number of cells in S and G2 phases, which were higher in dPLB-985 cells. 
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Figure 4.4 Representative flow cytometer dot plots showing DNA contents of 
PLB-985 and dPLB-985 cells. Cells were cultured for 6 d with unchanged culture 
media. Cells were prepared, stained with propidium iodide and cell cycle parameters 
were analysed on days 1, 3, 5 and 6 using the flow cytometer. After days 3-6 of culture 
there was accumulation of cells with low DNA contents (lower, green dots) indicating 
cells in G0 (apoptosis) and numbers of these cells were higher in dPLB-985 cells. 
 
 
 
 
 
128 
 
4.3.2 Effect of media changes on cell cycle kinetics of dPLB-985 cells 
  
The results in Chapter 3 (Figure 3.16) showed that changing the culture media after 
days 2 and 4 and supplementing the differentiation media with G-CSF and GM-CSF 
improved the efficiency of differentiation, and enhanced the survival of the 
differentiated cells. It was then necessary to determine if these morphological features 
were accompanied by changes in the cell cycle kinetics of these cells. Cells were 
cultured in differentiation media for 6 days, without (NMC) and with media changes 
on day 2 and 4 (MC). Cells were prepared, stained with propidium iodide and cell 
cycle parameters analysed on days 5 and 6 using the flow cytometer.  
 
As shown in Figure 4.5, in culture with media changes (MC) there was decrease in 
the number of cells in G0 and G2 phases, but only G0 reached statistically-significant 
(p≤0.05) levels. In contrast, there were more cells in G1 and S phases in culture with 
differentiation media changes, but only G1 reached significant (p≤0.01) levels. These 
results indicate that media changes decreased the accumulation of cells in G0 and 
G2 (apoptosis) and increased those in G1 and S (enhanced differentiation and 
survival), as the cells aged in culture. Representative flow cytometer traces for cells 
cycle stages histogram and corresponding dot plots of DNA staining are shown in 
Figures 4.6. 
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Figure 4.5 Effect of differentiation media changes on cell cycle kinetics of 
dPLB-985 cells. Differentiating PLB-985 cells were cultured for 6 d without (NMC) 
and with (MC) differentiation media changes on days 2 and 4. Cells were prepared, 
stained with propidium iodide and cell cycle parameters were analysed on days 5 and 
6 using the flow cytometer. Cells cultured with media changes (MC) had fewer 
number of cells in G0 and G2 phases, as well as increased number of cells in G1 
phase. These cell cycle parameters were calculated from the DNA distribution profiles 
shown in Figure 4.6A. Data are expressed as percentages of total cells (± SEM, n=3), 
* = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.6 Representative flow cytometer traces of cell cycle parameters of 
dPLB-985 cells cultured without and with media changes. Differentiating PLB-
985 cells cultured for 6 d without (NMC) and with (MC) media changes were stained 
with propidium iodide and cell cycle parameters were analysed on days 5 and 6 using 
the flow cytometer. Cells cultured with media changes (MC) had fewer number of 
cells with low DNA contents (G0 phase, lower dots). (A) Histogram plot of DNA 
distribution profiles (B) Dots plots of DNA contents. 
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4.3.3 Effect of G-CSF and GM-CSF on cell cycle parameters of dPLB-985 cells 
  
Differentiating PLB-985 cells cultured for 6 days were incubated without (NC) and 
with cytokines, G-CSF (10ng/mL) or GM-CSF (5ng/mL) after media changes on days 
2 and 4. The cells were prepared, stained with propidium iodide and cell cycle 
parameters were analysed on days 1, 3, 5 and 6 using the flow cytometer. Figure 4.7 
shows the cell cycle parameters under these conditions. Most of the cells were 
accumulated in G1 by day 1 (NC: 67.92% ± 3.21%, GC: 63.80% ± 0.22% and GM: 
74.34 ± 0.61%). After days 3-6, there was significant increase (p≤0.05, n=3) in the 
cells in G0.  
 
Incubation of dPLB-985 cells with G-CSF or GM-CSF during the differentiation media 
changes on days 2 and 4 of culture increased the number of cells that accumulated 
in G1 phase, as well as decreases cells in S and G2 phases. These differences were 
significant (p≤0.05 or 0.01) from day 3 onwards (Figures 4.7 and 4.8). This suggests 
that both G-CSF and GM-CSF delay cell cycle arrest and progression into apoptosis, 
as well as considerably prolong the survival of differentiated cells. Representative 
flow cytometer traces of dot blots for DNA staining and corresponding traces of 
histogram for cell cycle stages are shown in Figures 4.9 and 4.10, respectively. 
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Figure 4.7 Effect of G-CSF and GM-CSF on cell cycle parameters of dPLB-985 
cells. Differentiating PLB-985 cells were incubated for up to 6 days in the absence 
(NC) and presence of cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) after 
differentiation media changes on days 2 and 4. Cells were stained with propidium 
iodide and cell cycle parameters were analysed on days 1, 3, 5 and 6 using the flow 
cytometer. After day 3-6 of culture, there were significant increases in the number of 
cells accumulated in G0 phase and a decrease in the number of cells in S phase. 
These cell cycle parameters were calculated from the DNA distribution profiles shown 
in Figure 4.9. Data are expressed as percentages of total cells (± SEM, n=3), * = 
p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.8 Proportions of dPLB-985 cells in the cell cycle phases after cytokine 
supplementation. Differentiating PLB-985 cells were incubated for 6 days in the 
absence (NC) and presence of cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) 
after media changes on days 2 and 4. Cells were stained with propidium iodide and 
cell cycle kinetics were analysed on days 1, 3, 5 and 6 using the flow cytometer. Most 
of the cells were initially in G1 phase but after days 3-6 of culture, there was a 
significant increase in number of cells in G0 phase and decrease in S and G2 phases. 
These cell cycle parameters were calculated from the DNA distribution profiles shown 
in Figure 4.9. Data are expressed as percentages of total cells (± SEM, n=3), * = 
p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.9 Representative flow cytometer histogram plots of cell cycle 
parameters of dPLB-985 cells cultured with cytokine supplementation. dPLB-
985 cells were incubated for 6 days in the absence (NC) and presence of cytokines 
G-CSF (10ng/mL) or GM-CSF (5ng/mL) after media changes on days 2 and 4. Cells 
were stained with propidium iodide and cell cycle parameters were analysed on days 
1, 3, 5 and 6 using the flow cytometer. Most of the cells were initially in G1 phase but 
after days 3-6 of culture, there was an increase of cells in G0 phase (low DNA 
contents) and decrease in S and G2 phases. 
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Figure 4.10 Representative flow cytometer dot plots of cell cycle parameters of 
dPLB-985 cells cultured with cytokine supplementation. dPLB-985 cells were 
incubated for 6 days in the absence (NC) and presence of cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) after media changes on days 2 and 4. Cells were 
stained with propidium iodide and cell cycle parameters were analysed on days 1, 3, 
5 and 6 using the flow cytometer. After days 3-6 of culture there was an increase in 
number of cells in G0 (lower, green dots) indicating apoptotic cells. The number of 
which was higher after they had differentiated during culture. 
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4.3.4. Neutrophil cell cycle parameters 
  
Although circulating blood neutrophils are mature, terminally-differentiated, non-
dividing cells that have lost the ability to undergo cell cycle or DNA replication 
(Edwards, 1994), it was necessary to determine the cell cycle distribution patterns 
among live and apoptotic (aged) blood neutrophils, to compare with the neutrophil-
like differentiated PLB-985 cells. Freshly isolated neutrophils (0 h) and those 
incubated with human AB serum overnight (20 h) were therefore prepared, stained 
with propidium iodide and cell cycle progression analysed using the flow cytometer.  
 
As shown in Figures 4.11-12, in fresh neutrophils, most of the cells were initially 
accumulated in G1 phase: (70.89% ± 13.05%) with almost none in G0 (5.01% ± 
2.52%). An insignificant number of cells were however, observed in S (4.50% ± 
1.14%) and G2 (1.81% ± 0.42%) phases. Following 20 h incubation in culture, a 
significant number (p≤0.05) of cells had accumulated in G0 (25.30% ± 2.69%), 
indicating the development of apoptosis and death. The few cells that were observed 
in S and G2 phases also decreased significantly: S (2.59% ± 0.46%), G2 (1.51% ± 
0.71%). These distribution patterns parallel those of differentiated PLB-985 cells at 
day 6 (Figure 4.11). These observations confirm the similarity between differentiated 
PLB-985 cells and mature blood neutrophils in regard to their DNA staining and cell 
cycle parameters. Representative flow cytometer traces of dot blots for DNA staining 
and histograms of DNA distribution profiles are shown in Figure 4.12. 
 
 
 
 
137 
 
 
 
Figure 4.11 Distribution of cell cycle parameters in neutrophils and dPLB-985 
cells. Freshly-isolated neutrophils (0 h) and those incubated overnight (20 h) with 
human AB serum (A) as well as non-differentiated (PLB-985) and differentiated 
(dPLB-985) cells at d 6 (B) were prepared, stained with propidium iodide and cell 
cycle parameters were analysed using the flow cytometer. Fresh neutrophils and 
PLB-985 cells were accumulated in G1, whereas aged (apoptotic) neutrophils (20 h) 
and dPLB-985 (day 6) both showed significant increase in G0 phase (low DNA, 
apoptosis) and decrease in S and G2 phases (blockage of DNA replication and 
inhibition of proliferation). These cell cycle parameters were calculated from the DNA 
distribution profiles shown in Figure 4.12. Data are expressed as percentages of total 
cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.12 Representative flow cytometer traces of cell cycle parameters in 
neutrophils and dPLB-985 cells. Freshly-isolated neutrophils (0 h) and those 
incubated overnight (20 h) with human AB serum, as well as non-differentiated (PLB-
985) and differentiated (dPLB-985) cells at day 6 were prepared, stained with 
propidium iodide and cell cycle parameters were analysed using the flow cytometer. 
(A) Flow cytometer histogram traces of DNA distribution profiles, showing 
accumulation of cells in G0 phases in aged neutrophils (20 h) and dPLB-985 cells. 
(B) Dot plots of DNA staining, showing cells with low DNA contents in G0 (lower, 
green dots) in aged neutrophils (20 h) and dPLB-985 cells. 
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4.3.5 Apoptosis of neutrophils and differentiated PLB-985 cells 
 
Mature blood neutrophils are short-lived cells which rapidly and constitutively die by 
apoptosis (Edwards, 1994). To assess this, isolated blood neutrophils from healthy 
adult donors were incubated for 20 h with 10% human AB serum, in the absence and 
presence of cytokine GM-CSF (5ng/mL). Cells were then stained with Annexin V/PI 
and the percent apoptosis analysed using the flow cytometer.  
 
Figure 4.12 shows the percent apoptosis in neutrophils as 73% ± 3.17% and 43% ± 
2.90% in the absence and presence of GM-CSF respectively. Incubation of human 
neutrophils with GM-CSF significantly decreased the percent apoptosis after 20 h 
incubation, as detected by Annexin V staining (Figures 4.13 and 4.14). Levels of 
apoptosis were also confirmed by morphological examination of stained cytospin 
slides, prepared from fresh and aged neutrophils, viewed under a light microscope 
(Figure 4.15). 
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Figure 4.13 Percent neutrophil apoptosis after overnight incubation. Isolated 
blood neutrophils from healthy donors were incubated with 10% human AB serum for 
20 h, in the absence (NC) and presence of the cytokine GM-CSF (5ng/mL). Cells 
were stained with Annexin V/PI, and apoptosis was analysed using the flow 
cytometer. Neutrophils displayed high levels of spontaneous apoptosis which was 
significantly decreased (p≤0.01) following incubation with GM-CSF. These apoptosis 
parameters were calculated from DNA staining profiles of Annexin V and PI shown in 
Figure 4.14. Data are expressed as percentages of total cells (± SEM, n=3), ** = 
p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.14 Representative flow cytometer traces of neutrophil apoptosis after 
overnight incubation. Isolated blood neutrophils from healthy donors were 
incubated with 10% human AB serum for 20 h, in the absence (NC) and presence of 
the cytokine GM-CSF (5ng/mL). Cells were stained with Annexin V/PI, and apoptosis 
was analysed using the flow cytometer. The dot plots showed distribution of 
neutrophils as live (lower left quadrant), early apoptotic (lower right quadrant) and late 
apoptotic (upper right quadrant). Cells incubated with GM-CSF showed high cell 
proportion in the live quadrant and low proportion of cells in the apoptosis quadrant. 
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Figure 4.15 Morphology of viable and apoptotic neutrophils and dPLB-985 cells. 
Cytospin slides were prepared from neutrophils and differentiated PLB-985, stained 
with Romanowsky stain and viewed under a light microscope. (A) Freshly-isolated (0 
h) and apoptotic (20 h) neutrophils. (B) Viable dPLB-985 cells (at day 6, cultured with 
GM-CSF as described in Figure 3.16) and apoptotic dPLB-985 cells (at day 6, 
cultured without cytokine). Both viable neutrophils and dPLB-985 cells exhibited 
indented, convoluted, and segmented nuclei, decreased nucleoli and granulated 
cytoplasm, whilst both apoptotic neutrophils and dPLB-985 cells appeared smaller 
with dense cytoplasm, condensed chromatin and had round compact nuclei 
(especially insets at high magnifications). Also, GM-CSF delayed apoptosis of the 
differentiated PLB-985 cells. 
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4.3.6 Effect of differentiation of PLB-985 cells on the expression of Bcl-2 family 
proteins 
 
Human neutrophils do not express the anti-apoptotic proteins Bcl-2 or Bcl-XL, but 
express Mcl-1, and levels of this protein correlate with apoptosis: viable cells have 
high Mcl-1 levels, whereas Mcl-1 levels are low in apoptotic cells (Derouet et al., 2004, 
Edwards et al., 2004). It was therefore important to examine the expression levels of 
these proteins in PLB-985 cells during differentiation into neutrophil-like cells and 
during apoptosis of the differentiated cells. Hence, protein extracts were prepared 
from PLB-985 and dPLB-985 cells cultured with media changes on days 2 and 4. 
Western blot analysis was performed with a range of human anti-Bcl-2 protein family 
antibodies, to detect the expression levels of anti-apoptotic members of Bcl-2 protein 
family, Mcl-1, Bcl-XL and Bcl-2, as well as pro-apoptotic members, Bax and Bak. 
 
4.3.6.1 Expression of anti-apoptotic Bcl-2 proteins family in PLB-985 cells 
  
The expression of anti-apoptotic Bcl-2 family proteins, Mcl-1 and Bcl-XL were 
measured in PLB-985 cells cultures that were incubated in the absence (PLB-985) 
and presence (dPLB-985) of differentiation-inducing agents. Figure 4.16 shows the 
relative levels of expression of Mcl-1 and Bcl-XL in these cells with day 1 level taken 
as 100%. Levels of Mcl-1 in PLB-985 cells (non-differentiated) decreased after day 3 
in culture but then increased up to day 6. In contrast, Mcl-1 levels increased 
significantly after day 1 in differentiation culture (dPLB-985) but the levels decreased 
markedly and significantly by day 6, when there were significant numbers of apoptotic 
cells in these cultures (Figure 4.16). Similar changes in levels of expression of Bcl-XL 
protein were observed during culture, notably a marked decrease in the levels of this 
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protein as the PLB-985 cells differentiated into mature neutrophil-like cells and then 
underwent apoptosis by day 6.   
 
Figure 4.17 showed similar patterns of expression levels for Bcl-2 protein in PLB-985 
(non-differentiated) cells, which remained high over the culture period (D3: 52.12 ± 
7.50, D5: 73.63 ± 5.92 and D6: 95.04 ± 6.10). However, changes in the level of 
expression of this protein were more dramatic in differentiating cells, while Bcl-2 
protein was detected after day 1 in differentiation culture, it had decreased 
significantly from day 0 values. Also, from day 3 onwards, this protein was not 
detected. Thus, as PLB-985 cells differentiated into mature neutrophil-like cells, 
expression levels of this protein rapidly declined, which is in line with the observation 
that mature human neutrophils do not express Bcl-2 protein (Cross et al., 2005, 
Moulding et al., 1998). 
 
4.3.6.2 Expression of pro-apoptotic Bcl-2 proteins family in PLB-985 cells 
  
The expression levels of pro-apoptotic Bcl-2 proteins, Bax and Bak are shown in 
Figure 4.18. Bax and Bak proteins were expressed highly in both PLB-985 and dPLB-
985 cells and their expression levels in both cultures changed very little over the 6-
day period.  Again, this is in line with observations from human neutrophils in which 
levels of these proteins are largely unaltered in either viable or apoptotic cells 
(Edwards et al., 2004, Moulding et al., 2001). 
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Figure 4.16 Effect of differentiation of PLB-985 cells on expression of Mcl-1 and 
Bcl-XL proteins. Non-induced (PLB-985) and differentiation-induced (dPLB-985) 
cells were cultured for 6 d in unchanged media. Cells lysates were prepared after 
days 1, 3, 5, and 6 of culture and probed for Mcl-1, Bcl-XL and Actin proteins by 
western blotting. (A) Western blots showing Mcl-1(40KDa), Bcl-XL (30KDa) and Actin 
(42KDa) expression, representing three separate experiments. (B) Densitometric 
analysis of Mcl-1 and Bcl-XL levels (normalised to the Actin signal which was the 
loading control). Data are expressed as percentages of day 1 values that were taken 
as 100% (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (two-tailed student’s t-test). 
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Figure 4.17 Effect of differentiation of PLB-985 cells on expression of Bcl-2 
protein. Non-differentiating (PLB-985) and differentiation-induced (dPLB-985) cells 
were cultured for 6 days in unchanged media. Cells lysates were prepared after days 
1, 3, 5, and 6 of culture and probed for Bcl-2 and Actin proteins by western blotting. 
(A) Western blots showing Bcl-2 (26KDa) and Actin (42KDa) expression, representing 
three separate experiments. (B) Densitometric analysis of Bcl-2 levels (normalised to 
the Actin signal which was the loading control). Bcl-2 expression was lost in dPLB-
985 cells by day 3 following their differentiation into neutrophil-like cells, as blood 
neutrophils do not express this protein (± SEM, n=3). 
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Figure 4.18 Effect of differentiation of PLB-985 cells on expression of Bak and 
Bax proteins. Non-induced (PLB-985) and differentiation-induced (dPLB-985) cells 
were cultured for 6 d in unchanged media. Cells lysates were prepared after days 1, 
3, 5, and 6 of culture and probed for Bak, Bax and Actin proteins by western blotting. 
(A) Western blots showing Bak (25KDa), Bax (20KDa) and Actin (42KDa) expression, 
representing three separate experiments. (B) Densitometric analysis of Bak and Bax 
levels (normalised to the Actin signal which was the loading control). Data are 
expressed as percentages of day 1 values that were taken as 100% (± SEM, n=3). 
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4.3.7 Effects of media changes and GM-CSF on the expression of Bcl-2 proteins  
 
In line with the previous finding that Mcl-1 and Bcl-XL proteins levels correlated with 
differentiation and viability of the differentiated PLB-985 cells, it was then necessary 
to determine if supplementation of media changes with cytokine GM-CSF, which 
increased the differentiation levels and delayed apoptosis of the differentiated PLB-
985 cells, affected expression of these proteins. GM-CSF is known to enhance the 
survival of mature blood neutrophils by stabilising the level of Mcl-1 protein (Edwards 
et al., 2004, Moulding et al., 1998). Protein lysates were prepared from PLB-985 and 
dPLB-985 cells cultured without (NC) and with cytokine GM-CSF (5ng/mL) added 
after media changes on days 2 and 4. Western blot analysis was performed to detect 
the expression levels of the anti-apoptotic members of Bcl-2 protein family, Mcl-1, 
Bcl-XL and Bcl-2, as well as the pro-apoptotic members, Bax and Bak. 
 
4.3.7.1 Expression of anti-apoptotic Bcl-2 proteins family 
  
Figure 4.19 showed expression of Mcl-1 and Bcl-XL proteins following 
supplementation of media changes with GM-CSF. Supplementing the media changes 
with GM-CSF maintained the expression of both Mcl-1 and Bcl-XL up to day 4 (Figure 
4.19), above the levels measured in the absence of GM-CSF (Figure 4.16), and levels 
of both these proteins were still detectable after days 5 and 6 in the differentiated 
PLB-985 cells, albeit at decreased levels compared to day 1. These observations are 
in line with measurements of cell viability and apoptosis in Chapter 3 of this thesis: 
there was decreased apoptosis in differentiated PLB-985 cells following media 
changes (Figure 3.5B) and GM-CSF supplementation (Figure 3.9). Again, Bcl-2 
protein expression was not detected despite supplementation of media changes with 
GM-CSF addition (data not shown).         
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4.3.7.2 Expression of pro-apoptotic Bcl-2 proteins family 
  
As shown in Figure 4.20, there were no significant changes in the expression levels 
of pro-apoptotic proteins Bax and Bak, in differentiation cultures with GM-CSF 
supplementation after media changes. Similarly, Bak and Bax expression levels in 
both cultures changed very little over 6 days period, despite supplementation of 
differentiation media changes with GM-CSF. This is also in line with observation that 
Bax expression in neutrophils remains unchanged after treatment with apoptosis 
delaying agents, such as GM-CSF, IL-8, LPS or butyrate (Moulding et al., 1998). 
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Figure 4.19 Effects of media changes and GM-CSF supplementation on 
expression of Mcl-1 and Bcl-XL in dPLB-985 cells. Non-differentiated (PLB-985) 
and differentiation-induced (dPLB-985) cells were incubated for 6 days with GM-CSF 
(5ng/mL) addition after differentiation media changes on days 2 and 4. Cell lysates 
were prepared and probed for Mcl-1, Bcl-XL and Actin proteins by western blotting (A) 
Western blots showing Mcl-1(40KDa), Bcl-XL (30KDa) and Actin (42KDa) expression, 
representing three separate experiments. (B) Densitometric analysis of Mcl-1 and 
Bcl-XL levels (normalised to the Actin signal which was the loading control). Data are 
expressed as percentages of day 1 values that were taken as 100% (± SEM, n=3), * 
= p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 4.20 Effects of media changes and GM-CSF supplementation on 
expression of Bak and Bax in dPLB-985 cells. Non-differentiated (PLB-985) and 
differentiation-induced (dPLB-985) cells were incubated for 6 days with GM-CSF 
(5ng/mL) addition after differentiation media changes on days 2 and 4. Cell lysates 
were prepared and probed for Bak, Bax and Actin proteins by western blots. (A) 
Western blotting showing Bak (25KDa), Bax (20KDa) and Actin (42KDa) expression, 
representing three separate experiments. (B) Densitometric analysis of Bak and Bax 
levels (normalised to the Actin signal which was the loading control). Data are 
expressed as percentages of day 1 values that were taken as 100% (± SEM, n=3). 
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4.4 Discussion and conclusions 
 
When extracellular signals trigger a cell to commit to undergo differentiation, the cell 
must recognise (via receptors) and process the signal, then activate specific 
transcription factors that result in changes (increases or decreases) in the expression 
of specific genes, which change the molecular and phenotypic properties of the cell. 
These changes often limit cell proliferation and the terminally-differentiated cells, in 
this case neutrophils, may then begin to die by apoptosis (Kim & Seoh, 2015). The 
fact that the same initial signal can give rise to these different cellular changes, 
suggests that these different events are interconnected, but how they are regulated 
remains to be elucidated (Yen et al., 1985).  
 
This Chapter has measured the changes in cell cycle parameters, apoptosis and 
expression of key proteins that regulate apoptosis, as PLB-985 cells differentiate into 
neutrophil-like cells and then constitutively undergo apoptosis. It has also measured 
these changes when cells were incubated under conditions (described in Chapter 3), 
that optimised both their differentiation efficiency and survival period by delaying 
apoptosis. These optimised conditions involved both changing the differentiation 
medium and supplementation with cytokines, such as G-CSF and GM-CSF (Figure 
3.16). Although data measuring the effects of G-CSF were also obtained in parallel 
with GM-CSF, some of the G-CSF data were not presented in this Chapter, because 
they were essentially identical to those obtained with GM-CSF.  
 
The relative distribution of cells in G1, S and G2 phases of the cell cycle, as well as 
in G0, has been analysed after staining permeabilised, fixed cells with propidium 
iodide. The data presented show that induction of differentiation of PLB-985 cells 
initially triggers G1 arrest with little or no cells in G0, and subsequently after days 3-
6 of culture, there was a significantly increased number of cells in G0 phase and fewer 
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cells in S phase. These observations suggest that differentiation of PLB-985 cells into 
mature neutrophil-like, parallels the proliferation arrest of mature neutrophils at G1. 
Incubation with the cytokines G-CSF and GM-CSF increased the number of 
differentiated cells in G0, but contrary to the cells incubated with differentiation media 
changes alone (without cytokine supplementation), there was a decreased number of 
cells in G0, following incubation with the apoptosis-delaying cytokines, G-CSF and 
GM-CSF. Therefore, these observations confirm that these cytokines prolong the 
survival of the differentiated cells. In addition, there was a decrease in the number of 
cells in S and G2 phases, indicating that these cytokines have not reversed the effect 
of differentiation in inhibiting DNA synthesis and cell proliferation of differentiated 
PLB-985 cells.  
 
These results are consistent with the findings of Fibach, et al., who reported loss of 
proliferation capacity in HL-60 after 2-3 divisions in response to other differentiation 
inducers (Fibach et al., 1982). The accumulation of differentiated PLB-985 cells in G1 
means that these cells were arrested at G1/S and do not progress to the G1-to-S 
transition (Yen et al., 1985). Moreover, the G2/M arrest was observed which blocked 
their entry into mitosis, since this checkpoint is activated upon blockage of DNA 
synthesis and/or prevention of segregation of damaged or incompletely synthesized 
DNA (Pucci et al., 2000). These findings suggest that differentiation of PLB-985 into 
neutrophil-like cells triggers their growth arrest and progression into apoptosis. 
 
DNA distribution profiles of freshly-isolated blood neutrophils shown in Figures 4.11-
12, reveal that most of the cells were arrested in G1 phase, with little or none in G0 
phase. An insignificant number of cells were however, observed in the S and G2 
phases, which could have arisen from contaminating monocytes or lymphocytes in 
the neutrophil preparations, as it is a known fact that mature blood neutrophils do not 
undergo DNA replication or proliferation. Following a 20 h incubation however, a 
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significant number of cells accumulated in the G0 phase, indicative of apoptosis 
and/or cell death. The few cells that were observed in S and G2 phases in freshly-
isolated cells also decreased after 20 h culture. These distribution patterns are similar 
to that of differentiated PLB-985 cells at day 6: decrease in S phase and increase in 
G0 phase. Thus, these experiments confirm that terminally-differentiated PLB-985 
cells acquired some of the properties of blood neutrophils in respect to their cell cycle 
DNA distribution patterns.  
 
Aged neutrophils (20 h) and differentiated PLB-985 cells (day 6 of incubation without 
media changes and/or cytokines supplementation) exhibited morphological 
characteristics of apoptotic cells (Elmore, 2007; Vousden, 2001). Both types of cells 
acquired a blebbed nuclear membrane structure, became rounded, had shrunk due 
to cytoplasmic condensation, and had a condensed chromatin. These findings further 
suggest that they both underwent spontaneous apoptosis. 
 
The effect of differentiation of PLB-985 cells on the expression of anti- and pro-
apoptotic proteins of the Bcl-2 family were investigated to determine whether changes 
in their expression levels may parallel and correlate with differentiation and apoptosis. 
Differentiation of PLB-985 cells was accompanied by a progressive decrease in 
expression of the anti-apoptotic proteins, Mcl-1 and Bcl-XL levels. These findings 
indicate that Mcl-1 and Bcl-XL levels correlated with the survival of differentiated PLB-
985 cells as well as support the reports that Mcl-1 plays crucial role in the apoptosis 
of human blood neutrophils (Edwards et al., 2004, Moulding et al., 1998). Transfection 
studies have confirmed the role of Mcl-1 as an anti-apoptotic protein whose 
overexpression results in prolonged survival of cells (Reynolds et al., 1994). Emerging 
evidence also shows that enhanced overexpression of Mcl-1 confers a malignant cell 
phenotype. For example, Mcl-1 overexpression has been implicated in the resistance 
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to chemotherapy and impaired apoptosis of malignant myeloma cells (Zhang, et al., 
2002, Okaro, et al., 2001).  
 
Interestingly, and contrary to human blood neutrophils, which do not express 
detectable levels of Bcl-XL protein by immunoblots (Edwards et al., 2004, Moulding et 
al., 1998), differentiated PLB-985 cells expressed detectable levels of this protein, but 
like Mcl-1, levels decreased as the PLB-985 differentiated into neutrophil-like cells. 
Although, mRNA of Bcl-XL has been detected in human neutrophils, they do not 
express Bcl-XL protein (Moulding et al., 2001). Incubation of differentiating PLB-985 
cells in the absence of the pro-inflammatory agent GM-CSF, led to decreased 
expression levels of Mcl-1 and Bcl-XL by day 5 and 6 in culture in line with the 
differentiation, followed by apoptosis. However, in the presence of GM-CSF, and in 
line with the ability of this cytokine to delay apoptosis, levels of these two proteins, 
although decreased compared to levels at earlier time points, were increased at this 
time, above levels observed in the absence of the cytokine. The increased levels of 
these two proteins therefore, parallels the delayed apoptosis in the differentiated PLB-
985 cells. This result agrees with observations that GM-CSF considerably delays 
apoptosis of neutrophils and maintains Mcl-1 levels (Derouet et al., 2004, Moulding 
et al., 1998).  
 
Non-differentiated PLB-985 cells expressed anti-apoptotic protein Bcl-2, and another 
striking finding was that, like mature blood neutrophils (Edwards et al., 2004), 
expression of Bcl-2 was rapidly lost following initiation of differentiation of PLB-985 
into mature neutrophil-like cells. Many studies also reported the absence of Bcl-2 in 
mature blood neutrophils (Hsieh et al., 1997, Liles & Klebanoff, 1995, Lagasse & 
Weissman, 1994). Furthermore, these results are consistent with the findings by 
Okaro, et al. that inhibition of apoptosis by Mcl-1 and Bcl-XL, but not Bcl-2 was 
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responsible for the prolonged survival of both normal and tumorigenic cells in the 
biliary tree (Okaro et al., 2001).  
 
The pro-apoptotic proteins Bax and Bak, which are constitutively expressed by human 
neutrophils (Edwards et al., 2004) were also highly expressed by differentiated PLB-
985 cells, but their levels did not significantly change during proliferation, 
differentiation or apoptosis of these cells. Levels of these proteins were unchanged 
also, after incubation with the apoptosis-delaying agent, GM-CSF. The Bcl-2 
associated X protein (Bax) has been described to promote apoptosis through 
heterodimerizing with Bcl-2 protein, thereby counteracting the death repression 
activity of the latter (Oltvai, et al., 1993). Bax is cleaved by Calpain-1 into an 18kDa 
fragment incapable of interacting with Bcl-2 family members following its translocation 
to the mitochondria, thereby facilitating apoptosis (Altznauer et al., 2004, Maianski et 
al., 2002). Rossi et al. reported that in vivo inhibition of Bax cleavage can result in 
enhanced inflammation, suggesting the role of this protein in the resolution of acute 
inflammation (Rossi et al., 2006). Moreover, studies by Ohla et al. demonstrated an 
enhanced expression of Bcl-2 and Bax proteins in T-cells cultured with IL-2 in vitro. 
However, elevated levels of Bax, but not Bcl-2 were maintained following removal of 
IL-2, indicating that Bax expression is constitutive and independent of cell survival 
status (Ohta et al., 1995).  
 
The Bcl-2 homologous antagonist/killer protein (Bak) has also been reported to show 
strong immunoreactivity in terminally-differentiated granulocytes and that through its 
tissue-specific expression, it regulates apoptosis at specific stages of cell 
differentiation (Krajewski, et al., 1996). Bazzoni et al., reported constitutive 
expression of Bak in human neutrophils and levels were not modulated irrespective 
of the cell’s survival in culture (Bazzoni et al., 1999). Therefore, Bak expression like 
that of Bax, is constitutive and independent of cell’s survival status. Taken together, 
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these reports support my findings that differentiation of PLB-985 cells did not result in 
any significant change in the expression levels of the pro-apoptotic proteins Bax and 
Bak. 
 
In summary, the data presented in this Chapter have revealed some important 
findings. First, neutrophil-like differentiated PLB-985 cells expressed Bcl-XL protein, 
which is not detected in neutrophils by immunoblots and which, like Mcl-1, correlates 
with the cell’s survival. Second, non-differentiated PLB-985 cells expressed Bcl-2 
protein which is absent in human mature blood neutrophils, but this expression of Bcl-
2 was lost following differentiation of PLB-985 into mature neutrophil-like cells. This 
lends credence to the use of differentiated PLB-985 cells as a neutrophil model to 
understand more insights into neutrophil functional properties, such as regulation of 
apoptosis and cell cycle progression. 
 
In conclusion, the experiments described in this Chapter indicate that differentiation 
of PLB-985 cells triggers cell cycle arrest and progression into apoptosis, and 
suggests possible interconnection between the two processes. Differentiated PLB-
985 cells resembled isolated mature blood neutrophils with regards to their cell cycle 
parameters and apoptosis. Apoptotic neutrophils and differentiated PLB-985 cells 
exhibited similar morphological characteristics. Furthermore, apoptosis and survival 
of differentiated PLB-985 cells might be controlled by the differentiation-induced 
expression of anti-apoptotic proteins Mcl-1 and Bcl-XL and possibly, Bcl-2 depletion. 
However, similar to blood neutrophils the expression levels of pro-apoptotic proteins 
Bax and Bak, remain largely unchanged during proliferation, differentiation and 
apoptosis. 
 
 
 
158 
 
Chapter 5: Changes in phagocytosis and oxidative burst 
activity during differentiation of PLB-985 cells 
  
5.1 Introduction 
 
Phagocytosis is the process of uptake of relatively large particles (≥0.5µm) by 
phagocytic cells. It is an essential component of the innate immune response by 
which cells recognise, ingest and destroy invading microorganisms, such as bacteria 
or fungi. Phagocytosis is also a fundamental element of tissue homeostasis and 
remodelling, where it is involved in the clearance of apoptotic bodies formed from the 
daily turnover of billions of cells (Flannagan et al., 2012). Myeloid cells, such as 
neutrophils, macrophages, monocytes and dendritic cells function in innate immune 
responses and perform professional phagocytosis to clear pathogens from the site of 
infection (Wu et al., 2009, Thedrez et al., 2007).  
 
Phagocytosis is usually a receptor-mediated process whereby receptors on the cell 
surface of the phagocytes recognise and bind the foreign bodies either directly via 
pattern-recognition receptors (PAMPs) or indirectly via opsonic receptors before 
internalisation. It culminates with the formation of membrane-bound vacuole called 
the phagosome (Flannagan et al., 2012). The nascent phagosome itself is insufficient 
to mediate pathogen killing until a maturation process occurs, which transforms the 
phagosome into a potent cytotoxic phagolysosome that is acidic, oxidising and rich in 
hydrolase and protease enzymes. This transition involves influx and efflux of 
materials through the fusion of phagosomes to endosomes initially, and subsequently 
to lysosomes, thereby acquiring functions of both the endosome (protein recycling) 
and the lysosome (degradative functions) (Pitt et al., 1992). In neutrophils, the 
azurophilic and specific granules fuse with the newly-formed phagosome and via this 
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process, the ingested particle is exposed to a host of cytotoxic and degradative 
enzymes, such as myeloperoxidase, proteases and hydrolases (Edwards, 1994).  
 
The oxidative burst is a metabolic process that occurs during phagocytosis through 
which phagocytes produce reactive oxygen species (superoxide and hydrogen 
peroxide) that are either directly or indirectly toxic to the pathogens (Kim & Seoh, 
2015). Pathogen uptake triggers ROS generation following fusion of cytoplasmic 
granules (degranulation) leading to phagosome formation. Within the phagosome, 
ROS are generated by an activated membrane bound NADPH oxidase and cytotoxic 
proteins are released from the granules into the phagocytic vesicle, that kill and 
degrade the engulfed pathogen (Kennedy & Deleo, 2009). The multi-component 
enzyme complex, NADPH oxidase becomes assembled and activated and causes 
the formation of ROS from oxygen inside the phagosome (see Figure 1.4) (Edwards, 
1996).  
 
The NADPH oxidase complex is composed of at least 7 proteins that reside on the 
plasma membrane and membrane of specific granules and in the cytosol of resting 
neutrophils. Upon activation, e.g. via phagocytosis, the cytosolic proteins translocate 
to the phagosome membrane where they associate with the membrane proteins to 
assemble the NADPH oxidase. The assembled NADPH oxidase catalyses the 
formation of superoxide (O2-) by electron transfer from cytosolic NADPH to O2, which 
then rapidly dismutates into H2O2. A granule protein, myeloperoxidase (MPO) 
catalyses the reaction of hydrogen peroxide (H2O2) with chloride ions to form 
hypochlorous acid (HOCl) and other secondary derived ROS, such as the hydroxyl 
radical (OH.) and singlet oxygen (O-) (Kennedy & Deleo, 2009, Quinn et al., 2006). 
 
The capacity of differentiated PLB-985 cells to undergo phagocytosis and ROS 
generation would therefore be a good indication of their ability to have acquired the 
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properties of mature neutrophils. Martinez, et al., demonstrated that in vitro 
differentiated HL-60 cells undertook phagocytosis of labelled pneumococci in a 
similar manner to that of isolated blood phagocytes (Martinez et al., 1999). Several 
other studies involving differentiated leukaemia cell lines into granulocytes, under a 
variety of differentiation conditions reported that the differentiated cells displayed a 
range of phagocytic capacities (Pivot-Pajot et al., 2010, Kim & Seoh, 2015, 
Bissonnette et al., 2008, Pessach & Levy, 2002). The studies described in this 
Chapter were therefore performed to investigate phagocytosis and oxidative burst 
activity of blood neutrophils and neutrophil-like dPLB-985 cells, differentiated under 
the optimised culture conditions described in Chapters 3 and 4. 
 
The aims of the work in this Chapter, therefore were to: 
 
1. Determine the phagocytosis capacity of neutrophils and differentiated PLB-
985 cells by flow cytometry. 
2.  Analyse and compare the generation of oxidative burst activity by neutrophils 
and differentiated PLB-985 cells. 
3. Investigate the time course of differentiation of PLB-985 cells on phagocytosis 
and ROS production capacity, under conditions in which apoptosis of 
neutrophil-like cells was delayed. 
 
 
5.2 Methods 
 
To assay phagocytosis of blood neutrophils and differentiated PLB-985 cells, live S. 
aureus were heat-inactivated, PI-labelled and opsonised with human AB serum as 
described in detail in Chapter 2. Fluorescent red and non-fluorescent polystyrene 
latex beads (1.0µm) were also opsonised with human AB serum. Both SAPI and latex 
161 
 
beads were adjusted to the working concentrations to give cell: particle ratios of 1:10. 
Cells were incubated without and with priming agents, G-CSF (10ng/mL) or GM-CSF 
(5 ng/mL) for 30 min, followed by addition of SAPI or latex beads at 1:10 (cell to 
particle ratio), for further 30 min. DHR 123 (5µM) was added to the non-fluorescent 
latex beads for 15 min, to measure the intra-phagosomal ROS production following 
their internalisation, and unstained or unstimulated cells were included for negative 
fluorescence/control. Samples were prepared as described in Chapter 2 and 
phagocytosis of bacteria or latex beads by neutrophils and by differentiated PLB-985 
cells was measured using the flow cytometer. 
 
Flow cytometric analysis and luminol-enhanced chemiluminescence assays were 
used to measure the oxidative burst activity. For flow cytometry, neutrophils or 
differentiated PLB-985 cells were incubated with and without priming agents; G-CSF 
(10ng/mL) and GM-CSF (5 ng/mL) for 30 min, followed by addition of DHR 123 (5µM) 
for 15 min, as the ROS detection probe. Oxidative burst activity was then stimulated 
by a receptor-dependent agonist, fMLP (1µM), and a receptor-independent agonist, 
PMA (0.1µg/mL), or inert, non-fluorescent latex beads at 1:10 (cell to particle ratios). 
Dihydrorhodamine 123 (DHR 123) is a non-fluorescent dye which is permeable to 
cells, and is oxidised to fluorescent rhodamine 123 by the generated ROS that 
crosses the plasma membrane or those that are generated within the 
phagolysosomes (Henderson & Chappell, 1993). ROS generation by neutrophils and 
differentiated PLB-985 cells was measured using the flow cytometer. 
 
For the luminol-enhanced chemiluminescence assay, neutrophils or differentiated 
PLB-985 cells were incubated with and without priming agents; G-CSF (10ng/mL) or 
GM-CSF (5ng/mL) and the oxidative burst was stimulated with fMLP (1µM), PMA 
(0.1µg/mL) or unstimulated (control). Samples contained luminol (10μM) and photon 
emission was measured in a white, low adhesion 96-well plates using a luminometer. 
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Luminol passes through the cell membrane and becomes oxidised by the generated 
ROS, releasing energy in the form of light. Luminol enhanced luminescence therefore, 
measured both intra and extra-cellular oxidants. The total ROS generation was 
measured using FLUOstar Omega plate reader from BMG Labtech. 
 
 
5.3 Results 
 
5.3.1 Neutrophils phagocytosis of SAPI and latex beads 
  
Before the properties of differentiated PLB-985 cells could be characterised, it was 
first necessary to determine the phagocytic and oxidative burst properties of mature 
blood neutrophils. Isolated neutrophils from healthy donors, incubated without and 
with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL), were therefore incubated 
with S. aureus-PI (SAPI), fluorescent-red beads (F-Beads) and non-fluorescent 
beads, containing DHR123 (NF-B + DHR) and phagocytosis was measured using the 
flow cytometer. 
 
As shown on Figure 5.1A neutrophils displayed high fluorescence after phagocytosis 
of SAPI (MFI 236.24 ± 4.43) which was significantly increased (p≤0.05) by incubation 
with both G-CSF (MFI 283.55 ± 1.69) and GM-CSF (MFI 322.00 ± 13.64). Fluorescent 
latex beads showed moderate phagocytosis (MFI 242.34 ± 30.49) which also 
significantly increased (p≤0.05) after incubation with G-CSF (MFI 286.32 ± 10.59) and 
GM-CSF (MFI 317.58 ± 4.61). Non-fluorescent beads showed lowest response (MFI 
29.72 ± 3.12) as measured by oxidation of DHR 123 by generated ROS. A slight and 
an insignificant increase was observed following incubation with G-CSF (MFI 30.94 ± 
1.40) and GM-CSF (MFI 39.52 ± 1.44). 
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Figure 5.1B shows the phagocytic ability of neutrophils (% positive cells) to SAPI 
(93.85% ± 1.70%), which increased when incubated with G-CSF (96.14% ± 0.82%) 
and GM-CSF (94.79% ± 2.62%). Fluorescence after uptake of fluorescent beads 
(23.63% ± 0.88%) increased significantly (p≤0.05) following G-CSF (24.71% ± 0.64%) 
and GM-CSF (37.37% ± 2.43%) treatments, but not all cells showed a positive 
response. Conversely, there were more cells that stained positive after uptake of non-
fluorescent beads (42.67% ± 0.73%) and this increased following G-CSF (54.26% ± 
0.63%) and GM-CSF (91.94% ± 0.66%) treatments. Representative traces of 
neutrophil phagocytosis under these conditions are shown in Figure 5.2. The 
difference in fluorescence intensity is due the fact that while most neutrophils 
phagocytosed the non-fluorescent beads, the level of fluorescence obtained was 
dependent on the level of oxidation of the ROS probe, DHR 123. 
 
Closer analysis of the positive fluorescence traces obtained after uptake of 
fluorescent beads indicated complexes patterns that could be explained by uptake of 
different numbers of particles per cell (Figure 5.2, right hand traces). Comparison of 
the fluorescence of latex particles (in the absence of cytokines) indicate that the 
individual “peaks” in fluorescence were due to uptake of different numbers of particles 
per cell. This analysis is shown in Figure 5.3 and shows that most neutrophils took up 
2 particles per cell. Neutrophils incubated with the GM-CSF took up more particles 
per cell, but this did not reach statistical significance. 
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Figure 5.1 Neutrophil phagocytosis of SAPI and latex beads. Freshly-isolated 
blood neutrophils were incubated without (NC) and with the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by addition of SAPI or latex 
beads at 1:10 (cell to particles ratio) for a further 30 min. DHR 123 (5µM) was added 
to the non-fluorescent beads (NF-B+DHR) for 15 min, and unstimulated cells (no 
cytokine, no particles) were included to gate for negative fluorescence. Phagocytosis 
was then measured using the flow cytometer. (A) Mean fluorescence intensity (MFI) 
of neutrophil phagocytosis (B) Percent positive cells for phagocytosis. Data are 
expressed as means of MFI or percent total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 
(paired, two-tailed student’s t-test). 
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Figure 5.2 Representative traces of flow cytometer histogram for neutrophils 
phagocytosis of SAPI and latex beads. Freshly-isolated blood neutrophils were 
incubated without (NC) and with the cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min, followed by addition of SAPI or latex beads at 1:10 (cell to 
particles ratio) for further 30 min. DHR 123 (5µM) was added to the non-fluorescent 
beads (NF-B+DHR) for 15 min. Phagocytosis was then measured using the flow 
cytometer. Black traces (US) indicate unstimulated cells (no particles) used to gate 
for negative fluorescence. Red traces (SAPI) and blue traces (NF-Beads + DHR) 
were measured in the red fluorescence channel while green traces (F-Beads) were 
measured in the yellow fluorescence channel. 
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Figure 5.3 Proportions of neutrophils that phagocytosed different numbers of 
fluorescent latex beads. Freshly-isolated blood neutrophils were incubated without 
and with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed 
by addition of the fluorescent beads at 1:10 (cell to particles ratio) or unstimulated (no 
particles) to gate for negative fluorescence, for a further 30 min. Phagocytosis was 
then measured using the flow cytometer. (A) Percentages of cells that engulfed I, 2, 
3, 4, 5, 6 and 7 beads, under the different treatments, calculated from Figure 5.3B. 
(B) Representative flow cytometer traces for proportion of positive cells that engulfed 
1-7 numbers of beads (M1-M7). Green traces indicate cells that did not take up any 
particle. Data are expressed as means of percent positive cells (± SEM, n=3). 
 
 
 
 
 
167 
 
5.3.2 Differentiated PLB-985 cells phagocytosis of SAPI and latex beads 
  
PLB-985 cells were differentiated under the optimised conditions, involving media 
changes and cytokine addition as described in Figure 3.16. Samples of dPLB-985 
cells, incubated with and without cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) 
were incubated with S. aureus-PI (SAPI), fluorescent-red beads (F-beads) and non-
fluorescent beads with DHR 123 (NF-B + DHR), and phagocytosis was measured 
using the flow cytometer at daily intervals over 6 days in culture. 
 
Figures 5.4-5 shows that differentiated PLB-985 cells displayed increasing levels of 
phagocytosis of SAPI and latex beads in parallel with increases in the levels of 
differentiation from day 1 to 5. Incubation with G-CSF or GM-CSF increased the 
phagocytosis with statistically significant differences (p≤0.05 or 0.01), observed after 
day 5 and 6 of culture. In contrast to neutrophils, differentiated PLB-985 cells 
displayed highest phagocytosis with fluorescent beads, followed by SAPI. However, 
like neutrophils, levels of phagocytosis of non-fluorescent beads were low. Also, 
differentiated PLB-985 cells showed low phagocytic ability for SAPI compared to the 
other particles. Incubation with G-CSF or GM-CSF significantly (p≤0.05 or 0.01) 
increased the percentage of positive cells for SAPI and all other particles from day 1-
5 as shown in Figures 5.5-7. Representative traces of differentiated PLB-985 cells 
phagocytosis under these conditions are shown in Figure 5.7. 
 
Forward scatter (FS) versus side scatter (SS) dots plots in Figure 5.8 show that 
differentiated PLB-985 cells were capable of phagocytosing both the fluorescent and 
non-fluorescent latex beads, as evident by a population of cells with altered side 
scatter (SS), indicating increased granularity, and which was enhanced after 
incubation with the cytokines G-CSF and GM-CSF. In addition, different proportions 
of the differentiated cells took up between 1 to 6 fluorescent beads as shown in 
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Figures 5.9-10, which showed that at least 6%, 12%, 5%, 3% and 1% of differentiated 
PLB-985 cells took up 1, 2, 3, 4, 5 and 6 bead particles, respectively from day 3 to 6 
of culture under the various conditions. As for neutrophils, differentiated PLB-985 cells 
incubated with GM-CSF took up higher numbers of beads per cell, but these 
differences did not reach statistical significance. 
 
Another important observation revealed by the dot plot traces in Figure 5.8 was that 
there was increasing number of dead cells from day 4-6 of culture in cells without 
cytokines (green dots on the left-hand sides of the traces) indicating progression into 
apoptosis. This accumulation of dead cells was however, less in cells incubated with 
both G-CSF and GM-CSF, with the latter showing much lower numbers of apoptotic 
dPLB-985 cells. 
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Figure 5.4 Differentiated PLB-985 cells phagocytosis of SAPI and latex beads. 
dPLB-985 cells were cultured in optimized conditions, involving media changes and 
cytokine addition for 6 d (see Figure 3.16) and samples were incubated without (NC) 
and with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed 
by addition of SAPI or latex beads at 1:10 (cell to particles ratio), for a further 30 min. 
DHR 123 (5µM) was added to cells containing non-fluorescent beads (NF-B+DHR) 
and to the unstimulated cells (DHR only, no particles) for 15 min, and phagocytosis 
was measured on days 1, 3, 5 and 6 using the flow cytometer. Data are expressed 
as means of MFI (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s 
t-test). 
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Figure 5.5 Proportions of positive dPLB-985 cells for phagocytosis of SAPI and 
latex beads. Differentiated PLB-985 cells were cultured in optimized conditions 
involving media changes and cytokine addition (see Figure 3.16) and samples were 
incubated without (NC) and with cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) 
for 30 min, followed by addition of SAPI or latex beads at 1:10 (cell to particles ratio), 
for a further 30 min. DHR 123 (5µM) was added to cells containing non-fluorescent 
beads (NF-B+DHR) and to the unstimulated cells (DHR only, no particles) for 15 min, 
and phagocytosis was measured on days 1, 3, 5 and 6 using the flow cytometer. 
Similar to neutrophils, treatment with the cytokines significantly increased 
phagocytosis of both SAPI and latex beads by the differentiated cells. Data are 
expressed as means of percent positive cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 
(paired, two-tailed student’s t-test). 
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Figure 5.6 Proportions of different particle’s phagocytosis by dPLB-985 cells. 
dPLB-985 cells were cultured in optimized conditions involving media changes and 
cytokine addition for 6 d (see Figure 3.12) and samples were incubated without (NC)  
and with cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by 
addition of SAPI or latex beads at 1:10 (cell to particles ratio), for a further 30 min. 
DHR 123 (5µM) was added to cells containing non-fluorescent beads (NF-B+DHR) 
and to unstimulated cells (DHR only, no particles) for 15 min, and phagocytosis was 
measured on days 1, 3, 5 and 6 using the flow cytometer. Data are expressed as 
means of percent positive cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-
tailed student’s t-test), ( * = G-CSF, ˟ = GM-CSF). 
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Figure 5.7 Representative traces of flow cytometer histograms for dPLB-985 cells phagocytosis of SAPI and latex beads. dPLB-
985 cells were cultured in optimized conditions, involving media changes and cytokine addition for 6 d as described in Figure 3.16, and 
samples were incubated without and with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by addition of SAPI 
or latex beads at 1:10 (cell to particles ratio) or unstimulated (US, no particles), for a further 30 min. DHR 123 (5µM) was added to cells 
containing non-fluorescent beads (NF-B+DHR) and DHR only samples for 15 min. Phagocytosis was measured after days 1, 3, 5 and 6, 
using the flow cytometer. Unstimulated control (US) cells were used to gate for negative fluorescence. Black traces indicate unstimulated 
cells. SAPI (red traces) and NF-B + DHR (blue traces) were measured in the red fluorescence channel, while F-Beads (green traces) 
were read in the yellow fluorescence channel. (A) Days 1&3. (B) Days 5&6.  
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Figure 5.8 Representative traces of flow cytometer dots plots for dPLB-985 cells phagocytosis of SAPI and latex beads. dPLB-
985 cells were cultured in optimized conditions, involving media changes and cytokine addition for 6 d (see Figure 3.12) and samples 
were incubated without and with cytokine G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by addition of SAPI or latex beads 
at 1:10 (cell to particles ratio) or unstimulated (US, no particles), for a further 30 min. DHR 123 (5µM) was added to cells containing non-
fluorescent beads (NF-B+DHR) and DHR only samples for 15 min. Phagocytosis was measured after days 1, 3, 5 and 6, using the flow 
cytometer. There was apparent altered side scatter shift of cells population in both fluorescent and non-fluorescent beads, indicating 
increased granularity following beads uptake by the differentiated cells, and this altered SS is higher in the cytokines treated cells. Figures 
A, B, C, and D for days 1, 3, 5 and 6, respectively. 
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Figure 5.9 Proportions of dPLB-985 cells that phagocytosed different numbers 
of fluorescent beads. dPLB-985 cells were cultured in optimized conditions, 
involving media changes and cytokine addition for 6 d (see Figure 3.12) and samples 
were incubated without (NC) and with cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min, followed by addition of fluorescent beads at 1:10 (cell to particles 
ratio), for a further 30 min, and phagocytosis was measured on days 1, 3, 5 and 6, 
using the flow cytometer. The percentages of cells that have engulfed I, 2, 3, 4, 5 and 
6 beads under the different treatments were calculated from Figure 5.10. Data are 
expressed as means of percent positive cells (± SEM, n=3). 
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Figure 5.10 Representative flow cytometer traces for proportions of dPLB-985 
cells that phagocytosed different numbers of fluorescent beads. dPLB-985 cells 
were cultured in optimized conditions, involving media changes and cytokine addition 
for 6 d (described in Figure 3.16) and samples were incubated without and with the 
cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by addition of 
fluorescent beads at 1:10 (cell to particles ratio) or unstimulated samples (to gate for 
negative fluorescence), for a further 30 min, and phagocytosis was measured on days 
1, 3, 5 and 6, using the flow cytometer. Green traces indicate cells that did not take 
up any particle. M1-M6 indicate proportions of cells that have engulfed 1-6 numbers 
of fluorescent beads, under the various conditions. 
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5.3.3 Neutrophils oxidative burst activity by flow cytometry 
 
Phagosome formation following engulfment of particles by neutrophils triggers 
oxidative burst activity to generate ROS within the phagosome for bacterial killing. It 
was therefore necessary to measure the oxidative burst generation of isolated 
neutrophils and differentiated PLB-985 cells after phagocytosis. Freshly-isolated 
neutrophils, incubated without and with G-CSF (10ng/mL) or GM-CSF(5ng/mL), were 
stimulated for the oxidative burst by addition of fMLP (1µM), PMA (0.1µg/mL) or latex 
beads at 10:1 (particles to cell ratio). ROS generation was then measured by DHR 
123 fluorescence, using the flow cytometer.  
 
Figure 5.11A shows the fluorescence measurements of neutrophil oxidative burst 
activity. Neutrophils without cytokine (NC) stimulated by PMA displayed high activity 
(MFI 352.64 ± 1.85) which significantly (p≤0.05, or 0.01) increased following 
incubation with cytokines G-CSF (MFI 548.80 ± 14.13) and GM-CSF (MFI 627.32 ± 
24.18). The fMLP produced low activity in cells with no cytokine (NC) (MFI 39.77 ± 
0.98), which significantly (p≤0.01) increased by incubation with G-CSF (MFI 41.44 ± 
0.51) and GM-CSF (MFI 89.23 ± 4.43). Non-fluorescent beads also exhibited lower 
oxidative burst activity (MFI 30.43 ± 0.79) which increased slightly following 
incubation with G-CSF (MFI 32.41 ± 0.52) and significantly (p≤0.05) with GM-CSF 
(MFI 44.38 ± 2.40). DHR 123 only (no particles) cells showed the least ROS 
generation (MFI 26.65 ± 0.22), which increased insignificantly after incubation with G-
CSF (MFI 28.08 ± 1.55) and significantly (p≤0.01) with GM-CSF (MFI 29.75 ± 0.58). 
The fluorescence produced by DHR only cells was likely generated from 
mitochondrial oxidation, and the increased fluorescence observed in latex beads with 
DHR indicates that the beads have been taken up by neutrophils and have triggered 
ROS production. 
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The percent positive cells shown in Figure 5.11B followed similar patterns. However, 
the percentages of positive cells were very high with PMA (>98%), fMLP (>73%), 
latex beads (>71%) under the different conditions, while DHR only cells showed very 
low percentage of positive cells (23.42% - 42.77%). Representative flow cytometer 
traces of neutrophil oxidative burst activity, under these conditions is shown in Figure 
5.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
184 
 
 
 
Figure 5.11 Neutrophil oxidative burst activity by flow cytometry. Freshly-
isolated blood neutrophils were incubated without (NC) and with cytokine G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by DHR 123 (5µM) for 15 min 
and oxidative burst stimulated by addition of fMLP (1µM), PMA (0.1µg/mL), non-
fluorescent latex beads at 1:10 (cells to particles ratio) or unstimulated samples (to 
gate for negative fluorescence), for a further 15 min. ROS generation was then 
measured using the flow cytometer. (A) Mean fluorescence intensity (MFI) of 
neutrophils oxidative burst. (B) Percentage of positive cells for oxidative burst activity 
calculated from Figure 12. Data are expressed as means of MFI or percent total cells 
(± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 5.12 Representative traces of flow cytometer histogram for neutrophil 
oxidative burst activity. Freshly-isolated neutrophils were incubated without and 
with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by 
DHR 123 (5µM) for 15 min and oxidative burst stimulated by addition of fMLP (1µM), 
PMA (0.1µg/mL), non-fluorescent latex beads at 1:10 (cells to particles ratio) or 
unstimulated (US) to gate for negative fluorescence, for a further 15 min. ROS 
generation was then measured using the flow cytometer. Black traces indicate 
unstimulated control cells. All traces were measured in the red fluorescence channel. 
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5.3.4 dPLB-985 cells oxidative burst activity by flow cytometry 
 
Non-differentiated PLB-985 and dPLB-985 cells differentiated under the optimised 
conditions, involving media changes and cytokine addition as described in Figure 
3.16, were incubated without and with G-CSF (10ng/mL) or GM-CSF (5ng/mL), and 
then stimulated for oxidative burst activity by addition of fMLP (1µM), PMA 
(0.1µg/mL), latex beads at 1:10 (cell to particles ratio) or unstimulated (US, for 
negative fluorescence), in cultures containing DHR 123 (5µM). ROS generation was 
then measured using the flow cytometer. 
 
Non-differentiated PLB-985 cells did not produce oxidative burst activity, under any 
of these conditions (data not shown). However, following differentiation into 
neutrophil-like cells, these cells displayed increasing ROS generation parallel with the 
levels of differentiation from day 1 to 6 as shown in Figure 5.13. Like the isolated 
neutrophils, differentiated PLB-985 cells stimulated with PMA showed high oxidative 
burst activity which increased significantly (p≤0.05, or 0.01) after incubation with both 
G-CSF and GM-CSF from day 1-6 of culture. However, contrary to neutrophils, both 
fMLP and latex beads induced only slight and insignificant oxidative burst activity in 
the differentiated PLB-985 cells under these conditions. The fMLP response in 
neutrophils is mediated by formyl peptide receptors (Hallett & Lloyds, 1995), which 
might not be expressed on the surface of differentiated PLB-985 cells. The latex 
beads were also unable to trigger oxidative burst activity, even though they can be 
internalised by the differentiated PLB-985 cells as shown in Figures 5.5-7. 
 
Figure 5.14 shows the percentage of positive differentiated PLB-985 cells for 
oxidative burst activity which revealed the same patterns with the fluorescence 
intensities described in Figure 5.13, but in contrast to the MFI data, after incubation 
with G-CSF or GM-CSF, fMLP and latex beads showed significant (p≤0.05, or 0.01) 
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increase in percent positive cells from day 3-5. In cultures without cytokine (NC), the 
PMA response showed biphasic change on days 3-5 (high and low responders) and 
then declined to low responders on day 6. However, incubation with both G-CSF and 
GM-CSF maintained high responders for longer times. Representative traces of 
differentiated PLB-985 cells oxidative burst activity under these conditions is shown 
in Figure 5.15. 
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Figure 5.13 Differentiated PLB-985 cells oxidative burst activity by flow 
cytometry. dPLB-985 cells were cultured in optimized conditions, involving media 
changes and cytokine addition for 6 d (see Figure 3.16) and samples were incubated 
without (NC) and with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 
min, followed by addition of DHR 123 (5µM). The oxidative burst activity was then 
stimulated by addition of fMLP (1µM), PMA (0.1µg/mL), non-fluorescent latex beads 
at 1:10 (cell to particles ratio) or unstimulated (for negative fluorescence), for a further 
15 min, and ROS generation was measured using the flow cytometer. Data are 
expressed as means of MFI (± SEM, n=4), * = p≤0.05, ** = p≤0.01 (paired, two-tailed 
student’s t-test). 
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Figure 5.14 Percentage of positive dPLB-985 cells for oxidative burst activity 
by flow cytometry. dPLB-985 cells were cultured in optimized conditions, involving 
media changes and cytokine addition for 6 d (described in Figure 3.16) and samples 
were incubated without (NC) and with the cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min, followed by addition of DHR 123 (5µM) for further 15 min. The 
oxidative burst activity was then stimulated by addition of fMLP (1µM), PMA 
(0.1µg/mL), non-fluorescent latex beads at 1:10 (cell to particles ratio) or unstimulated 
(for negative fluorescence) for a further 15 min, and ROS generation was measured 
using the flow cytometer. Data are expressed as means of percent total cells (± SEM, 
n=4), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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Figure 5.15 Representative traces of flow cytometer histograms for dPLB-985 cells oxidative burst activity. dPLB-985 cells were 
cultured in optimized conditions, involving media changes and cytokine addition for 6 d, as described in Figure 3.16 and samples were 
incubated without and with the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, followed by addition of DHR 123 (5µM) for 
15 min. The oxidative burst activity was then stimulated by addition of fMLP (1µM), PMA (0.1µg/mL), non-fluorescent latex beads at 1:10 
(cell to particles ratio) or unstimulated (to gate for negative fluorescence) for a further 15 min, and ROS generation was measured using 
the flow cytometer. Black traces indicate unstimulated (control) cells. All traces were measured in the red fluorescence channel. In 
cultures without cytokines (NC), the PMA response showed a biphasic change on days 3-5 (high and low responders) and then declined 
to low responders on day 6, whilst incubation with both G-CSF and GM-CSF maintained high responders for longer time. (A) Day 1-3. 
(B) Day 3-6. 
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5.3.5 Neutrophils oxidative burst activity by chemiluminescence assay 
  
To measure the total (intra- and extra-cellular) ROS generation by neutrophils and 
differentiated PLB-985 cells following phagocytosis, luminol enhanced luminescence 
assay was used as luminol can pass through the cell membrane and become oxidised 
by ROS, releasing energy in the form of light that gives a measure of total oxidant 
generation. Freshly-isolated neutrophils were cultured without and with GM-CSF 
(5ng/mL), and then oxidative burst activity was stimulated with fMLP (1µM) or PMA 
(0.1µg/mL), or un-stimulated (control) samples, and the total ROS generation was 
measured by the luminol-enhanced chemiluminescence assay using a luminometer. 
 
As shown in Figure 5.16, neutrophils with no cytokine (NC) stimulated by PMA 
produced a very high chemiluminescence response (RLU 468.01 ± 28.15) followed 
by cells stimulated by fMLP (RLU 112.03 ± 15.64) while un-stimulated cells (US) 
showed the lowest response (RLU 24.74 ± 7.28). Strikingly, incubation with GM-CSF 
significantly (p≤0.01 or 0.001) increased responses in fMLP stimulated cells (RLU 
534.97 ± 20.99) and un-stimulated cells (RLU 81.77 ± 3.47), but there was only a 
slight and insignificant increase in PMA stimulated cells (RLU 493.17 ± 36.24). PMA 
is membrane permeable and does not require priming to activate neutrophils. In 
contrast, fMLP binds formyl peptide receptors (FPR) on the granules and therefore, 
requires priming of neutrophils to mobilise the granules to the cell surface, to stimulate 
an oxidative burst (Hallett & Lloyds, 1995). Representative traces for oxidative burst 
activity of neutrophils under these conditions are shown in Figure 5.17. 
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Figure 5.16 Total chemiluminescence for neutrophil oxidative burst activity. 
Freshly-isolated blood neutrophils were incubated without (NC) and with the cytokine 
GM-CSF (5ng/mL) for 45 min. The oxidative burst activity was then stimulated by 
addition of fMLP (1µM), PMA (0.1µg/mL) or un-stimulated (US). Luminol-enhanced 
chemiluminescence assay was used to measure ROS generation, using a 
luminometer. Data are expressed as means of total chemiluminescence (± SEM, n=4, 
** = p≤0.01, *** = p≤0.001 (paired, two-tailed student’s t-test). 
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Figure 5.17 Representative chemiluminescence traces for neutrophil oxidative 
burst activity. Freshly-isolated blood neutrophils were incubated without (NC) and 
with the cytokine GM-CSF (5ng/mL) for 45 min. The oxidative burst was then 
stimulated by addition of fMLP (1µM) or PMA (0.1µg/mL) including un-stimulated (US) 
and cell-free (CF) samples (for negative chemiluminescence). The luminol-enhanced 
chemiluminescence assay was used to measure ROS generation using a 
luminometer. The fMLP induces a biphasic chemiluminescence response peaks in 
neutrophils with the initial peak within 2-3 min and the second peak at within 5-7 min 
after addition of stimulus, indicating extra-and intra-cellular oxidants generation, 
respectively. In contrast, PMA induces a single response peak reaching maximum at 
around 5-7 min, indicating intracellular oxidant generation.  
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5.3.6 dPLB-985 cells oxidative burst activity by chemiluminescence assay 
 
Non-differentiated PLB-985 and dPLB-985 cells differentiated under the optimised 
conditions, involving media changes and cytokine addition as described in Figure 
3.16, were incubated without and with the cytokine GM-CSF (5ng/mL) for 45 min. The 
oxidative burst activity was then stimulated by addition of fMLP (1µM), PMA 
(0.1µg/mL), or un-stimulated (US). Total ROS generation was measured by luminol-
enhanced chemiluminescence assay using a luminometer. 
 
Figure 5.18 shows the total ROS produced by non-differentiated PLB-985 (A) and 
dPLB-985 cells (at day 5 in culture) (B). Non-differentiated PLB-985 cells produced 
insignificant total ROS following stimulation with both fMLP and PMA, and which did 
not change significantly, after incubation with the cytokine GM-CSF. This shows that 
non-differentiated PLB-985 cells are incapable of ROS generation. Interestingly, 
differentiated PLB-985 cells showed high PMA stimulated total ROS (RLU 148.37 ± 
23.93) which increased slightly but insignificantly, after incubation with GM-CSF (RLU 
160.88 ± 9.09). This is not unexpected, as PMA response is receptor-independent 
and it activates ROS production by directly stimulating protein kinase C. The fMLP 
stimulated differentiated PLB-985 cells showed insignificant total ROS generation 
(RLU 57.03 ± 2.11), which increased slightly but insignificantly after incubation with 
GM-CSF (RLU 59.87 ± 12.78). Like blood neutrophils, differentiated PLB-985 cells 
showed oxidative burst activity in response to PMA stimulation. However, in contrast 
to neutrophils, these cells could not be stimulated for ROS production by fMLP (which 
activates the receptor-coupled oxidative burst). These observations are consistent 
with the flow cytometry data of ROS generation by differentiated PLB-985 cells, 
described in section 5.3.4. Representative traces of oxidative burst activity of PLB-
985 and dPLB-985 cells under these conditions is shown in Figure 5.19. 
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Figure 5.18 Total chemiluminescence for PLB-985 cells oxidative burst activity. 
Non-differentiated PLB-985 and dPLB-985 cells (day 5) differentiated under the 
optimised conditions, involving media changes and cytokine addition (see Figure 
3.16), were incubated without (NC) and with the cytokine GM-CSF (5ng/mL) for 30 
min. The oxidative burst was then stimulated by addition of fMLP (1µM), PMA 
(0.1µg/mL), or un-stimulated (US) samples. Luminol-enhanced chemiluminescence 
assay was used to measure ROS generation using a luminometer. (A) Total ROS 
generated by non-differentiated PLB-985 cells. (B) Total ROS generated by dPLB-
985 cells. Data are expressed as means of total chemiluminescence (± SEM, n=4). 
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Figure 5.19 Representative chemiluminescence assay traces for dPLB-985 cells 
oxidative burst activity. PLB-985 and dPLB-985 cells (day 5) differentiated under 
the optimised conditions as described in Figure 3.16, were incubated without (NC) 
and with the cytokine GM-CSF (5ng/mL) for 30 min. The oxidative burst activity was 
stimulated by addition of fMLP (1µM) or PMA (0.1µg/mL), including unstimulated (US) 
and cells-free (CF) samples (for negative chemiluminescence). The luminol-
enhanced chemiluminescence assay was used to measure ROS generation using a 
luminometer. PMA induced a single response peak in dPLB-985 cells, but no activity 
was detected with fMLP stimulation in these cells. The non-differentiated PLB-985 
cells did not produce chemiluminescence in response to either PMA or fMLP 
stimulation.  
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5.4 Discussion and conclusions 
 
Phagocytic cells of the immune system protect the host against microbial infection by 
their ability to recognise, engulf and eliminate invading pathogens and cell debris, 
through complex and tightly-regulated mechanisms of phagocytosis and oxidative 
burst (Pivot-Pajot et al., 2010, Martin & Bhakdi, 1991). Landmark work by Baldridge 
and Gerard revealed a marked association between the processes of phagocytosis 
and the generation of the oxidative burst during pathogen killing, when they 
demonstrated that phagocytosis of bacteria was accompanied by rapid burst of 
oxygen uptake (Gerard & Baldrige, 1933). Allen et al. also observed an emission of a 
burst of chemiluminescence by neutrophils during phagocytosis (Allen, et al., 1972). 
The primary product of respiratory burst was later confirmed to be the superoxide 
anion (O2-)  derived from NADPH oxidase system and that it was responsible for 
initiation of the bacterial killing (Babior, et al., 1973). 
 
Neutrophils possess many cytotoxic components and associated pathways, such as 
variety of cytotoxic enzymes (e.g., hydrolases, nucleases and proteases) in their 
granules plus the ability to generate reactive oxygen metabolites via non-
mitochondrial O2 uptake during an oxidative burst, from activated NADPH oxidase 
and myeloperoxidase systems. The reactive oxygen metabolites play a crucial role in 
pathogen killing and are perhaps involved in destroying some types of tumours 
(Edwards et al., 1989). These properties have made neutrophils the most adapted for 
microbial killing and they have the highest cytotoxic capacity of all phagocytic cells 
(Thieblemont et al., 2016, Edwards, 1996). DeChatelet et al. reported that phagocytic 
challenge triggers certain biochemical changes in resting neutrophils, such as 
increases in oxygen consumption and hexose monophosphate (HMP) shunt activity 
which generate the NADPH that is subsequently oxidised by the assembled NADPH 
oxidase for bactericidal activity (DeChatelet, et al., 1976). 
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Stimulation of neutrophils in vitro, whether by phagocytic (e.g. heat-killed bacteria) or 
by soluble (e.g. fMLP, PMA) agents triggers an increased production of oxidative 
metabolites, that can be assayed using a variety of techniques which measure the 
cell’s collective oxidative response, such as spectrophotometry, fluorimetry and 
chemiluminescence (Smith & Weidemann, 1993, Briheim, et al., 1984). Therefore, 
the experiments described in this Chapter investigated phagocytosis and oxidative 
burst generation capacities of neutrophils and differentiated PLB-985 cells using flow 
cytometry and luminol-amplified chemiluminescence assay.  
 
The data presented from the flow cytometric analysis of phagocytosis clearly 
demonstrated that neutrophils (without cytokine) highly phagocytosed opsonised PI-
labeled S. aureus (SAPI) and opsonised fluorescent latex beads, and to a lower 
extent, opsonised non-fluorescent latex beads. Incubation of neutrophils with the 
cytokine G-CSF or GM-CSF significantly enhanced the levels of phagocytosis of 
these particles. This agrees with observation by Sémiramoth et al., that priming of 
neutrophils by proinflammatory cytokines and by LPS optimises their functional 
responses (Sémiramoth et al., 2009). Furthermore, exposure of blood neutrophils to 
GM-CSF, like with other priming agents promotes their phagocytic, oxidative and 
cytotoxic capacities (Edwards et al., 1989). Phagocytosis of fluorescent beads by 
neutrophils displayed a multi-phasic fluorescence peak signifying different 
proportions of cells engulfing different numbers of beads of between 1 to 7, with most 
cells taking up two particles. 
 
Similarly, flow cytometric analysis of differentiated PLB-985 cells also revealed that 
these cells displayed increasing levels of phagocytosis of SAPI and latex beads in 
parallel with the increasing levels of their differentiation into neutrophil-like 
phenotypes. As seen with neutrophils, levels of phagocytosis by differentiated PLB-
985 increased also, after incubation with G-CSF or GM-CSF. However, in contrast to 
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neutrophils, differentiated PLB-985 cells displayed higher phagocytosis of fluorescent 
beads, followed by SAPI and to a lower extent non-fluorescent beads.  
 
The difference in responses of neutrophils and differentiated PLB-985 cells to SAPI 
is likely due to difference in the expression of specific receptors between these cell 
types, as neutrophils express receptors for molecules, such as  chemoattractants and 
opsonins (e.g., fMLP, C5a and IL-8) that facilitate recognition, binding and uptake of 
the bacteria (Naccache, 2013), which might not be expressed on the surface of 
differentiated PLB-985 cells. Phagocytosis of inert polystyrene beads is achieved 
through hydrophobic interactions with the cells, which may partly, explain why the 
differentiated cells were able to take up these particles. As for blood neutrophils, 
differentiated PLB-985 cells took up different numbers of fluorescent bead particles 
ranging from 1 to 6 as evidenced by multiple fluorescent peaks. Most differentiated 
PLB-985 cells phagocytosed two particles per cell, after day 3 to 6 of culture, under 
the different culture conditions. 
  
Oxidative burst generation assayed by flow cytometry shows that neutrophils (without 
cytokine) displayed strong oxidative response when stimulated with PMA and a 
moderate response was exhibited upon fMLP stimulation. Incubation with cytokine G-
CSF or GM-CSF increased the oxidative burst activity significantly in PMA and fMLP 
stimulated cells, which is particularly higher in the latter. This clearly demonstrated 
the importance of priming/cytokines to the receptor mediated signalling, such as in 
fMLP. Latex beads showed a low oxidative burst activity which increased significantly 
following incubation with both G-CSF and GM-CSF.  
 
Fluorescence distribution patterns of differentiated PLB-985 cells oxidative burst 
displayed a very similar pattern to that of isolated blood neutrophils. Highest activity 
was observed in PMA stimulated cells whilst a very weak response was observed in 
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cells stimulated by fMLP. However, dPLB-985 cells response to both stimulants 
increased after incubation with cytokine G-CSF or GM-CSF. Latex beads showed 
lowest oxidative burst activity which also increased slightly when dPLB-985 cells were 
incubated with G-CSF or GM-CSF. Non-differentiated PLB-985 cells are incapable of 
oxidative burst generation, as these cells produced negligible amounts of total ROS 
with both fMLP, PMA or latex beads, which did not change significantly, following 
incubation with cytokines G-CSF or GM-CSF. Therefore, the small observed ROS 
could be the result of mitochondrial respiration, and thus strongly suggests that 
changes associated with differentiation of PLB-985 cells were responsible for their 
ability to generate the oxidative burst. 
 
Total ROS generation by neutrophils and differentiated PLB-985 cells measured 
using luminol-enhanced chemiluminescence assay revealed striking consistency with 
the data obtained from flow cytometric measurements, as well as similarity between 
neutrophils and differentiated PLB-985 cells. Neutrophils (without cytokine) produced 
high total chemiluminescence in response to PMA stimulation, which was low in 
response to fMLP.  Following incubation with GM-CSF however, the fMLP induced 
chemiluminescence was highly and significantly increased, whilst only slight and 
statistically-insignificant increase was observed in PMA-induced cells. This is not 
surprising, because PMA being membrane permeable, does not require priming to 
activate neutrophils, though their response to PMA can be accelerated by priming 
(DeChatelet et al., 1976). The unstimulated neutrophils expressed very little and 
insignificant total chemiluminescence. 
 
PMA, a structural analog of diacylglycerol (DAG) activates neutrophil response 
exogenously by direct activation of protein kinase C (PKC), hence activation of 
NADPH oxidase by PMA is independent of receptor binding or generation of second 
messages (Edwards, et al., 1990). Whereas the bacterial peptide fMLP activates 
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neutrophils via the formyl peptide receptors (FPR) that may be present on the 
granules, and priming is required to mobilise these granules to the cell surface (Hallett 
& Lloyds, 1995). Normally, in vivo neutrophil activation occurs by receptor-coupled 
mechanisms, which usually, are regulated by pre-exposure to priming agents such 
as GM-CSF, that enhance their functional responsiveness (Edwards et al., 1990).  
 
Reports of chemiluminescence studies in patients with MPO deficiencies have 
revealed that luminol-amplified light emission by neutrophils is entirely dependent on 
the MPO-H2O2 system (Dahlgren & Stendahl, 1983). The chemotactic peptide fMLP 
induces a biphasic chemiluminescence peak in normal neutrophils with the initial 
sharp peak of activity within 2-3 min and the second peak at around 5-7 min after 
addition of stimulus. In contrast, PMA induces a single response peak, reaching 
maximum at around 5-7 min also, as shown in Figure 5.17. The first peak of the fMLP 
response is a result of extracellular oxidants generation, while the second peak is a 
result of intracellular oxidants caused by internalisation of fMLP by endocytosis or 
entrance of luminol into the cells to become oxidised intracellularly (Briheim, et al., 
1984). Most of the PMA induced response is believed to be due to intracellular 
oxidants (Dahlgren, 1987). While differentiated PLB-985 did not produce any 
chemiluminescence response after fMLP stimulation, PMA showed a single response 
peak similar to that of blood neutrophils. Interestingly, non-differentiated PLB-985 
cells did not produce chemiluminescence in response to both stimulants, another 
strong indication that differentiation of PLB-985 cells was in deed responsible for the 
PMA observed chemiluminescence responses in Figure 5.19.  
 
In conclusion, these data show that isolated blood neutrophils have variable 
phagocytic and oxidative burst generation capacities to a variety of particles and 
stimuli, and the neutrophil-like differentiated PLB-985 cells expressed similar but 
weaker phagocytic and oxidative burst activities in response to the same particles 
203 
 
and stimuli. This suggests that differentiated PLB-985 cells, like the isolated mature 
blood neutrophils, can display functions of professional phagocytosis and oxidative 
killing. 
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Chapter 6: Effect of differentiation of PLB-985 cells on 
expression of cell surface markers, chemotaxis and 
intracellular signalling  
  
6.1 Introduction 
 
Neutrophil functions are mediated by several cell surface receptors which upon 
activation, trigger complex intracellular signal transduction pathways. The 
microbicidal activity of neutrophils is dependent upon effective pathogen recognition 
and binding, mediated by many classes of receptors expressed on their plasma 
membranes, including adhesion receptors (e.g. selectins and integrins), 
immunoglobulin receptors (FcγRs), G-protein-coupled receptors (GPCRs), cytokine 
receptors and Toll-like receptors (Bruhns, 2012; Migeotte et al., 2006).  Activation of 
these receptors triggers cellular responses required for pathogen elimination, such 
as chemotactic transmigration, phagocytosis, degranulation and oxidative burst 
generation (Futosi et al., 2013). 
 
Circulating blood neutrophils constitutively express the β2-integrin adhesion 
receptors, and their expression increases rapidly following activation (Drayson et al., 
2001; Repo et al., 1993). Integrins are heterodimeric transmembrane glycoproteins 
expressed on almost all mammalian cells. The most important integrins expressed on 
neutrophils belong to the β2-integrin family, including the CD11b/CD18 heterodimer 
or CR3 or Mac-1 complex (Futosi et al., 2013). CD11b/CD18 mediates cell-cell 
interactions and firm adhesion of neutrophils to the endothelium during transcellular 
migration through vessel walls and intestinal tissues (Siddiqi et al., 2001). Elevated 
expression of CD11b leads to an increased recruitment of neutrophils to the infection 
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sites  (van Eeden et al., 1999). CD11b is described as an early expressed marker 
during granulocyte differentiation and maturation (Drayson et al., 2001). 
 
The LPS receptor, CD14 is a 55 KDa plasma membrane glycoprotein expressed 
strongly on monocytes and macrophages, but in lower amounts on granulocytes 
(Simmons et al., 1989). However, its expression on resting neutrophils can be rapidly 
upregulated upon stimulation with cytokines, such as TNF, G-CSF and GM-CSF 
(Fleck, 2005). CD14 is a multifunctional receptor that can act as an opsonic receptor 
by binding bacterial lipopolysaccharide (endotoxin) to promote phagocytosis of 
bacteria and LPS-coated particles, and trigger inflammatory responses by 
macrophages. In addition, it is an important receptor in the clearance of apoptotic 
cells, where it recognises and interacts with apoptotic cells, leading to their phagocytic 
uptake. However, contrary to LPS, uptake of apoptotic cells does not provoke the 
macrophages to release pro-inflammatory cytokines (Devitt et al., 1998; Wright et al., 
1991). 
 
The immunoglobulin receptors are also plasma membrane glycoproteins called the 
Fcγ receptors because they recognise and bind the Fc domain of IgG. They primarily 
recognise IgG-opsonised pathogens and particles, but are also involved in immune 
complex-coupled inflammatory responses (Futosi et al., 2013). Three classes of 
FcγRs have been identified: FcγRIII (CD16), FcγRII (CD32) and FcγRI (CD64) 
(Hazan-Eitan et al., 2006; Edwards, 1994). Human neutrophils constitutively express 
low affinity Fcγ receptors; FcγRIII and FcγRII, but the high affinity FcγRI is not 
expressed on resting neutrophils, unless activated by cytokines, such as GM-CSF 
and interferon-γ (Perussia et al., 1983). The low affinity FcγRs bind monomeric IgG 
with low affinity and are the most abundant FcγRs on neutrophils. FcγRIII (CD16) 
receptors are also present intracellularly in numerous small vesicles (120-180nm) 
distributed within the cytoplasm. These vesicles represent an internal pool of Fc 
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receptors that can readily be mobilised and transported to the plasma membrane 
upon activation (Jost et al., 1990). 
 
Extravasation and chemotaxis of neutrophils are critical events and prerequisites for 
their efficient microbicidal and clearance roles, because they allow neutrophils to be 
rapidly recruited to the sites of infection or inflammation.  The chemotactic migration 
of neutrophils in vivo, occurs towards a gradient of chemoattractants (see Figure 1.3), 
such as inflammatory mediators (e.g. fMLP and IL-8) or other chemotactic factors 
(e.g. C5a, casein and activated serum) (Singh et al., 2014). These attractants are 
released during inflammation, and in turn, trigger rapid morphological changes in 
neutrophils from spherical to polarized shape, exhibiting a front, leading lamella and 
a contracted, trailing tail. This is followed by re-orientation of actin filaments (for 
detection of the chemotactic gradient) and subsequently, directed migration up the 
gradient (Nuzzi et al., 2015; Hauert et al., 2002). 
 
The complex networks of signalling systems in neutrophils are mediated by plasma 
membrane receptors, downstream G-protein and/or tyrosine kinases, including lipid-
activated kinases (e.g. phospholipase C and phosphatidylinositol 3-kinase), and their 
activation regulates activation of various neutrophil functions. Apart from rapid 
activation of specific enzymes via post-translational modifications, these signalling 
networks activate transcription factors, hence trigger transcript to modify functional 
responses (Futosi et al., 2013; Naccache, 2013). 
 
Results in the previous Chapter showed that neutrophils and differentiated PLB-985 
cells expressed certain receptor-mediated processes, such as phagocytosis and 
oxidative burst generation. This Chapter will therefore, investigate the expression of 
some cell surface markers on isolated blood neutrophils and on neutrophil-like 
differentiated PLB-985 cells to identify their functional responses, and compare the 
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expression levels between the two cell types, to get further insights into the functional 
and structural similarities of differentiated PLB-985 cells to mature blood neutrophils. 
 
The aims of the work described in this Chapter therefore are: 
 
1. To compare the expression of the adhesion receptor CD11b, the LPS receptor 
CD14 and the immunoglobulin receptor CD16 on isolated blood neutrophils 
and differentiated PLB-985 cells. 
2. To measure the transmigration and chemotaxis of neutrophils and 
differentiated PLB-985 cells in response to various chemoattractants. 
3. To determine the activation status of the STAT3 intracellular signalling 
pathway in differentiated PLB-985 cells. 
 
 
6.2 Methods 
 
Detailed methodologies are described in Chapter 2. Expression of plasma membrane 
surface markers on neutrophils and differentiated PLB-985 cells was analysed by flow 
cytometry. Cells were prepared, fixed with 4% PFA and stained with specific 
conjugated antibodies to CD11b, CD14 and CD16, including isotype-matched 
conjugated IgG as control. For intracellular CD16 expression, cells were 
permeabilised using 0.1% saponin (in PBS) prior to staining, as described in the 
methods Chapter. Expression of the various surface receptors was then analysed 
using the flow cytometer.  
 
Chemotaxis of neutrophils and differentiated PLB-985 cells was analysed by a 
transwell assay, using Millipore hanging inserts, fitted with 3 µm pore sized filters. 
Cells were prepared and loaded onto the hanging inserts, suspended in a 24-well 
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poly-hema coated tissue culture plate, containing the chemoattractants; fMLP (10-
8M), IL-8 (0.1µg/mL), casein (0.5 mg/mL), or zymosan A activated serum (1µg/mL) as 
described in Methods. Cells that transmigrated into each well were counted using a 
Multisizer 3 cell coulter counter, following a 1:1000 dilution with Isoton II and the 
results were expressed as percentages of the total number of cells originally added. 
 
The activation status of the STAT3 intracellular signalling pathway in differentiated 
PLB-985 cells was determined by western blot analysis. Protein extracts were 
prepared as described in the Methods and probed for the expression of activated 
STAT3 using relevant anti-human antibodies. 
  
 
6.3 Results 
 
6.3.1 Expression of surface CD11b on neutrophils 
 
Freshly-isolated neutrophils from healthy donors were incubated for 30 min in the 
absence or presence of G-CSF (10ng/mL) or GM-CSF (5ng/mL) and then stained 
with saturating PE-conjugated CD11b antibody or isotype-IgG control. Cells were 
then analysed for the expression of CD11b using the flow cytometer. Figure 6.1 
showed that CD11b surface receptor was highly expressed on neutrophils with no 
cytokine (NC) (MFI 1252.03 ± 54.95) and this significantly increased (p≤0.05) after 
incubation with the cytokines G-CSF (MFI 1470.55 ± 61.74) or GM-CSF (MFI 1475.73 
± 82.46). The percent positive cells in the absence of cytokine (NC) was also high 
(80.01% ± 2.01%), which increased significantly (p≤0.05) following incubation with G-
CSF (88.82% ± 1.22%) or GM-CSF (90.29% ± 0.94%). Representative traces of 
CD11b expression on neutrophils under these conditions are shown in Figure 6.4. 
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Figure 6.1 Expression of CD11b on the surface of neutrophils. Freshly-isolated 
neutrophils incubated in the absence (NC) and presence of the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and stained with saturating 
PE-conjugated CD11b antibody or isotype-IgG control. The cells were washed with 
PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and PFA (4%), 
pelleted and re-suspended in PBS (+BSA). Cells were then analysed for expression 
of surface CD11b antigen using the flow cytometer. (A) Mean fluorescence intensity 
(MFI) (B) Percent positive cells. Data are expressed as means of MFI or percent total 
cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test).  
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6.3.2 Expression of surface CD14 on neutrophils 
 
Freshly-isolated neutrophils from healthy donors were incubated in the absence or 
presence of G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min and stained with 
saturating PerCP-conjugated CD14 antibody or isotype-IgG control. Cells were then 
analysed for the expression of CD14 surface antigen using the flow cytometer. CD14 
expression was very low on neutrophils in the absence of cytokines (NC) (MFI 35.75 
± 2.38) as shown on Figure 6.2. This was, however, significantly increased (p≤0.05) 
upon incubation with cytokine G-CSF (MFI 44.54 ± 2.21) or GM-CSF (MFI 45.04 ± 
1.93). Similarly, small percentage of the cells stained positive for CD14 (15.89% ± 
2.81%), and this proportion increased in cells incubated with G-CSF (19.14.27% ± 
3.84%, NS) and GM-CSF (26.63% ± 2.49%, p≤0.05). This confirms previous reports 
that CD14 is expressed at low levels on granulocytes, but treatment with pro-
inflammatory cytokines, such as TNF, G-CSF and GM-CSF can enhance its 
expression (Fleck, 2005). Representative traces of CD14 expression on neutrophils 
under these conditions are shown in Figure 6.4. 
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Figure 6.2 Expression of CD14 on the surface of neutrophils. Freshly-isolated 
neutrophils incubated in the absence (NC) and presence of the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and stained with saturating 
PerCP-conjugated CD14 antibody, including isotype-IgG control.  Stained cells were 
washed with PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and 
PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were then analysed for 
expression of CD14 surface marker using the flow cytometer. (A) Mean fluorescence 
intensity (MFI) (B) Percent positive cells. Data are expressed as means of MFI or 
percent total cells (± SEM, n=3), * = p≤0.05 (paired, two-tailed student’s t-test). 
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6.3.3 Expression of surface CD16 on neutrophils 
  
Freshly-isolated neutrophils from healthy donors incubated in the absence and 
presence of G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min were stained with 
saturating FITC-conjugated CD16 antibody or isotype-matched IgG control. Cells 
were then analysed for expression of CD16 surface marker using the flow cytometer. 
 
As shown in Figure 6.3, neutrophils incubated in the absence of cytokine (NC) 
expressed high levels of surface CD16 (MFI 145.71 ± 18.72), which increased 
following incubation with the cytokines G-CSF (MFI 166.42 ± 17.11) or GM-CSF (MFI 
182.13 ± 12.26), but these increases did not reach statistical significance (p≤0.05). 
There was however, a high percent positive cells for surface CD16 (75.74% ± 3.96%), 
which increased significantly (p≤0.05) in cells incubated with cytokine G-CSF (82.36% 
± 2.09%) or GM-CSF (89.88% ± 2.74%). CD16 is constitutively expressed at high 
concentrations on neutrophils. Representative traces of surface CD16 expression on 
neutrophils under these conditions is shown in Figure 6.4. 
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Figure 6.3 Expression of CD16 on the surface of neutrophils. Freshly-isolated 
neutrophils incubated in the absence (NC) and presence of the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and stained with saturating 
FITC-conjugated CD16 antibody or isotype-IgG control. Stained cells were washed 
with PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and PFA 
(4%), pelleted and re-suspended in PBS (+BSA). Cells were then analysed for 
expression of CD16 surface antigen using the flow cytometer. (A) Mean fluorescence 
intensity (MFI) (B) Percent positive cells. Data are expressed as means of MFI or 
percent total cells (± SEM, n=3). 
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Figure 6.4 Representative flow cytometer traces for CD11b, CD14 and CD16 
expression on the surface of neutrophils. Freshly-isolated neutrophils incubated 
in the absence (NC) and presence of the cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min were prepared and stained with saturating conjugated antibodies 
or isotype-IgG control (ISO), including unstained (US) samples to gate for negative 
fluorescence. Cells were washed with PBS (+BSA) and fixed by addition of equal 
volumes of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). 
Cells were then analysed for expression of the surface antigens using the flow 
cytometer. 
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6.3.4 Expression of surface CD11b on differentiated PLB-985 cells 
  
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were stained 
with saturating PE-conjugated CD11b antibody or isotype-matched IgG control and 
then analysed for expression of CD11b marker using the flow cytometer. Figure 6.5A-
B shows the expression of CD11b on PLB-985 and dPLB-985 cells. Very low and 
insignificant expression of the surface receptor was measured on the non-
differentiated PLB-985 cells (MFI 13.01 ± 2.69 – 16.00 ± 2.81) over the 6 days culture 
period.  
 
However, following differentiation into neutrophil-like cells, expression of this receptor 
significantly (p≤0.05) increased in these cells; day 3 (MFI 37.87 ± 5.56), day 5 (MFI 
45.22 ± 1.19) and day 6 (MFI 37.99 ± 5.33), with day 5 showing the highest 
expression. The percent positive cells showed a similar and parallel trend for cells 
grown under both culture conditions. This shows that differentiation induces the 
expression of surface CD11b on differentiated PLB-985 cells, but this was lower than 
the expression levels observed on neutrophils (Figure 6.1). Representative traces of 
surface CD11b expression on PLB-985 and dPLB-985 cells is shown in Figure 6.5C. 
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Figure 6.5 Effect of differentiation of PLB-985 cells on the expression of CD11b. 
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were prepared 
and stained with saturating PE-conjugated CD11b antibody or isotype-IgG control. 
Stained cells were washed with PBS (+BSA) and fixed by addition of equal volumes 
of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were 
then analysed for the expression of surface CD11b using flow cytometry. (A) Mean 
fluorescence intensity (MFI) (B) Percent positive cells. (C) Representative flow 
cytometer traces of CD11b expression. Data were expressed as means of MFI or 
percent total cells (± SEM, n=3), * = p≤0.05 (paired, one-tailed student’s t-test). 
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6.3.5 Expression of surface CD14 on differentiated PLB-985 cells 
  
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were stained 
with saturating PerCP-conjugated CD14 antibody or isotype-matched IgG control. 
Cells were then analysed for expression of CD14 receptor using the flow cytometer. 
As shown in Figure 6.6A-B, expression of CD14 surface marker on the non-
differentiated PLB-985 cells is very low and statistically insignificant (MFI 10.37 ± 2.16 
– 14.27 ± 0.35) over the culture period. This increased slightly and insignificantly 
following differentiation into neutrophil like cells (D5: MFI 16.83 ± 1.03; D6: MFI 15.15 
± 2.32). The same trend was also observed for the percent positive cells, but this 
increased significantly (p≤0.05) on day 3 (48.22% ± 2.09%) and day 5 (53.71% 
±3.64%). Therefore, differentiation increased the expression of surface CD14 on PLB-
985 cells, but as with neutrophils, this was very low. Figure 6.6C shows representative 
traces of surface CD14 expression on PLB-985 and dPLB-985 cells. 
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Figure 6.6 Effect of differentiation of PLB-985 cells on the expression of CD14. 
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were prepared 
and stained with saturating PerCP-conjugated CD14 antibody or isotype-IgG control. 
Stained cells were washed with PBS (+BSA) and fixed by addition of equal volumes 
of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were 
then analysed for expression of surface CD14 using flow cytometry. (A) Mean 
fluorescence intensity (MFI) (B) Percent positive cells. (C) Representative flow 
cytometer traces of CD14 expression. Data are expressed as means of MFI or 
percent total cells (± SEM, n=3), * = p≤0.05 (paired, one-tailed student’s t-test). 
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6.3.6 Expression of surface CD16 on differentiated PLB-985 cells 
  
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were stained 
with saturating FITC-conjugated CD16 antibody or isotype-matched IgG control. Cells 
were then analysed for expression of surface CD16 receptor by flow cytometry, 
shown in Figure 6.7A-B. There was very low or no expression of CD16 on non-
differentiated PLB-985 cells (MFI 9.85 ± 1.68 – 13.07 ± 1.14) throughout the culture 
period. However, differentiated PLB-985 cells showed a low but significant (p≤0.05) 
increase in the expression of this receptor on day 3 (MFI 14.00 ± 1.51), day 5 (MFI 
17.27 ± 2.04) and day 6 (MFI 15.93 ± 1.33) of culture. There was also a significant 
increase in the percent positive cells for CD16 on day 3 (9.98% ± 1.60%) and day 5 
(13.90% ±1.17%). Therefore, differentiation of PLB-985 cells induced a small 
expression of CD16, but this was very low compared to blood neutrophils. 
Representative traces of CD16 expression on PLB-985 and dPLB-985 cells are 
shown in Figure 6.7C. 
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Figure 6.7 Effect of differentiation of PLB-985 cells on the expression of CD16. 
PLB-985 and dPLB-985 cells cultured for 6 days in unchanged media were prepared 
and stained with saturating FITC-conjugated CD16 antibody or isotype-IgG control. 
Stained cells were washed with PBS (+BSA) and fixed by addition of equal volumes 
of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were 
then analysed for expression of surface CD16 using flow cytometry. (A) Mean 
fluorescence intensity (MFI) (B) Percent positive cells. (C) Representative flow 
cytometer traces of CD16 expression. Data are expressed as means of MFI or 
percent total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, one-tailed student’s 
t-test). 
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6.3.7 Effects of media changes and cytokine addition on the expression of 
CD11b on dPLB-985 cells 
 
dPLB-985 cells differentiated under the optimised conditions involving media changes 
and cytokine supplementation for 6 days as described in Figure 3.16, were incubated 
in the absence (NC) and presence of the cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min and stained with saturating FITC-conjugated CD11b antibody or 
isotype-IgG control. Cells were then analysed for expression of surface CD11b 
receptors by flow cytometry. 
 
Figure 6.8 shows CD11b expression on the surface of differentiated PLB-985 cells. 
The expression level of the receptor in the absence of the cytokine (NC) was low (MFI 
17.18 ± 1.23 – 23.97 ± 2.55) during this culture period. This was, even lower than the 
level of expression measured on dPLB-985 cultured in unchanged media (see Figure 
6.5), this was likely due to the difference in the antibody used: in these experiments, 
the antibody is FITC-conjugated while in Figure 6.5, PE-conjugated CD11b was used. 
Following incubation with the cytokines, this expression increased from day 3: G-CSF 
(D3: MFI 25.32 ± 1.62; D5: MFI 33.71 ± 2.84; D6: MFI 32.58 ± 2.68) and GM-CSF 
(D3: MFI 24.03 ± 3.20; D5: MFI 34.73 ± 2.49; D6: MFI 32.95 ± 3.06), but only on days 
5 and 6 did these increases reached statistical significance (p≤0.05). Representative 
traces of CD11b surface marker expression on differentiated PLB-985 cells under 
these conditions are shown in Figure 6.9. 
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Figure 6.8 Effect of media changes and cytokine addition on the expression of 
surface CD11b on dPLB-985 cells. Cells differentiated under the optimised 
conditions for 6 days (see Figure 3.16) and incubated in the absence (NC) and 
presence of the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min were 
prepared and stained with saturating FITC-conjugated CD11b antibody or isotype-
IgG control. Stained cells were washed with PBS (+BSA) and fixed by addition of 
equal volumes of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS 
(+BSA). Cells were then analysed for expression of CD11b using flow cytometry. (A) 
Mean fluorescence intensity (MFI) (B) Percent positive cells. Data are expressed as 
means of MFI or percent total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, 
two-tailed student’s t-test). 
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Figure 6.9 Representative flow cytometer traces of CD11b expression on dPLB-
985 cells. Cells differentiated under the optimised conditions for 6 days (described in 
Figure 3.16) and incubated in the absence (NC) and presence of the cytokines G-
CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, were prepared and stained with 
saturating FITC-conjugated CD11b antibody or isotype-IgG control (ISO) including 
unstained (US) samples (to gate for negative fluorescence). Cells were washed with 
PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and PFA (4%), 
pelleted and re-suspended in PBS (+BSA). Cells were then analysed for expression 
of CD11b using flow cytometry. 
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6.3.8 Effects of media change and cytokine addition on the expression of CD14  
 
dPLB-985 cells differentiated under the optimised conditions involving media changes 
and cytokine supplementation for 6 days as described in Figure 3.16, were incubated 
in the absence or presence of the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL), 
and stained with saturating PerCP-conjugated CD14 antibody or isotype-IgG control. 
Cells were then analysed for expression levels of CD14 receptors by flow cytometry. 
 
As shown in Figure 6.10, expression of CD14 on the surface of differentiated PLB-
985 cells did not significantly increase over 6 days culture with media changes alone 
(NC) (MFI 14.04 ± 0.83 – 15.28 ± 1.78) when compared to dPLB-985 cells grown in 
unchanged media (Figure 6.6). This however, increased from day 3 following 
incubation with the cytokines G-CSF (D3: MFI 21.64 ± 1.95; D5: MFI 22.67 ± 1.79; 
D6: MFI 19.52 ± 2.87) or GM-CSF (D3: MFI 22.09 ± 1.52; D5: MFI 25.48 ± 1.40; D6: 
MFI 22.62 ± 1.28), but only GM-CSF levels reached statistical significance (p≤0.05) 
on days 5 and 6. Similar to isolated blood neutrophils, expression of surface CD14 on 
differentiated PLB-985 cells was low. Figure 6.11 shows representative traces of 
CD14 surface marker expression on differentiated PLB-985 cells under these 
experimental conditions. 
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Figure 6.10 Effect of media changes and cytokine addition on the expression of 
CD14 on dPLB-985 cells. Cells differentiated under the optimised conditions for 6 
days (described in Figure 3.16) and incubated in the absence (NC) and presence of 
the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, were prepared and 
stained with saturating PerCP-conjugated CD14 antibody or isotype-IgG control. 
Cells were washed with PBS (+BSA) and fixed by addition of equal volumes of PBS 
(+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were then 
analysed for expression of CD14 using flow cytometry. (A) Mean fluorescence 
intensity (MFI) (B) Percent positive cells. Data are expressed as means of MFI or 
percent total cells (± SEM, n=3), * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s 
t-test). 
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Figure 6.11 Representative flow cytometer traces of surface CD14 expression 
on dPLB-985 cells. Cells differentiated under the optimised conditions for 6 days 
(see Figure 3.16) and incubated in the absence (NC) and presence of the cytokines 
G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and stained with 
saturating PerCP-conjugated CD14 antibody or isotype-IgG control (ISO) including 
unstained (US) samples (to gate for negative fluorescence). Stained cells were 
washed with PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and 
PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were then analysed for 
expression of CD11b using flow cytometry. 
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6.3.9 Effects of media changes and cytokine addition on the expression of CD16 
 
dPLB-985 cells differentiated under the optimised conditions involving media changes 
and cytokine supplementation for 6 days as described in Figure 3.16, were incubated 
in the absence or presence of the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL), 
and stained with saturating FITC-conjugated CD16 antibody or isotype-IgG control. 
Cells were then analysed for expression levels of CD16 receptor by flow cytometry. 
 
The expression of CD16 on the surface of differentiated PLB-985 cells is shown in 
Figure 6.12. There was a slight increase in expression of this receptor on dPLB-985 
cells in cultures with media changes alone (NC) (MFI 13.53 ± 0.24 - 14.19 ± 0.63) 
over the culture period, when compared to culture with unchanged media (see Figure 
6.7). This expression was also increased from day 5 following incubation with cytokine 
G-CSF (D5: MFI 17.79 ± 2.17; D6: MFI 16.22 ± 0.75) or GM-CSF (D5: MFI 18.55 ± 
3.05; D6: MFI 17.57 ± 2.40). These increases in MFI however, did not reach statistical 
significance (p≤0.05), but there were significantly more positive cells after days 5 and 
6 of culture in the presence of the cytokines. Overall, expression of CD16 on the 
surface of differentiated PLB-985 remained very low under all experimental conditions 
in comparison to isolated blood neutrophils. Representative traces of CD16 surface 
marker expression on dPLB-985 cells under these conditions is shown on Figure 
6.13. 
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Figure 6.12 Effects of media changes and cytokine addition on the expression 
of CD16 on dPLB-985 cells. Cells differentiated under the optimised conditions for 
6 days (see Figure 3.16) and incubated in the absence (NC) and presence of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, were prepared and 
stained with saturating FITC-conjugated CD16 antibody or isotype-IgG control. 
Stained cells were washed with PBS (+BSA) and fixed by addition of equal volumes 
of PBS (+BSA) and PFA (4%), pelleted and re-suspended in PBS (+BSA). Cells were 
then analysed for the expression of CD16 using flow cytometry. (A) Mean 
fluorescence intensity (MFI) (B) Percent positive cells. Data are expressed as means 
of MFI or percent total cells (± SEM, n=3), * = p≤0.05 (paired, two-tailed student’s t-
test). 
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Figure 6.13 Representative flow cytometer traces of CD16 expression on dPLB-
985 cells. Cells differentiated under the optimised conditions for 6 days (described in 
Figure 3.16) and incubated in the absence (NC) and presence of the cytokines G-
CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, were prepared and stained with 
saturating FITC-conjugated CD16 antibody or isotype-IgG control (ISO), including 
unstained (US) sample (to gate for negative fluorescence). Stained cells were washed 
with PBS (+BSA) and fixed by addition of equal volumes of PBS (+BSA) and PFA 
(4%), pelleted and re-suspended in PBS (+BSA). Cells were then analysed for 
expression of CD11b using flow cytometry. 
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6.3.10 Expression of intracellular CD16 in dPLB-985 cells 
  
The above experiments showed that surface levels of CD16 receptors were low on 
differentiated PLB-985 cells, even in those cultures with cytokine addition and which 
showed good morphological features of neutrophils (Chapters 3 and 4). CD16 
receptors can be located on the cell surface and also intra-cellularly within the 
granules of human neutrophils (Jost et al., 1990). Therefore, it was important to 
determine if there were any intracellular pools of CD16 in differentiated PLB-985 cells. 
 
dPLB-985 cells differentiated under the optimised conditions, involving media 
changes and cytokine supplementation for 6 days as described in Figure 3.16 were 
therefore, incubated in the absence and presence of G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min. The cells were prepared, fixed, permeabilized with 0.1% saponin 
(in PBS) and stained with saturating FITC-conjugated CD16 antibody or isotype-IgG 
control as described in the Methods. The permeabilized cells were then analysed for 
intracellular CD16 receptor expression by flow cytometry. Figure 6.14 shows that 
there was very low, if any, expression of intracellular CD16 in differentiated PLB-985 
cells without cytokine (NC, MFI 11.91 ± 0.58 - 14.86 ± 0.72), as well as with cytokine 
G-CSF (MFI 12.55 ± 0.50 - 15.55 ± 0.59) or GM-CSF (MFI 13.30 ± 0.40 - 15.42 ± 
0.69) over the 6 days culture period. The very small increase in expression observed 
following G-CSF and GM-CSF supplementations, also did not reach statistical 
significance (p≤0.05). 
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Figure 6.14 Expression of intracellular CD16 in differentiated PLB-985 cells. 
Cells differentiated under the optimised conditions for 6 days (described in Figure 
3.16) and incubated in the absence (NC) and presence of the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and fixed by addition of 
equal volumes of PBS (+BSA) and PFA (4%). The cells were permeabilised with PBS 
(+0.1% saponin) and stained with saturating FITC-conjugated CD16 antibody or 
isotype-IgG control. Cells were then washed with PBS (+BSA), pelleted, re-
suspended in PBS (+0.1% saponin) and analysed for the expression of intracellular 
CD16 using flow cytometry. (A) Mean fluorescence intensity (MFI). (B) Percent 
positive cells. Data are expressed as means of MFI or percent total cells (± SEM, 
n=3). 
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Figure 6.15 Representative flow cytometer traces of intracellular CD16 
expression in dPLB-985 cells. Cells differentiated under the optimised conditions 
for 6 days (see Figure 3.16) and incubated in the absence (NC) and presence of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min, were fixed by addition 
of equal volumes of PBS (+BSA) and PFA (4%). The cells were permeabilised with 
0.1% saponin (in PBS) and stained with saturating FITC-conjugated CD16 antibody 
or isotype-IgG control, including unstained (US) samples (to gate for negative 
fluorescence). Cells were then washed with PBS (+BSA), pelleted and re-suspended 
in PBS (+0.1% saponin) and analysed for the expression of intracellular CD16 using 
flow cytometry. 
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6.3.11 Transmigration and chemotaxis of neutrophils  
 
Freshly-isolated blood neutrophils incubated in the absence and presence of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) for 30 min were added into upper 
wells of 24-well poly-hema coated plate, separated by Millipore hanging inserts from 
the lower wells containing fMLP (10-8M), IL-8 (0.1µg/mL), casein (0.5 mg/mL), 
zymosan A activated serum (ZAS) (1µg/mL) or no attractant (NA) in the lower 
chambers, and incubated at 37oC for 90 min. Neutrophil chemotaxis was then 
analysed by counting the number of cells that migrated into each lower well using a 
Multisizer 3 cell coulter counter. 
 
Figure 6.16 shows the transmigration of neutrophils in response to the chemotactic 
factors in the absence of the cytokine (NC): (fMLP 55% ± 4.36%, IL-8 27.67% ± 
3.28%, casein 39.33% ± 4.41% and ZAS 27% ± 3.79%). The number of migrated 
cells increased after incubation with the cytokines G-CSF (fMLP 60.33% ± 4.63%, IL-
8 31% ± 4.04%, casein 42.67% ± 6.01% and ZAS 29.33% ± 4.10%) or GM-CSF (fMLP 
64.67% ± 4.91%, IL-8 34.33% ± 6.64%, casein 47.67% ± 2.03% and ZAS 31.67% ± 
2.73%), but none of these increases reached statistical significance (p≤0.05). 
Neutrophils showed strong responses to all the chemotactic factors, with fMLP being 
the strongest. 
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Figure 6.16 Transmigration of neutrophils towards chemotactic attractants. 
Freshly-isolated neutrophils incubated without (NC) and with the cytokines G-CSF 
(10ng/mL) or GM-CSF (5ng/mL) for 30 min were prepared and added into upper wells 
of 24-well poly-hema coated plate, separated by Millipore hanging inserts (3 µm pore 
sized filters) from the lower wells containing fMLP (10-8M), IL-8 (0.1µg/mL), casein 
(0.5 mg/mL), zymosan-activated serum (1µg/mL) (ZAS contains complement factor 
C5a, as the active attractant) or no attractant (NA) in the lower chambers. Samples 
were incubated at 37oC for 90 min and neutrophil chemotaxis assessed by counting 
the number of cells that transmigrated into each well using a Multisizer 3 cell coulter 
counter, following a 1:1000 dilution with Isoton II. Data are expressed as percentages 
of total number of cells added originally and compared to non-cytokine treated 
samples (± SEM, n=3). 
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6.3.12 Transmigration and chemotaxis of differentiated PLB-985 cells  
 
dPLB-985 cells differentiated under the optimised conditions involving media changes 
and cytokine supplementation for 6 days as described in Figure 3.16, were incubated 
as discussed in section 6.3.10. The migration of differentiated PLB-985 cells in 
response to the different chemotactic factors is shown in Figure 6.17. The assay was 
performed on days 5 and 6 of culture and the cells displayed similar responses, with 
day 5 responses slightly higher. For example, at day 5 (Figure 6.17A), the percent 
chemotactic responses in the absence of the cytokine (NC) were: fMLP 10.33% ± 
0.88%, IL-8 15.40% ± 2.03%, casein 37.33% ± 3.53% and ZAS 31.00% ± 2.08%. 
These responses were increased following incubation with the cytokines G-CSF or 
GM-CSF.  
Unlike neutrophils which showed strongest chemotactic response to fMLP, 
differentiated PLB-985 cells showed lowest response to this formyl peptide, whereas 
their responses to casein and zymosan-activated serum (ZAS) were greater. This 
difference in chemotactic responses of neutrophils and differentiated PLB-985 cells 
to fMLP is consistent with that observed for chemiluminescence and oxidative burst 
activation as described in Chapter 5, and is likely explained by the same reason: 
differences in the expression of formyl peptide receptors, which may not be expressed 
on the differentiated PLB-985 cells. Casein and activated serum on the other hand 
may have attracted these cells via different receptors or via receptor-independent 
mechanism. Non-differentiated PLB-985 did not show chemotactic migration in 
response to stimulation with any of the attractants (data not shown). This further 
suggests that differentiation of PLB-985 into mature neutrophil-like cells triggered the 
observed chemotactic migration.  
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Figure 6.17 Transmigration of dPLB-985 cells towards chemotactic attractants. 
Cells differentiated under the optimised conditions for 6 days (see Figure 3.16) and 
incubated without (NC) and with the cytokines G-CSF (10ng/mL) or GM-CSF 
(5ng/mL) for 30 min were, prepared and added into upper wells of 24-well poly-hema 
coated plates, separated by Millipore hanging inserts (3 µm pore sized filters) from 
the lower wells containing fMLP (10-8M), IL-8 (0.1µg/mL), casein (0.5 mg/mL), ZAS 
(complement factor C5a) (1µg/mL) or no attractant (NA) in the lower chambers. 
Samples were incubated at 37oC for 90 min and dPLB-985 cells chemotaxis assessed 
by counting the number of cells that transmigrated into each well using a Multisizer 3 
cell coulter counter, following a 1:1000 dilution with Isoton II. (A) dPLB-985 cells at 
day 5 of culture (B) dPLB-985 cells at day 6 of culture. Data are expressed as 
percentages of total number of cells added originally and compared to the NC 
samples (± SEM, n=3), * = p≤0.05 (paired, two-tailed student’s t-test). 
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6.3.13 Effect of differentiation of PLB-985 cells on the activation of STAT3 
  
dPLB-985 cells differentiated under the optimised conditions involving media changes 
and cytokine supplementation for 6 days as described in Figure 3.16, were incubated 
in the absence or presence of the cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL) 
for 30 min. Protein lysates were then prepared and probed for activated STAT3 
(pSTAT3), pan STAT3 and Actin protein levels by western blotting. 
 
Figures 6.18-19 shows that pSTAT3 was not detected in dPLB-985 cells under these 
experimental conditions. However, pan STAT3 was detected in differentiated PLB-
985 cells cultured with media changes, which slightly increased in cells incubated with 
G-CSF (Figure 6.18) and GM-CSF (Figure 6.19). Levels of expression of the protein 
decreased with increasing differentiation and the rate of decline was lower in cells 
incubated with cytokines than those with media changes alone. The expression of 
activated STAT3 (pSTAT3) in non-differentiated PLB-985 cells was equally not 
detected (data not shown). The activity of the pSTAT3 antibody used in these 
experiments was confirmed in other studies in our laboratory, in which the expression 
of pSTAT3 in protein extracts from isolated neutrophils and Lama 84 cells both 
incubated with GM-CSF for 15-30 min were detected (data not shown). 
 
 
 
 
 
 
 
238 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.18 Effect of differentiation of PLB-985 cells and G-CSF on STAT3 
activation. Cells were differentiated under the optimised conditions for 6 days (see 
Figure 3.16) and incubated in the absence (NC) and presence of the cytokines G-
CSF (10ng/mL) for 30 min. Protein extracts were prepared on days 1, 3, 5, and 6 of 
culture and probed for activated STAT3 (pSTAT3), pan STAT3 and Actin expression 
levels by western blotting. (A) Western blots showing pSTAT3 (not detected), STAT3 
(79-86 KDa) and Actin (42 KDa) representing three separate experiments as 
described above. (B) Densitometric analysis of pan STAT3 levels (normalised to the 
Actin signal which was the loading control). Data are expressed as percentages of 
day 1 taken as 100% (± SEM, n=3), * = p≤0.05 (paired, two-tailed student’s t-test). 
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Figure 6.19 Effect of differentiation of PLB-985 cells and GM-CSF on STAT3 
activation. Cells were differentiated under the optimised conditions for 6 days (as 
described in Figure 3.16) and incubated in the absence or presence of GM-CSF 
(5ng/mL) for 30 min. Protein extracts were prepared on days 1, 3, 5, and 6 of culture 
and probed for activated STAT3 (pSTAT3), pan STAT3 and Actin expression levels 
by western blotting. (A) Western blots showing pSTAT3 (not detected), STAT3 (79-
86 KDa) and Actin (42 KDa) representing three separate experiments as described 
above. (B) Densitometric analysis of pan STAT3 levels (normalised to the Actin signal 
which was the loading control). Data are expressed as percentages of day 1 taken as 
100% (± SEM, n=3). 
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6.4 Discussion and conclusions 
 
Molecular heterogeneity of pathogens, particularly heterogeneity of their surface 
properties makes their recognition by neutrophils for binding and elimination, a 
challenging task. However, by virtue of various cell surface receptors, neutrophils 
recognise pathogens and other particles, which may or may not be opsonised by 
immunoglobulins or complement fragments. Some of these receptors recognise 
innate microbial structures, while others recognise opsonins generated during the 
inflammatory environment (e.g. complement fragments), while other receptors (e.g. 
FcγRs) are associated with activation of the adaptive immune response (Futosi et al., 
2013). Priming of neutrophils by cytokines enhances the number and/or affinity of 
these receptors (Hallett & Lloyds, 1995). These receptors orchestrate the multi-step 
antimicrobial and inflammatory responses culminating in the clearance of invading 
pathogens, as well as the initiation of adaptive immune response (Parker, et al., 
2005). Many of these essential components of the neutrophil cytotoxic machinery are 
present in the membranes of mobilizable intracellular granules which are recruited to 
the plasma membrane following stimulation of degranulation (Sengelov, et al., 1993).  
 
The data presented in this Chapter have shown that CD11b (α-subunit of CR3/Mac-
1) is highly expressed on both neutrophils and differentiated PLB-985 cells, with 
higher expression levels on neutrophils compared to differentiated PLB-985 cells. 
CD11b is one of the most abundant β2-integrin on neutrophils, and is essential for 
their adherence to the endothelium during chemotaxis, diapedesis and phagocytosis 
of opsonised particles (Futosi et al., 2013). Both the isolated blood neutrophils and 
the neutrophil-like differentiated PLB-985 cells showed significantly increased 
expression of CD11b following incubations with the pro-inflammatory cytokines G-
CSF and GM-CSF. This finding agrees with other published reports on up-regulation 
of CD11b expression on neutrophils by G-CSF and GM-CSF  (Drayson, et al., 2001; 
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Repo, et al., 1993). Similarly, Volk et al., reported an increased cell surface 
expression of CD11b on neutrophils and differentiated cells following priming with 
TNF-α (Volk et al., 2011). GM-CSF was shown to up-regulate the expression of 
CD11b and CD18 rapidly, as well as enhance fMLP- induced ROS generation in 
neutrophils (Edwards, et al., 1990). 
 
CD11b receptors are stored intracellularly in neutrophil granules from where they are 
recruited to replenish the cell surface levels following stimulation with inflammatory 
mediators or during phagocytosis (Edwards, 1994). Mobilization of intracellular stores 
of some proteins, such as the adhesion molecules, is one of the underlying 
mechanisms for the generation of a ‘primed’ cell phenotype, which enhances the 
readiness of neutrophils to respond to subsequent stimuli (Volk et al., 2011). 
Furthermore, some abnormalities of phagocytic functions in humans have been 
associated with deficiencies in adhesion proteins, such as the Mac-1/CD11b/CD18 
family (Springer, et al., 1984).  
 
The expression of myeloid cell receptor, CD14 on neutrophils and differentiated PLB-
985 cells investigated in this Chapter has demonstrated that CD14 surface receptor 
is expressed at low levels in both cell types. This is not unexpected, because CD14 
is known to be strongly expressed on monocytes and macrophages only, and at lower 
levels on granulocytes (Simmons, et al., 1989). However, consistent with other 
reports (Fleck & Nahm, 2005; Wright et al., 1991), both neutrophils and differentiated 
PLB-985 cells showed significantly enhanced expression of CD14 following 
incubations with stimulatory cytokines G-CSF and GM-CSF, but the level of 
expression on differentiated PLB-985 was not as high as that observed on isolated 
blood neutrophils. 
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CD14 on the surface of neutrophils serves several roles in innate immunity. It 
recognises LPS-opsonised particles and LPS-binding protein (LBP) and mediates the 
formation of LPS-LBP complex, thereby playing a role in the clearance of Gram-
negative bacteria (Vosbeck et al., 1990). Also, LPS binding to CD14 causes increased 
activity of the adhesion receptor CD11b/CD18, promoting the neutrophils response 
to bacterial endotoxin, LPS (Dahinden et al., 1983). Besides its role as an innate 
immune receptor for ‘non-self’ infectious particles, CD14 also interacts with ‘self’ 
apoptotic bodies, in a receptor-ligand manner on the surface of apoptotic cells, 
leading to their non-inflammatory elimination (Devitt et al., 1998). In fact, CD14 serves 
as a recognition molecule for several other microbial constituents, in addition to LPS, 
including peptidoglycans, streptococcal cell wall polysaccharides, yeast cell wall 
protein as well as Gram-positive and Gram-negative bacteria cell wall components. 
In this way, CD14 potentially makes several molecules available when it binds 
apoptotic cells surface (Pugin et al., 1994). 
 
The data presented on the expression of the low affinity immunoglobulin G receptor, 
CD16 showed that it was strongly expressed on isolated blood neutrophils, while 
incubation with G-CSF and GM-CSF further enhanced its expression levels. These 
data lend support to the reports by others (Bruhns, 2012; Perussia et al., 1983) that 
stimulation of neutrophils with cytokines, such as GM-CSF triggers rapid shedding of 
FcγRIIIb from the surface and concurrent replenishment from the internal pools. 
FcγRIII has two isoforms a and b, but human neutrophils constitutively express only 
FcγRIIIb (CD16b) and this is expressed at higher densities than all other FcγRs. CD16 
is heavily glycosylated and anchored to the membrane via a glycosyl-phosphatidyl-
inositol (GPI) linkage which enables its cleavage from the cell surface during shedding 
to provide regulation of surface expression. Hence, stimulation by cytokines, such as 
GM-CSF triggers rapid shedding and concurrent replenishment of FcγRIIIb to the cell 
surface (Bruhns, 2012; Perussia et al., 1983). GM-CSF also stimulates neutrophil 
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gene expression, delays apoptosis and maintains the expression of cell surface CD16 
through mobilisation of intracellular stores of the pre-formed receptor (Moulding, et 
al., 1999).  
 
Paradoxically, the neutrophil-like differentiated PLB-985 cells did not express 
appreciable amounts of surface CD16. While incubation with G-CSF and GM-CSF 
significantly enhanced its expression on these cells, the levels were nevertheless, 
very low compared to blood neutrophils. A previous study (Selmeczy, et al., 2003) 
however, reported expression of CD16 on DMF-differentiated PLB-985 cells by FACS 
analysis, whereas contrary to this, Pivot-pajot et al., reported a failure to detect CD16 
expression on any of the PLB-985 cells differentiated with DMSO, DMF or dbcAMP 
by western blot analysis (Pivot-Pajot, et al., 2010). There was also an extremely low, 
or zero expression of intracellular CD16 by differentiated PLB-985 cells, which could 
mean that there were little if any, internal stores of this receptor in these differentiated 
cells.  
 
Neutrophils displayed a strong directional chemotactic transmigration towards fMLP 
and casein, and slightly lower chemotaxis towards IL-8 and zymosan-activated 
serum. Interestingly, differentiated PLB-985 cells also responded positively to all 
these factors. However, contrary to neutrophils which showed greater response 
towards fMLP, differentiated PLB-985 cells displayed a very low response towards 
this bacterial peptide and the cytokine IL-8, whereas their responses towards casein 
and zymosan activated serum were higher. The differences in chemotactic responses 
of neutrophils and differentiated PLB-985 cells to fMLP and IL-8 were similar to the 
responses observed previously in chemiluminescence and oxidative burst activation, 
between the two cell types described in Chapter 5, and were likely to be explained by 
the same reason, i.e. absence or low expression of specific receptors, on the 
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differentiated PLB-985 cells, as functions of these molecules are receptor-coupled 
(Futosi, et al., 2013; Bruhns, 2012; Migeotte et al., 2006).  
 
Chemotactic responses of both neutrophils and differentiated PLB-985 towards all 
these attractants were slightly enhanced following incubations with G-CSF and GM-
CSF. This observation concurs with the effects of the two colony stimulating factors 
(CSFs) on the regulation of various functional responses of blood neutrophils, 
including enhancement of differentiation, activation and survival (Barreda et al., 2004; 
Biethahn et al., 1999), receptor expression (Moulding et al., 1999), respiratory burst 
activation (Edwards et al., 1989) and chemotaxis (Wright  et al., 2014; Kennedy & 
Deleo, 2000). Sirak et al., reported that fMLP stimulated the production of hydrogen 
peroxide in dbcAMP differentiated HL-60 cells, but failed to induce chemotactic 
migration (Sirak et al., 1990). On the contrary, another study found that fMLP induced 
chemotaxis in DMF differentiated HL-60 cells (Fontana, et al., 1980), whilst Hauert et 
al., reported that the cytokine IL-8 was less effective in stimulating chemotaxis of 
differentiated HL-60, compared to neutrophils (Hauert et al., 2002). Under my 
experimental conditions, both fMLP and IL-8 induced chemotaxis in differentiated 
PLB-985 cells but fewer cells transmigrated as compared to blood neutrophils. 
 
Chemotaxis is a special form of movement that involves temporal and spatial 
regulation of the cytoskeleton and intracellular signal transduction pathways, as well 
as re-organisation of the plasma membrane lipids. Migration of a cell towards a 
chemotactic attractant requires interaction of the attractant with the cell surface (Van 
Epps et al., 1977). Neutrophils are among the fastest moving cells in mammals, and 
their recruitment from the blood into the surrounding tissues, essentially involve three 
steps: tethering and rolling of the cells along the vascular endothelium; firm adhesion 
to the endothelium and finally their emigration into the tissue, through the endothelium 
(Kubes, 2002). To effectively clear an infection or inflammation, neutrophils must 
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reach the affected sites very rapidly. Upon stimulation, they can respond to both 
endogenous and exogenous chemotaxins, polarize and migrate directionally along 
the attractant’s gradient. However, the mechanisms by which the cell detects the 
gradient, prioritize the numerous, divergent signals and migrate directionally up the 
gradient still remain to be completely elucidated (Nuzzi et al., 2015). Once at the site, 
neutrophils release antimicrobial peptides, reactive oxygen metabolites, and secrete 
many cytokines and chemokines, that collectively degrade and eliminate the invading 
microbe. 
 
It was important to investigate the effects of differentiation of PLB-985 cells and 
cytokines on the activation status of signalling pathways related to the neutrophil 
functions. Under my experimental conditions, differentiated PLB-985 cells failed to 
activate STAT3 as no expression of pSTAT3 was detected. This activated protein 
was equally not expressed in non-differentiated PLB-985 cells, whereas pan STAT3 
was detected in differentiated PLB-985 cells which was slightly raised following 
incubation with the cytokines G-CSF and GM-CSF. The levels of expression of this 
protein decreased with increasing differentiation time or as the cells aged in the 
culture, but the decline rate was slowed in G-CSF and GM-CSF incubated cells. 
Further studies are however, necessary to investigate the validity of this finding as 
well as the activities of other important neutrophil intracellular signalling pathways, 
such as STAT5, Akt, Erk and p38-MAPK in the differentiated PLB-985 cells.  
 
In conclusion, results presented in this Chapter showed that, except for STAT3 
activation, differentiated PLB-985 cells exhibited strikingly similar responses to the 
neutrophils in the functions investigated, such as expression of various cell surface 
receptors, transmigration and chemotaxis, even though the levels of expression 
and/or responses were lower in magnitude compared to those of isolated blood 
neutrophils. 
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Chapter 7: Effect of JAK inhibitors, Baricitinib and Tofacitinib 
on growth, differentiation and viability of dPLB-985 cells 
    
7.1 Introduction 
 
The Janus Associated Kinase-Signal Transducer and Activator of Transcription (JAK-
STAT) is a critical intracellular signal transduction pathway, downstream of many 
cytokine receptors in almost all multicellular organisms. Janus associated kinases are 
a family of tyrosine kinases that play important roles in both innate and adaptive 
immunity, as well as in haematopoiesis. JAK family kinases consist of four members, 
JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase 2) and while JAK1, JAK2 and TYK2 
are expressed ubiquitously, JAK3 is only expressed in haematopoietic cells  (Clark et 
al., 2014). Nearly 40 cytokine receptors signal through combinations of the four JAKs 
and seven STATs, indicating common features across the JAK-STAT signalling 
cascade (Murray, 2007).  
 
Cytokines regulate many important cellular functions related to haematopoiesis, 
proliferation, differentiation, maturation and apoptosis (Wu & Sun, 2012). Several 
cytokine receptors signal through the JAK-STAT and the MAP Kinase pathways 
(Murray, 2007).  Inflammatory cytokine receptors signal through JAK1 and JAK2, and 
conversely, several growth factor receptors required for myeloid and erythroid 
haematopoiesis signal through JAK3 (Meyer et al., 2010). In resting cells, JAKs 
interact with subcellular domains of type I and type II cytokine receptors, and upon 
binding of a cytokine to its cognate receptor, JAKs are activated, which in turn 
activates STAT proteins by tyrosine phosphorylation, leading to a rapid signalling from 
the plasma membrane to the nucleus, where the activated transcription factors 
modulate the expression of target genes (see Figure 1.9) (Meyer et al., 2010; 
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Vijayakrishnan et al., 2010). Aberrant expression of cytokines and growth factors has 
been implicated in the pathogenesis of autoimmune and chronic inflammatory 
diseases (Imada & Leonard, 2000). 
 
Biologic drugs targeting specific cytokines and their receptors, such as TNF-α 
inhibitors have been developed and have proven effective in the treatment of chronic 
inflammatory diseases, including rheumatoid arthritis (Maini & Taylor, 2000). 
However, factors such as emerging resistance, increased rates of infection, high 
costs of treatment, as well as injection-related complications, have led to the search 
for safer drugs that can selectively interfere with molecular mediators of cytokine 
signalling and whose actions are limited to immune cells (Pesu et al., 2008). In this 
context, several orally-active, low molecular weight (<800 Da) JAK inhibitors that 
target specifically the disease-associated molecules and cytokine receptor signalling 
pathways are being developed as therapeutic agents (Meyer et al., 2010). Currently, 
there are at least 10 different JAK inhibitors at various phases of clinical trials (Furqan 
et al., 2013). 
 
Baricitinib (LY-3009104) and Tofacitinib (CP-690550) are among the JAK inhibitors 
in advanced stages of clinical trials, for the treatment of haematopoietic disorders, 
transplant rejection as well as autoimmune and inflammatory diseases (Miossec, 
2013). Baricitinib  is a potent and selective inhibitor of JAK1 and JAK2 enzymes (Shi 
et al., 2014) while Tofacitinib is a novel and specific inhibitor of JAK3 and JAK1 (JAK3 
forms a complex with JAK1, so JAK3 inhibition affects JAK1). Tofacitinib was initially 
developed as a selective JAK3 inhibitor, but recent studies in cell culture have shown 
that it suppressed JAK1/3, JAK1/2, and JAK1/TYK2 cytokine signalling, but with much 
lower activity against JAK2. Many of these effects on different JAKs are however, 
concentration dependent (Miossec, 2013, Ghoreschi et al., 2011).   
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 JAK-STAT signalling enhances the expression of many inflammatory cytokines and 
chemokines. This suggests that JAK inhibitors may inhibit production of cytokines and 
chemokines (Hu & Ivashkiv, 2009), which partly explains their efficacy in the treatment 
of inflammatory diseases (Yarilina et al., 2012). Thus, it would be worthwhile to 
investigate the effects of these small molecule JAK inhibitors on proliferation, 
differentiation and survival of differentiated PLB-985 cells, with focus on the 
proinflammatory cytokines G-CSF and GM-CSF, because of their pivotal roles in 
differentiation and survival of granulocytes. 
 
The aims of the work in this Chapter therefore were: 
 
1. To determine the effect of JAK inhibitors, baricitinib and tofacitinib on the 
growth, differentiation and viability of dPLB-985 cells cultured without and with 
differentiation media changes. 
2. To determine the effect of these JAK inhibitors on growth, differentiation and 
viability of dPLB-985 cells in presence of the cytokines, G-CSF and GM-CSF. 
 
 
7.2 Methods 
 
dPLB-985 cells were differentiated under the different conditions described in Chapter 
3. The cells were incubated in the absence and presence of JAK inhibitors baricitinib 
(200ng/mL) or tofacitinib (200ng/mL) for 30 min followed by addition of the cytokines 
G-CSF (10ng/mL) or GM-CSF (5ng/mL) and the cells were assayed for the following 
functions. 
 
i. Cell growth: Cell numbers were measured using the Multisizer 3 coulter 
cell counter, following a 1:1000 dilution with Isoton II.  
249 
 
ii. Cell viability: Cell’s viability was analysed using the Guava viaCount 
assay on the flow cytometer. 
iii. Cell morphology: Differentiation and apoptosis were determined via cell 
morphology examination. Following different incubations, cytospin slides 
of cells samples were prepared and stained with rapid Romanowsky 
stains. Cell morphology was then viewed under a light microscope. Cells 
images were captured using a microscope-mounted camera and percent 
differentiated or apoptotic cells determined manually by differential cell 
counting.  
 
 
7.3 Results 
 
7.3.1 Effects of Jak inhibitors on growth of dPLB-985 cells 
 
Cells at 4×105/mL were incubated without (NI) and with JAK inhibitors baricitinib 
(200ng/mL) or tofacitinib (200ng/mL) in differentiation media for 7 days, without and 
with media changes and inhibitor replenishment on days 2 and 4, and the cell 
numbers were counted using the Multisizer 3 coulter cell counter.  
 
Figure 7.1 shows the growth curve of dPLB-985 cells cultured under these conditions. 
Uninhibited cells cultured without media changes (Figure 7.1A) grew exponentially, 
reaching a maximum population density on day 4: 2.44×106 ± 5.87×104 and then 
numbers declined over the following 3 days of culture. In the presence of baricitinib, 
cell numbers were consistently lower than in the absence of this inhibitor, while 
tofacitinib further decreased the cell counts. Cells cultured with media changes on 
days 2 and 4 (Figure 7.1B) showed enhanced exponential growth, with maximum 
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density on day 5: 2.60×106 ± 9.56×104, which then declined during culture over the 
following 3 days. In the presence of baricitinib, cell numbers were decreased 
significantly (p≤0.05) and a maximum cell density at day 5 was 2.24×106 ± 5.73×104. 
Similarly, in the presence of tofacitinib, cell numbers were decreased at day 5 to 
2.02×106 ± 8.00×104. Hence, while the media changes significantly enhanced the 
growth rate of dPLB-985 cells compared to no media changes, this enhanced growth 
was downregulated by inhibition with baricitinib and tofacitinib, with the latter showing 
a more inhibitory effect. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
251 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Effect of JAK inhibitors on the growth of differentiated PLB-985 cells. 
Exponentially growing PLB-985 cells at a starting density of 4×105/mL were incubated 
without (NI) and with the JAK inhibitors baricitinib (200ng/mL) or tofacitinib 
(200ng/mL) in differentiation media. The cultures were incubated for 7 days without 
(A, NMC) and with media changes (B, MC) and inhibitor replenishments on days 2 
and 4 of culture, and cell numbers counted daily using the multisizer 3 coulter counter 
following a 1:1000 dilution with Isoton II. Data are expressed as mean of total cell 
number (± SEM, n=3), * = p≤0.05, ** = p≤0.01, * and ˟ indicate significant levels of 
baricitinib and tofacitinib respectively, compared to cell numbers of uninhibited cells 
at the same time point (paired, two-tailed student’s t-test). 
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7.3.2 Effects of Jak inhibitors on growth of dPLB-985 cells in the presence of 
cytokines 
 
Cells seeded at 4×105/mL were incubated without (NI) and with the JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by addition of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5 ng/mL). The cultures were incubated for 
7 days with differentiation media changes and replenishment of inhibitors and 
cytokines on days 2 and 4, and the cell numbers were counted using the Multisizer 3 
coulter cell counter. 
 
Growth of dPLB-985 cells incubated with JAK inhibitors and cytokines is shown in 
Figure 7.2. Uninhibited cells (NI) incubated with G-CSF (Figure 7.2A) exhibited a 
maximum population density on day 5: 2.85×106 ± 8.33×104, which declined over 
days 6 and 7. This is a markedly high growth compared to uninhibited cells with 
differentiation media changes alone (MC, Figure 7.1B). However, these cell numbers 
significantly decreased following incubation with baricitinib, which showed cell density 
of 2.41×106 ± 8.50×104 at day 5. Uninhibited cells (NI) incubated with GM-CSF (Figure 
7.2B) showed enhanced cell number, with maximum growth of 3.26×106 ± 6.49×104 
on day 5, also compared to uninhibited cultures with differentiation media changes 
alone (MC, Figure 7.1B). Again, incubation with baricitinib significantly (p≤0.05) 
decreased the growth: at day 5 the cell density was 2.35×106 ± 7.83×104. Similarly, 
tofacitinib inhibited GM-CSF enhanced cell growth: day 5 cell density of 2.06×106 ± 
4.91×104. Both cytokines therefore, significantly enhanced the growth of dPLB-985 
cells with GM-CSF showing stronger effect. However, these growth-stimulating 
effects of the cytokines were downregulated significantly by both inhibitors, with 
tofacitinib showing greater effects. 
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Figure 7.2 Effect of JAK inhibitors on growth of dPLB-985 cells in the presence 
of cytokines. Exponentially-growing PLB-985 cells at a starting density of 4×105/mL 
were incubated without (NI) and with the JAK inhibitors baricitinib (200ng/mL) or 
tofacitinib (200ng/mL) for 30 min, followed by the addition of the cytokines G-CSF 
(A,10ng/mL) or GM-CSF (B, 5ng/mL) and incubated for 7 days. Fresh differentiation 
media changes and replenishment of inhibitors and cytokines were made on days 2 
and 4. Cell numbers were counted daily using the multisizer 3 coulter counter, 
following a 1:1000 dilution with Isoton II. Data are expressed as mean of total cell 
number (± SEM, n=3), * = p≤0.05, ** = p≤0.01, * and ˟ indicate significant levels of 
baricitinib and tofacitinib respectively, compared to cell numbers of uninhibited cells 
at the same time point (paired, two-tailed student’s t-test). 
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7.3.3 Effects of Jak inhibitors on the viability of dPLB-985 cells 
 
Cells were seeded at 4×105/mL and incubated without (NI) and with the JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) in differentiation media for 7 days, 
without and with media changes and inhibitor replenishments on days 2 and 4. Cells 
viability was measured using the Guava viaCount assay by flow cytometry. The initial 
viability of PLB-985 cells at day 0 before induction of differentiation was 97.10% ± 
0.30%. In cells cultured with unchanged differentiation media (NMC: Figure 7.3A), 
this viability declined progressively over the incubation period, being 60.11% ± 2.91% 
at day 5 and 26.97% ± 0.60% at day 7.  
 
There was also significant (p≤0.05) decrease in viability following incubation with 
baricitinib, for example 53.45% ± 3.69% at day 5 and 21.97% ± 2.29% at day 7. These 
effects on viability were even more pronounced after incubation with tofacitinib: 
48.45% ± 1.32% at day 5 and 20.30% ± 2.82% at day 7. Whereas in cells cultured 
with media changes (MC: Figure 7.3B), the viability also declined: 68.82% ± 2.31% 
viability at day 5 and 43.60% ± 2.94% at day 7, but this was higher than culture with 
unchanged media. There was also a significant (p≤0.05) progressive decrease in this 
viability following incubation with baricitinib: 63.50% ± 1.60% at day 5 and 36.92% ± 
2.86% at day 7, and with tofacitinib: 60.16% ± 1.93% at day 5 34.92% ± 2.41% at day 
7. Therefore, the viability of dPLB-985 cells was markedly enhanced when the 
differentiation media was replaced at day 2 and 4, but the JAK inhibitors, baricitinib 
and tofacitinib reversed this increase in viability.  
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Figure 7.3 Effect of JAK inhibitors on viability of differentiated PLB-985 cells. 
Exponentially-growing dPLB-985 cells at a starting density of 4×105/mL were 
incubated without (NI) and with the JAK inhibitors baricitinib (200ng/mL) or tofacitinib 
(200ng/mL), for 7 days without (A, NMC) and with fresh media changes (B, MC) and 
inhibitor replenishment on days 2 and 4. Cell viability was measured using the Guava 
viaCount assay by flow cytometry. Data are expressed as mean of percent total cells 
(± SEM, n=3), * = p≤0.05, ** = p≤0.01, * and ˟ indicate significant levels of baricitinib 
and tofacitinib respectively, compared to cell numbers of uninhibited cells at the same 
time point (paired, two-tailed student’s t-test). 
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7.3.4 Effects of Jak inhibitors on viability of dPLB-985 cells in the presence of 
cytokines 
 
Cells seeded at 4×105/mL were incubated without (NI) and with the JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by addition of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5 ng/mL). The cultures were incubated for 
7 days with differentiation media changes and replenishment of inhibitors and 
cytokines on days 2 and 4, and cell viability was measured using the Guava viaCount 
assay by flow cytometry. 
 
Cell viability under these experimental conditions are shown in Figure 7.4. The initial 
viability at the cells at d 0 was 97.03% ± 0.23%. In uninhibited cells (NI) incubated 
with the G-CSF (Figure 7.4A), the cell viability declined during culture: 80.75 ± 0.13% 
at day 5 and 52.88% ± 2.18% at day 7. Therefore, incubation with G-CSF enhanced 
the survival of dPLB-985 cells compared to media changes alone (MC, Figure 7.3B). 
However, in the presence of JAK inhibitors, this viability significantly (p≤0.05) 
decreased. For example, with baricitinib viability was 72.87% ± 1.13% at day 5 and 
44.81% ± 2.34% at day 7, and with tofacitinib viability was 67.02% ± 1.90% at day 5 
and 43.16% ± 1.65% at day 7. 
 
For GM-CSF incubated cultures (Figure 7.4B), the viability of cells in the absence of 
JAK inhibitors (NI) declined slightly over culture period. For example, 86.77% ± 2.86% 
at day 5 and 68.20% ± 1.43% at day 7, which was greater viability compared to 
cultures containing no cytokine (MC, Figure 7.3B). Following incubation with 
inhibitors, the viability decreased significantly (p≤0.05) with baricitinib: 74.90% ± 
2.32% at day 5 and 54.85% ± 0.57% at day 7, and with tofacitinib: 70.24% ± 1.64% 
at day 5 and 48.80% ± 1.30% at day 7. The cytokines G-CSF and GM-CSF promoted 
the survival of dPLB-985 cells considerably, but their effect was also significantly 
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downregulated by both JAK inhibitors. GM-CSF was more potent than G-CSF in 
promoting viability and tofacitinib was more potent than baricitinib in decreasing the 
viability. 
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Figure 7.4 Effect of JAK inhibitors on viability of dPLB-985 cells in the presence 
of cytokines. Exponentially-growing PLB-985 cells at a starting density of 4×105/mL 
were incubated without (NI) and with JAK inhibitors baricitinib (200ng/mL) or 
tofacitinib (200ng/mL) for 30 min, followed by the addition of the cytokines G-CSF 
(A,10ng/mL) or GM-CSF (B, 5ng/mL) and incubated for 7 days. Fresh differentiation 
media changes and replenishment of inhibitors and cytokines were done after day 2 
and 4. Cell viability was measured using the Guava viaCount assay by flow cytometry. 
Data are expressed as mean of percent total cells (± SEM, n=3), * = p≤0.05, ** = 
p≤0.01, * and ˟ indicate significant levels of baricitinib and tofacitinib respectively, 
compared to cell numbers of uninhibited cells at the same time point (paired, two-
tailed student’s t-test). 
 
 
 
259 
 
7.3.5 Effects of Jak inhibitors on differentiation of PLB-985 cells 
 
Cells seeded at 4×105/mL were incubated without (NI) and with JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) in differentiation media. The cultures 
were incubated for 7 days without and with media changes and inhibitor 
replenishment on days 2 and 4. Cytospin slides of differentiated PLB-985 cells were 
prepared daily, stained with rapid Romanowsky stains, and percent differentiated 
cells was determined by differential counting, manually under a light microscope. 
 
Figure 7.5 shows the percent differentiation of dPLB-985 cells. For cultures with no 
media changes (NMC, Figure 7.5A), the percent differentiation in the absence of 
inhibitors (NI) was 51.23% ± 3.11% at day 4 and 54.37% ± 5.01% at day 6, which 
decreased during culture with JAK inhibitors, baricitinib: 47.91% ± 1.68% at day 4 and 
54.05% ± 2.99% at day 6, and tofacitinib: 44.95% ± 2.90% at day 4 and 51.80% ± 
4.97% at day 6, but this decrease did not reach statistical significance. In cultures 
with media changes (MC, Figure 7.5B), percent differentiated cells in the absence of 
inhibitors (NI) was 56.90% ± 3.14% at day 4 and 65.04% ± 3.01% at day 6, indicating 
an increased differentiation compared to no media changes (NMC, Figure 7.5A). 
However, percent differentiation decreased during culture with the JAK inhibitors. For 
example, with baricitinib: 51.91% ± 4.93% at day 4 and 60.05% ± 3.40% at day 6, 
and with tofacitinib: 48.29% ± 3.96% at day 4 and 58.47% ± 2.42% at day 6, but these 
decreases did not reach statistical significance. Therefore, while media changes 
enhanced the differentiation of dPLB-985 cells, this was insignificantly decreased by 
the JAK inhibitors, baricitinib and tofacitinb. Representative cytospin slides images of 
dPLB-985 cells differentiated under these experimental conditions are shown in 
Figure 7.9. 
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Figure 7.5 Effect of JAK inhibitors on differentiation of PLB-985 cells. 
Exponentially-growing PLB-985 cells at a starting density of 4×105/mL were incubated 
without (NI) and with JAK inhibitors baricitinib (200ng/mL) or tofacitinib (200ng/mL) 
for 6 days without (A, NMC) and with media changes (B, MC) and inhibitors 
replenishment on days 2 and 4. Cytospin slides of cells were prepared, stained with 
rapid Romanowsky stain daily, and percent differentiated cells determined by 
differential counting manually under the light microscope. Data are expressed as 
mean of percent total cells (± SEM, n=3), and compared to cell numbers of uninhibited 
cells at the same time point. 
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7.3.6 Effects of Jak inhibitors on differentiation of PLB-985 cells in the presence 
of cytokines 
 
Cells seeded at 4×105/mL were incubated without (NI) and with the JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by addition of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5 ng/mL). The cultures were incubated for 
7 days with differentiation media changes and replenishment of inhibitors and 
cytokines on days 2 and 4. Cytospin slides of differentiated PLB-985 cells were 
prepared daily, stained with rapid Romanowsky stain, and percent differentiated cells 
was determined by differential counting manually, under the light microscope. As 
shown in Figure 7.6, the percent differentiation of cells incubated with G-CSF in the 
absence (NI) of JAK inhibitors (Figure 7.6A) was 67.21% ± 1.76% at day 4 and 
76.51% ± 2.11% at day 6, but this decreased significantly (p≤0.05) following 
incubation with baricitinib: 59.45% ± 2.97% at day 4 and 70.35% ± 2.12% at day 6 
and with tofacitinib: 54.36% ± 3.35% at day 4 and 66.40% ± 2.26% at day 6. In GM-
CSF incubated cultures (Figure 7.6B), the percent differentiated cells in the absence 
of JAK inhibitors (NI) was higher than that observed with G-CSF. For example, 
71.70% ± 1.33% on day 4 and 77.53% ± 2.53% on day 6, which also decreased 
significantly (p≤0.05) following incubation with baricitinib: 63.33% ± 3.24% at day 4 
and 70.37% ± 2.17% at day 6, and with tofacitinib: 57.97% ± 4.52% at day 4 and 
66.67% ± 3.30% at day 6.  
 
It is therefore, evident from these data that incubation with both G-CSF and GM-CSF 
substantially enhanced the differentiation of PLB-985 cells, compared to media 
changes alone. However, these effects were down-regulated by incubations with 
baricitinib and tofacitinib. Representative cytospin slides images of dPLB-985 cells 
differentiated under these experimental conditions are shown in Figures 7.10 and 
7.11. 
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Figure 7.6 Effect of JAK inhibitors on differentiation of PLB-985 cells in the 
presence of cytokines. Exponentially-growing PLB-985 cells at a starting density of 
4×105/mL were incubated without (NI) and with the JAK inhibitors baricitinib 
(200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by addition of the cytokines 
G-CSF (A, 10ng/mL) or GM-CSF (B, 5ng/mL) and incubated for 6 days. Fresh 
differentiation media changes and replenishment of inhibitors and cytokines were 
done on days 2 and 4. Cytospin slides of cells were prepared, stained with rapid 
Romanowsky stain daily, and percent differentiated cells determined by differential 
counting manually under the light microscope. Data are expressed as mean of 
percent total cells (± SEM, n=3), and compared to cell numbers of uninhibited cells at 
the same time point, * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test). 
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7.3.7 Effects of Jak inhibitors on apoptosis of dPLB-985 cells 
  
Cells seeded at 4×105/mL were incubated without (NI) and with JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) in differentiation media. The cultures 
were incubated for 6 days without and with media changes and inhibitor 
replenishment on days 2 and 4. Cytospin slides of cells samples were prepared daily, 
stained with rapid Romanowsky stain, and percent apoptotic cells was determined by 
differential counting manually under a light microscope. 
 
Figure 7.7 shows the apoptosis of dPLB-985 cells under these conditions. For 
cultures with unchanged media (NMC, Figure 7.7A), percent apoptosis in the absence 
of inhibitors (NI) was 32.00% ± 1.73% at day 4 and 38.73% ± 2.05% at day 6. 
Following incubation with JAK inhibitors, apoptosis increased significantly (p≤0.05). 
For example, with baricitinib: 38.00% ± 2.08% at day 4 and 42.70% ± 2.26% at day 
6, and with tofacitinib: 41.74% ± 0.70% at day 4 and 45.17% ± 1.92% at day 6. 
Whereas in cultures with media changes (MC, Figure 7.7B), percent apoptosis in the 
absence of the inhibitors (NI) was: 28.67% ± 2.03% at day 4 and 35.40% ± 1.76% at 
day 6. Although this was lower than the percent apoptosis observed in cultures with 
no media changes (NMC, Figure 7.7A), again the apoptosis markedly increased 
following incubation with JAK inhibitors, baricitinib: 34.67% ± 2.33% at day 4 and 
39.37% ± 1.37% at day 6, and tofacitinib: 38.41% ± 3.28% at day 4 and 41.83% ± 
2.32% at day 6.  
 
This data clearly indicates that differentiation media changes decrease the apoptosis 
of dPLB-985 cells, thereby promoting their survival, but the JAK inhibitors, baricitinib 
and tofacitinib decreased this protective effect of the media changes. Representative 
cytospin slides images of apoptotic dPLB-985 cells under these experimental 
conditions are shown in Figure 7.9. 
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Figure 7.7 Effects of JAK inhibitors on apoptosis of differentiated PLB-985 cell. 
Exponentially-growing PLB-985 cells at a starting density of 4×105/mL were incubated 
without (NI) and with the JAK inhibitors baricitinib (200ng/mL) or tofacitinib 
(200ng/mL) in differentiation media, and the culture incubated for 6 days without (A, 
NMC) and with media changes (B, MC) and inhibitor replenishment on days 2 and 4. 
Cytospin slides of cells samples were prepared, stained with rapid Romanowsky stain 
daily, and percent apoptotic cells determined by differential counting manually under 
the light microscope. Data are expressed as mean of percent total cells (± SEM, n=3) 
and compared to cell numbers of uninhibited cells at the same time point, * = p≤0.05, 
(paired, two-tailed student’s t-test).  
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7.3.8 Effects of Jak inhibitors on apoptosis of dPLB-985 cells in the presence 
of cytokines 
 
Cells seeded at 4×105/mL were incubated without (NI) and with JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by addition of the 
cytokines G-CSF (10ng/mL) or GM-CSF (5ng/mL). The cultures were incubated for 6 
days with differentiation media changes and replenishment of inhibitors and cytokines 
additions on days 2 and 4. Cytospin slides of cells samples were prepared daily, 
stained with rapid Romanowsky stain, and percent apoptotic cells was determined by 
differential counting manually under a light microscope. 
 
For G-CSF incubated cultures (Figure 7.8A), the percent apoptosis in the absence of 
inhibitor (NI) was 21.37% ± 1.89% at day 4 and 30.10% ± 1.88% at day 6, which were 
lower than percent apoptosis observed in cells with media changes alone (MC, 7.7B). 
However, the apoptosis levels were higher in cultures containing the JAK inhibitors. 
For example, with baricitinib: 26.79% ± 1.98% at day 4 and 35.97% ± 1.39% at day 
6, and with tofacitinib: 28.57% ± 2.08% at day 4 and 38.30% ± 1.65% at day 6. 
Similarly, in GM-CSF incubated cultures (Figure 7.8B), the percent apoptosis in the 
absence of inhibitor (NI) was 21.13% ± 1.92% at day 4 and 29.57% ± 1.94% at day 
6, which were also significantly lower than the apoptosis levels observed in cells with 
media changes alone (MC, 7.7B). Apoptosis was significantly increased by incubation 
with JAK inhibitors, baricitinib: 25.62% ± 2.36% at day 4 and 34.00% ± 1.91% at day 
6, and tofacitinib: 27.40% ± 2.42% at day 4 and 36.53% ± 1.36% at day 6. 
 
These data suggest that cytokines G-CSF and GM-CSF significantly delayed 
apoptosis of dPLB-985 cells, thereby prolonging their survival, with the effect of GM-
CSF being higher than that of G-CSF. Also, the JAK inhibitors baricitinib and 
tofacitinib significantly down-regulated the effects of these cytokines, thereby 
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increasing the apoptosis of dPLB-985 cells. Representative cytospin slides images of 
apoptotic dPLB-985 cells under these experimental conditions are shown in Figures 
7.10 and 7.11. 
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Figure 7.8 Effect of JAK inhibitors on apoptosis of dPLB-985 cells in the 
presence of cytokine. Exponentially-growing PLB-985 cells at a starting density of 
4×105/mL were seeded in differentiation media without (NI) and with JAK inhibitors 
baricitinib (200ng/mL) or tofacitinib (200ng/mL) for 30 min, followed by the addition of 
the cytokines G-CSF (A, 10ng/mL) or GM-CSF (B, 5ng/mL) and incubated for 6 days. 
Fresh differentiation media changes and replenishment of inhibitors and cytokines 
were made on days 2 and 4. Cytospin slides of cells were prepared, stained with rapid 
Romanowsky stain daily, and percent apoptotic cells determined by differential 
counting manually under the light microscope. Data are expressed as mean of 
percent total cells (± SEM, n=3) and compared to cell numbers of uninhibited cells at 
the same time point, * = p≤0.05, ** = p≤0.01 (paired, two-tailed student’s t-test).  
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Figure 7.9 Representative cytospin slides images of dPLB-985 cells incubated without and with JAK inhibitors. PLB-985 cells 
were incubated without (UI) and with JAK inhibitors baricitinib (BAR, 200ng/mL) or tofacitinib (TOF, 200ng/mL) in differentiation media 
and for 6 days. Fresh media changes and replenishment of inhibitors and cytokines were made on days 2 and 4. Cytospin slides of cells 
were prepared, stained with rapid Romanowsky stains on days 3-6, and the images captured using a microscope-mounted camera (×40).  
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Figure 7.10 Representative cytospin slides images of dPLB-985 cells incubated with JAK inhibitors and G-CSF. dPLB-985 cells 
were incubated without (UI) and with JAK inhibitors baricitinib (BAR, 200ng/mL) or tofacitinib (TOF, 200ng/mL) for 30 min, followed by 
the addition of the G-CSF (10ng/mL) for 6 days. Fresh media changes and replenishment of inhibitors and cytokines were done on days 
2 and 4. Cytospin slides of cells were prepared, stained with rapid Romanowsky stain on days 3-6, and the images captured using a 
microscope-mounted camera (×40).  
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Figure 7.11 Representative cytospin slides images of dPLB-985 cells incubated with JAK inhibitors and GM-CSF. dPLB-985 
cells were incubated without (UI) and with JAK inhibitors baricitinib (BAR, 200ng/mL) or tofacitinib (TOF, 200ng/mL) for 30 min, followed 
by the addition of the GM-CSF (5ng/mL) for 6 days. Fresh differentiation media changes and replenishment of inhibitors and cytokines 
were done on days 2 and 4. Cytospin slides of cells were prepared, stained with rapid Romanowsky stain on days 3-6, and the images 
captured using a microscope-mounted camera (×40). 
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7.4 Discussion and conclusions 
 
Dysregulation of the JAK-STAT pathway can give rise to imbalances between pro- 
and anti-inflammatory cytokine production by immune cells, which are implicated in 
the pathogenesis of autoimmunity and chronic inflammation (McInnes & Schett, 
2011). The development of cell-permeable, selective, small molecule JAK inhibitors 
has therefore been a major advance in both understanding the molecular pathology 
and use for the therapy of haematopoietic, autoimmune and inflammatory disorders, 
in the past two decades (Furqan et al., 2013). Inhibition of JAK-dependent STATs 
phosphorylation, may down-regulate the activation and proliferation of key immune 
cells, thereby producing immunosuppressive and anti-inflammatory effects (Shi et al., 
2014). 
  
Results shown in Chapters 3 and 4 of this thesis have demonstrated that PLB-985 
cells cultured in the absence and presence of differentiation inducers, undergo a 
limited number of divisions followed by growth arrest and apoptosis, and that the 
differentiation-induced cells had longer population doubling time (~24-36 h) and lower 
population density than their non-induced counterparts. Those initial experiments 
have also shown that the proliferation, differentiation capacity, and viability of the 
differentiated PLB-985 cells, were enhanced when the differentiation media was 
replaced with fresh media during culture, and these were even further enhanced when 
the media was supplemented with the pro-inflammatory cytokines, G-CSF and GM-
CSF. These cytokines can also delay progression of the differentiated cells into 
apoptosis and death.  
 
The experiments in this Chapter have examined the effects of orally-active, low 
molecular weight JAK inhibitors, baricitinib and tofacitinib on the proliferation, 
differentiation capacity and viability of differentiation-induced PLB-985 cells, as well 
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as on the protective effects of culture media replacements and cytokines additions, 
against apoptosis. Results of experiments involving differentiation media changes 
alone, indicated that both JAK inhibitors suppressed the growth rate, percent 
differentiation and viability of differentiated PLB-985 cells, cultured in unchanged 
media compared to the uninhibited cells. There were enhancements in these 
functions following differentiation media changes (at days 2 and 4), but these were 
also greatly down-regulated by the JAK inhibitors baricitinib and tofacitinib compared 
to the uninhibited (control) cells of the same culture. Therefore, these inhibitors have 
stimulated growth arrest and lowered the population densities of dPLB-985 cells 
under the two culture conditions. 
 
The proliferation and differentiation of precursor cells committed to neutrophilic- 
granulocytic lineage is regulated by colony stimulating factors (CSFs) (Shimoda et 
al., 1997). In agreement with this, incubations with cytokines G-CSF and GM-CSF 
significantly increased the growth rate, percent differentiation and viability of 
uninhibited dPLB-985 cells compared to cultures involving media changes alone. 
Following incubation with both JAK inhibitors, however, these effects were also 
significantly decreased compared to the uninhibited (control) cells in the presence of 
the cytokines. This suggests that both CSFs stimulated the in vitro proliferation and 
differentiation of PLB-985 cells and equally, both JAK inhibitors down-regulated the 
effects of these cytokines.  
 
Conversely, there was increasing percent apoptosis of uninhibited (control) cells 
cultured in unchanged media during the culture period, and this was considerably 
decreased following differentiation media changes. However, inhibition with baricitinib 
and tofacitinib, markedly increased the percent apoptotic cells, indicating that both 
JAK inhibitors induced apoptosis and death, in cultures with and without media 
changes. In a similar manner, percent apoptosis of uninhibited (control), cytokine-
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incubated cells was low compared to cultures with media changes alone (no 
cytokine). However, in the presence of the JAK inhibitors, apoptosis increased 
significantly, which also implies that inhibitors, baricitinib and tofacitinib induced the 
differentiated cells to undergo apoptosis and abrogated the effect of cytokines in 
delaying apoptosis. In all these experiments, GM-CSF was more effective than G-
CSF in delaying apoptosis and tofacitinib had stronger inhibitory effect on the 
differentiating cells, compared to baricitinib. 
 
The four members of Janus-associated tyrosine kinases are activated differentially in 
response to various cytokines. JAK1 is essential for G-CSF mediated tyrosine 
receptor phosphorylation. G-CSF has also been shown to stimulate the activation of 
JAK2 and TYK2 in the absence of JAK1, but it fails to induce tyrosine receptor 
activation, suggesting that JAK2 and TYK2 plays only redundant or auxiliary functions 
(Shimoda et al., 1997). Parganas et al., reported JAK2 activation along with JAK1 
and TYK2 in response to G-CSF, with JAK2 activation being the most significant 
(Parganas et al., 1998). JAK2 is the predominant JAK activated in response to a wide 
array of cytokines including IL-3, IL-5 and GM-CSF. Haematopoietic growth factors 
including G-CSF and GM-CSF and other cytokines signal through JAK2 (Quintas-
Cardama & Verstovsek, 2013; Meyer et al., 2010). JAK2 deficient cells have been 
reported to be unable to respond to hormone-like cytokines, such as GM-CSF, 
thrombopoietin and erythropoietin (Parganas et al., 1998). 
 
JAK3 plays an important, nonredundant role in the signalling of the cytokine family 
group that functions through the γc chain (Parganas et al., 1998). It associates 
specifically with the common gamma chain (γc) subunit of six cytokine receptors (IL-
2, IL-4, IL-7, IL-9, IL-15 and IL-21) that have critical roles in lymphopoiesis and 
homeostasis (Vijayakrishnan et al., 2011). The absence of JAK3 in humans has been 
associated with severe combined immunodeficiency (SCID) (Macchi et al., 1995). 
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JAK inhibitors are amongst the successful therapeutic agents that have reached 
clinical application (Passamonti et al., 2012). Baricitinib, a novel and potent JAK 
inhibitor selectively inhibits JAK1 and JAK2 enzymes with IC50 values in the 
nanomolar range (Shi et al., 2014). It has been shown to be effective in the treatment 
of arthritis, without adverse hematologic effects or suppression of humoral immunity 
(Fridman et al., 2010).  
 
Tofacitinib on the other hand, associates exclusively with the common gamma chain 
(γc) subunit and has been shown to block signalling by JAK3-dependent cytokine 
receptors, which are required for lymphocyte proliferation and functions. It also blocks 
other cytokine receptors signalling through JAK1 (Yarilina et al., 2012; Ghoreschi et 
al., 2011). Tofacitinib interferes with Th1 and Th2 differentiation as well as 
inflammatory Th17 cells production. Recently, in vivo and in vitro studies by Tanaka 
and Maeshima demonstrated that tofacitinib acts on CD4+ T cells to inhibit cell 
proliferation and inflammatory cytokines production (Tanaka and Maeshima, 2012). 
In addition, Ghoreschi et al., suggested that tofacitinib can target the cytokine 
signalling cascades of innate immunity, in vivo (Ghoreschi et al., 2011), and it has 
anti-inflammatory and neutrophil reduction activities (Meyer et al., 2010). 
 
In conclusion, results of this preliminary study with baricitinib and tofacitinib 
demonstrated that both JAK inhibitors can suppress the proliferation, differentiation 
and viability of the differentiated PLB-985 cells, and they may therefore, inhibit the in 
vitro granulopoiesis. These JAK inhibitors also down-regulated the responses of the 
differentiated PLB-985 cells to cytokines G-CSF and GM-CSF signalling, suggesting 
that they could have a negative impact on granulopoiesis in vivo and/or perhaps 
down-regulate cytokine-regulated neutrophil apoptosis, effects which could be anti-
inflammatory. 
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Chapter 8: General discussion and conclusions 
 
Neutrophils are highly potent, motile phagocytic cells that are critical to the functions 
of the innate immune system. The relatively high abundance of these cells in the 
bloodstream highlights their importance. Approximately, 5×1010 neutrophils are 
produced in the bone marrow, in the adult human, per day, accounting for 40-65% of 
the total white blood cells population. This number rises significantly during infection 
(Edwards, 1994). Owing to their large phagocytic capacity, neutrophils destroy a wide 
variety of pathogens with an array of cytotoxic mechanisms, such as release of 
multiple degradative enzymes and reactive oxidants, without dependence on any 
single cytotoxic mechanism (Segal, 2005). 
 
Mobilisation of circulating neutrophils to the site of inflammation occurs very rapidly, 
and constitutes a major event in the neutrophil-mediated inflammatory responses. 
They are recruited through a series of controlled, exocytic events, including priming, 
rolling and adhesion, transmigration/chemotaxis that culminates in opsono-
phagocytosis and respiratory burst generation. These events change their functional 
status, converting them from ‘resting’ circulating cells to ‘active’ killing cells at the 
infection and/or inflammatory locus (Borregaard & Cowland, 1997). Neutrophils are 
the first leukocytes recruited to the inflamed tissue, they recognise, destroy and clear 
the pathogen. Following clearance of infection or inflammation, the effete neutrophils 
undergo a safe and non-pathological process of cell death, i.e. apoptosis and their 
apoptotic corpses are subsequently eliminated in a controlled manner by 
macrophages (Lagasse & Weissman, 1994). 
 
Due to their high potency, cytotoxic contents and non-specific nature, neutrophils may 
also contribute to the pathophysiology of many autoimmune and inflammatory 
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diseases, such as rheumatoid arthritis, where non-specifically activated neutrophils 
accumulate in the joints and release reactive oxygen species (ROS) and granule 
proteins into the extracellular milieu, causing localised tissue damage (Cross et al., 
2005), and in chronic obstructive pulmonary disease (COPD), where neutrophils 
undergoing necrosis (thought to be induced by H. influenza) infiltrate tissues and 
result in the tissue damage (Naylor et al., 2007). Effective control of neutrophil 
mobilisation and functions is therefore, imperative to prevent their inappropriate 
activation and impending tissue damage or persistent inflammation. This is largely 
achieved by a two-step activation process, and auto-regulatory mechanisms, 
including constitutive apoptosis. 
 
Considering the foregoing, a clear understanding of the molecular signalling 
processes of neutrophils in health and disease is thus necessary. Neutrophils 
circulate the blood in a mature, terminally differentiated form. Hence, they lack 
proliferation capacity, have a short life-span, and spontaneously die by apoptosis. 
Furthermore, human neutrophils are currently impossible to transfect to express 
exogenous genes or proteins. These limitations have made their experimental 
manipulation ex vivo, challenging, and have hindered biochemical studies of their 
signal activation mechanisms and genetic makeup.  
 
Establishment of a human neutrophil model, which exhibits morphological and 
functional properties similar to mature blood neutrophils would therefore, be very 
important tool in transfection studies to enable the manipulation of key genes to 
express modified versions of regulatory proteins and determine the effects of such 
modulations on neutrophil functional responses. Immunological studies involving 
genetically manipulated mice have shown them to be valid model system for human 
biology, and have continued to provide vital information on human immunology. 
However, there exist significant differences between human and mouse immune 
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systems, and many aspects of human immunology do not occur or cannot be 
modelled in mice (Haley, 2003; Monaco, 2003). For example, the balance of 
neutrophils and lymphocytes in the blood between human and mice adults are 
significantly different. Human blood is rich in neutrophils (50-70% neutrophils, 30-50% 
lymphocytes), whilst mouse blood is rich in lymphocytes (50-70% lymphocytes, 30-
50% neutrophils) (Doeing et al., 2003). The functional consequences of this shift of 
neutrophil-rich blood in humans are therefore, not clear.  In addition, many receptors 
expressed on human neutrophils are either not expressed at all, or are expressed 
differently on mouse neutrophils (Mestas & Hughes, 2004). Hence, the development 
of human myeloid cell lines, capable of in vitro differentiation, into mature neutrophil-
like granulocytes, remain the most relevant model for genetic studies of human 
neutrophil and addresses the challenges posed by the limitations of blood neutrophils. 
 
The first demonstration of in vitro differentiation of a leukaemia cell line into mature 
phenotype was in 1971, when Friend induced a murine erythroid leukaemia cell line 
to differentiate into orthochromic erythroblasts in vitro, using dimethylsulfoxide 
(DMSO) (reviewed in Watanabe et al., 1988). Following this, several other cell lines 
with the capacity to differentiate along the myeloid lineage into mature neutrophil-like 
cells in response to a wide range of inducing and maturation agents have been 
established. The more recently-established human promyelocytic leukaemia PLB-
985 cell line, has been demonstrated to show greater levels of differentiation and was 
described as the current ‘best’ model of neutrophil differentiation (Hauert et al, 2002, 
Tucker et al., 1987). Previous reports have shown that PLB-985 cell line has the 
potential to differentiate into neutrophil-like phenotypes under the influence of various 
chemical agents (Tucker et al., 1987; Katschinski et al., 1999; Hazan-Eitan et al., 
2006; Kim & Seoh, 2015). However, the efficiency of differentiation reported was very 
low, and the differentiated cells only partly, resembled mature blood neutrophils.  
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Therefore, the main aim of this research was to terminally differentiate PLB-985 cell 
line into neutrophil-like phenotypes that resemble mature blood neutrophils mostly, in 
particular, with respect to the typical multi-lobular nucleus and granulated cytoplasm, 
which are the defining features of mature neutrophils. However, terminally 
differentiated neutrophils undergo spontaneous apoptosis and so differentiated cells 
also rapidly undergo this process. A second aim was to determine ways to extend the 
lifespan of the differentiated PLB-985 cells. The third aim was to characterise the 
molecular and functional properties of the differentiated PLB-985 cells, to establish 
their usefulness as model of neutrophil differentiation and fuctions. The in vitro 
differentiation protocol described in this study has enabled the consistent production 
of morphologically- and functionally-neutrophil-like, differentiated PLB-985 cells, 
within periods of 4-7 days, with peak numbers occurring between days 5-6. 
 
The main findings of the study are:  
 
1. A modified differentiation protocol and optimisation procedures using the 
differentiation and maturation-inducing agents; ATRA, DMF and sodium 
pyruvate has been established that produced terminally differentiated, 
neutrophil-like PLB-985 cells that resemble mature blood neutrophil’s 
morphology, evident by acquisition of the multi-lobed nucleus and granulated 
cytoplasm. 
2. The cytokines G-CSF and GM-CSF, which are pro-survival for human 
neutrophils, enhance the growth rate, differentiation efficiency and viability of 
differentiated PLB-985 cells, with GM-CSF being more effective than G-CSF. 
3. Terminally-differentiated PLB-985 cells undergo cell cycle arrest and 
progression into apoptosis and they resembled mature blood neutrophils in 
terms of cell cycle parameters and apoptotic morphology. 
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4. Differentiation of PLB-985 cells induced expression of anti-apoptotic proteins; 
Mcl-1 and Bcl-XL, and their expression levels correlated with the cell’s survival 
status, whilst Bcl-2 expression expression was lost following differentiation. 
5. Differentiated PLB-985 cells undergo phagocytosis and oxidative burst 
activity, in response to various particles and stimuli, and in a similar manner, 
but with lower responses than blood neutrophils. 
6. Differentiated PLB-985 cells express cell surface receptors for CD11b, CD14 
and CD16. CD11b expression was high, and similar to mature neutrophils, 
whilst expression of CD14 and CD16 were very low in contrast to neutrophils. 
7. Differentiated PLB-985 cells express strong chemotactic transmigration 
towards casein and activated serum, like neutrophils, but their response to 
fMLP and IL-8, is lower than in neutrophils. 
8. Small molecule JAK inhibitors; baricitinib and tofacitinib can suppress the 
proliferation, differentiation and viability of the differentiated PLB-985 cells, 
increase their progression into apoptosis, and down-regulate their responses 
to G-CSF and GM-CSF signalling. They may therefore, inhibit in vitro 
granulopoiesis, and may have an anti-inflammatory activity. 
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Table 8.1 Morphological and functional properties of neutrophils and dPLB-985 cells. 
Property Neutrophils dPLB-985 cells 
Morphology 
Segmented, Multi-lobed nucleus 
Granulated cytoplasm 
 
+++ 
+++ 
 
+++ 
+++ 
Cell cycle and Nuclear DNA 
G1 arrest 
S-phase    
G2-phase 
G0 accumulation (18 h) 
 
+++ 
-- 
-- 
+++ 
 
++ 
++ 
+ 
+++ 
Phagocytosis 
SAPI 
F-beads 
NF-beads 
 
+++ 
+++ 
++ 
 
++ 
++ 
+ 
Oxidative burst activity 
PMA-induced 
fMLP-induced 
 
+++ 
+++ 
 
++ 
-- 
Chemotaxis 
fMLP 
IL-8 
Zymosan ctivated serum (C5a) 
Casein 
 
+++ 
++ 
++ 
+++ 
 
+ 
++ 
++ 
+++ 
Receptor expression 
CD11b 
CD14 
CD16b 
 
+++ 
+ 
++ 
 
++ 
+ 
-- 
Apoptosis 
Apoptotic features 
Apoptotic proteins 
Mcl-1 
Bcl-XL 
Bcl-2  
Bax 
Bak 
 
+++ 
 
+++ 
-- 
-- 
+++ 
+++ 
 
+++ 
 
+++ 
+++ 
+++ 
+++ 
+++ 
               
           +++ = strong, ++ = moderate, + = low, -- = no activity/expression 
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In Chapter 3 of this thesis, PLB-985 cells were induced to terminally differentiate into 
neutrophil-like granulocytes that resembled mature blood neutrophils, with multi-
lobed nucleus and granulated cytoplasm. These cells also stained with eosin and 
methylene blue to produce purple nuclei and pale cytoplasm, like blood neutrophils 
(Horobin, 2011; Horobin &  Walter, 1989). Myeloid cells are categorized as immature; 
comprising blasts, promyelocytes and promonocytes or as mature; comprising 
myelocytes, metamyelocytes, bands and segmented neutrophils, according to the 
standard morphologic/staining criteria (Chomienne et al., 1990). The non-
differentiated PLB-985 cells are characterised as being at the promyelocytic stage, 
but the combined effects of ATRA, DMF and sodium pyruvate successfully 
transformed them along the myeloid pathway into myelocytes, metamyelocytes, band 
neutrophils and lastly, segmented neutrophils, the final cells in the myeloid lineage. 
After 3-4 days of differentiation induction, metamyelocytes and band neutrophils were 
the predominant cells in the culture medium, while after 5-6 days in culture, 
segmented neutrophils predominated. This pattern of differentiation is analogous to 
that of neutrophil differentiation and maturation during in vivo granulopoiesis (Iwasaki 
& Akashi, 2007, Lieber et al., 2004). The differentiated PLB-985 cells exhibited other 
morphological features of mature neutrophils, including small cell size (~ 10-12 µm), 
indented, convoluted and segmented nuclei, decreased number or absence of 
nucleoli and granulated cytoplasm (Collins et al., 1978). To the best of my knowledge, 
this high level of differentiation and survival of the differentiated cells has been 
obtained for the first time in this thesis. 
 
There was an increase in the proportion of cells showing morphological features of 
apoptosis, such as condensation of chromatin and fragmentation of nuclei (Elmore, 
2007) in parallel with increase in the proportion of cells showing mature neutrophil 
morphology. Interestingly, these apoptotic cells appeared in appreciable numbers 
only when differentiated cells with mature neutrophil morphology predominated in the 
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culture, usually after day 5-7. Apoptosis is constitutively activated as neutrophils age 
in culture, in vitro (Edwards et al.,  2004). In contrast, PLB-985 cells cultured in routine 
media without the differentiation-inducing agents remained in their promyelocytic 
form, exhibiting large rounded nuclei containing 2-4 nucleoli each, with a dispersed 
chromatin, agranulatar cytoplasm and relatively high nuclear/cytoplasmic ratio. Only 
very few of these non-differentiated cells displayed any sign of apoptosis. Thus, the 
differentiated PLB-985 cells acquired one of the most definitive features of mature 
neutrophils, i.e. rapid progression into apoptosis. 
 
Another significant finding in this study was the importance of the cytokines G-CSF 
and GM-CSF in promoting both the efficiency of differentiation and the survival of the 
differentiated cells. The growth rate, differentiation capacity and viability of 
differentiated PLB-985 cells were enhanced when the differentiation media was 
periodically replaced with fresh media, but more greatly enhanced when the media 
was supplemented with the pro-inflammatory cytokines, G-CSF and GM-CSF. These 
cytokines also delayed the progression of differentiated cells into apoptosis (Thomas 
et al., 2010, Derouet et al., 2004, Edwards et al., 2004). The experimental approach 
described in this thesis, involving the combination of three differentiation- and 
maturation-agents, periodic medium replacements and cytokine supplementation, is 
unique from previously published differentiation systems. Again, to the best of my 
knowledge, these culture modifications and resulting enhancement of differentiation 
and survival of the differentiated cells have not been reported. 
 
The changes in cell cycle parameters, progression into apoptosis and expression of 
key proteins that regulate apoptosis in differentiated PLB-985 cells, measured in 
Chapter 4 have shown that differentiation of PLB-985 cells triggers G1 arrest with little 
or no cells in G0 initially, but subsequently after days 3-6 of culture, there was a 
significantly increased number of cells in G0 phase and fewer cells in S phase. This 
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arrest of differentiated PLB-985 cells in G1 following differentiation into granulocytes 
means that the differentiated cells do not progress to the G1-to-S transition (Yen et 
al., 1985). G2/M arrest was also observed, suggesting that differentiation inhibited 
these cells from entry into mitosis, since this checkpoint is activated upon blockage 
of DNA synthesis and/or prevention of segregation of damaged or incompletely 
synthesized DNA (Pucci et al., 2000). These findings indicate that differentiation of 
PLB-985 cells triggers cell cycle arrests and progression into apoptosis. 
 
DNA distribution profiles of freshly-isolated blood neutrophils revealed that most of 
the cells were arrested in G1 phase, with little or none in G0 (Figure 4.9). Mature 
blood neutrophils are terminally differentiated cells that do not replicate their DNA or 
proliferate. Following a 20 h incubation however, a significant number of cells 
accumulated in the G0 phase, indicating apoptosis and/or death. These distribution 
patterns are similar to those observed in the differentiated PLB-985 cells at day 6, i.e. 
decrease in S phase and increase in G0. This observation, further confirms that 
terminally-differentiated PLB-985 cells acquired some of the properties of blood 
neutrophils in respect to their cell cycle DNA distribution patterns.  
 
The expression of anti- and pro-apoptotic proteins of the Bcl-2 family was investigated 
to determine whether changes in their expression levels may parallel and correlate 
with differentiation and apoptosis. This revealed that differentiation of PLB-985 cells 
was accompanied by a progressive decrease in the expression levels of the anti-
apoptotic proteins, Mcl-1 and Bcl-XL, suggesting that Mcl-1 and Bcl-XL levels 
correlated with the survival of the differentiated cells. Transfection studies have 
confirmed the role of Mcl-1 as an anti-apoptotic protein whose overexpression results 
in prolonged survival of cells (Reynolds et al., 1994), and plays a crucial role in the 
apoptosis of human blood neutrophils (Edwards et al., 2004, Moulding et al., 1998). 
As previously stated, Mcl-1 is the only anti-apoptotic Bcl-2 protein family member 
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expressed in human neutrophils, that has been measured reliably and reproducibly 
at both the protein and mRNA levels (Edwards et al., 2004).  
 
Another striking finding was that contrary to human neutrophils, which do not express 
detectable levels of Bcl-XL protein by immunoblots (Edwards et al., 2004, Moulding et 
al., 1998), differentiated PLB-985 cells expressed detectable levels of this protein, 
and like Mcl-1, levels decreased as the cells differentiate. Although, Bcl-XL mRNA has 
been detected in human neutrophils, they do not express Bcl-XL protein (Moulding et 
al., 2001). In the presence of GM-CSF, and in line with the ability of this cytokine to 
delay apoptosis, levels of these two proteins, were increased above levels observed 
in the absence of the cytokine. The increased levels of these two proteins parallels 
the delayed apoptosis in differentiated PLB-985 cells. GM-CSF has been shown to 
considerably delay apoptosis of neutrophils, by maintaining Mcl-1 levels (Derouet et 
al., 2004, Moulding et al., 1998).  
 
Mcl-1 is an unusual member of the Bcl-2 protein family. Alignment algorithms have 
identified sequence similarities of Mcl-1 to other Bcl-2 family members, but the protein 
has some unusual properties not shared by other members of the Bcl-2 family. Its 
large N-terminal domain contains many motifs that determines many of its unique 
properties, such as subcellular localization, rate of turnover and phosphorylation 
status. These post-translational modifications provide Mcl-1 protein with the ability to 
respond to environmental signals rapidly and reversibly, and to switch the cell’s fate 
from survival to apoptosis and vice versa. Mcl-1 contains 3 putative BH domains (Bcl-
2 and Bcl-XL possess 4 each) as revealed by the sequence analysis (Lutz, 2000). It 
is also a larger protein (40 KDa) of 350 residues, with a long N-terminal region 
compared to Bcl-2 (22 KDa) and Bcl-XL (26 KDa) with 239 and 233 residues, 
respectively. The N-terminal region of Mcl-1 contains potential regulatory motifs, 
which were predicted to regulate its function and later confirmed experimentally after 
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mutagenesis, whereas the C-terminal region has a transmembrane domain, which is 
responsible for its membrane insertion and sub-cellular localization (Akgul et al., 
2000). 
 
Non-differentiated PLB-985 cells grown in routine culture media express the anti-
apoptotic protein Bcl-2, but another interesting finding was that, expression of Bcl-2 
was rapidly lost following initiation of differentiation after day 3 of culture, acquiring 
yet another characteristic feature of mature blood neutrophils that do not express Bcl-
2 protein (Edwards et al., 2004). Okaro et al. reported that inhibition of apoptosis by 
Mcl-1 and Bcl-XL, but not, Bcl-2 was responsible for the prolonged survival of both 
normal and tumorigenic cells in the biliary tree (Okaro et al., 2001).  
 
The pro-apoptotic proteins, Bax and Bak were expressed highly in differentiated PLB-
985 cells and their levels did not significantly change upon treatment with the 
apoptosis-delaying agent, GM-CSF. This was in line with observations in mature 
blood neutrophils which constitutively express a range of pro-apoptotic members of 
the Bcl-2 family proteins, including the Bax and Bak, which may partly explain the 
ability of neutrophils to undergo apoptosis spontaneously and rapidly (Edwards et al., 
2004). Taken together, these results confirm that differentiated PLB-985 cells share 
important similarities with isolated blood neutrophils, in terms of cell cycle progression 
and apoptosis, as well as suggest an interconnection between the processes of cell 
cycle and apoptosis in myeloid cells. 
 
Next, my study measured the phagocytosis and oxidative burst activity of human 
neutrophils and the changes in differentiated PLB-985 cells during these two vital 
processes of pathogen destruction and elimination. The flow cytometry data 
presented in Chapter 5  shows that neutrophils highly phagocytosed the opsonised 
PI-labeled S. aureus (SAPI) and opsonised fluorescent latex beads, and to a lower 
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extent, opsonised non-fluorescent latex beads. Priming of neutrophils by G-CSF or 
GM-CSF significantly enhanced the levels of phagocytosis of these particles. 
Similarly, differentiated PLB-985 cells showed increasing levels of phagocytosis of 
SAPI and latex beads in parallel with the increasing levels of their differentiation into 
neutrophil-like cells. The levels of phagocytosis of these particles by differentiated 
PLB-985 increased when primed by G-CSF or GM-CSF. However, in contrast to 
neutrophils, differentiated PLB-985 cells displayed higher phagocytosis of fluorescent 
beads, than SAPI and non-fluorescent beads.  
 
Neutrophil phagocytosis is mediated by plasma membrane receptors which must 
recognise and bind the foreign bodies, either directly via pattern-recognition receptors 
(PAMPs) or indirectly via opsonic receptors, before internalisation and subsequent 
formation of a membrane-bound vacoule, the phagosome (Flannagan et al., 2012). 
Neutrophils express receptors for molecules such as chemoattractants (e.g., fMLP, 
C5a, IL-8) and opsonins (e.g. IgG, complement proteins) that facilitate recognition, 
binding and rapid uptake of the opsonised particles (Naccache, 2013). The observed 
differences in the responses of neutrophils and differentiated PLB-985 cells to SAPI 
are likely due to differences in the expression of receptors between the two cell-types 
that mediate recognition of these opsonised particles. These surface receptors may 
not be expressed or are expressed at different levels on the differentiated PLB-985 
cells. Like blood neutrophils, differentiated PLB-985 cells took up different numbers 
of fluorescent bead particles, ranging from 1 to 6 resulting in multi-phasic fluorescent 
distribution patterns. The distribution of differentiated PLB-985 cells that took up 1, 2, 
3, 4, 5 and 6 bead particles was 6%, 12%, 5%, 3% and 1% respectively, i.e. most 
cells took up 1-3 particles per cell. 
 
Analysis of oxidative burst activities by flow cytometry showed that neutrophils 
express strong and weak responses when stimulated by PMA and fMLP, respectively. 
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Priming by G-CSF or GM-CSF increased the oxidative burst generation stimulated by 
PMA and fMLP, but this increase was particularly, greater in fMLP stimulated cells. 
The PMA response reaches a peak value more rapidly in primed cells. This clearly 
demonstrated the relevance of priming to receptor-mediated response of fMLP. Latex 
beads showed lower oxidative burst activity which also increased significantly when 
primed by G-CSF or GM-CSF. Differentiated PLB-985 cells showed very similar 
oxidative burst activity to blood neutrophils. High and low activities were observed in 
differentiated cells stimulated with PMA and fMLP respectively, and both responses 
increased when the differentiated cells were incubated with G-CSF or GM-CSF. Latex 
beads showed lowest activity which increased slightly when incubated with G-CSF or 
GM-CSF.  
 
Non-differentiated PLB-985 cells are incapable of oxidative burst generation, as they 
produced extremely low levels of ROS with fMLP, PMA or latex beads, that did not 
change significantly, following incubation with the cytokines G-CSF or GM-CSF. The 
very low levels of ROS observed in non-differentiated PLB-985 cells could be the 
result of mitochondrial respiration, indicating that changes associated with 
differentiation of PLB-985 cells into neutrophil-like cells were responsible for their 
ability to elicit NADPH-dependent oxidative burst activity. 
 
The oxidative burst activity was also measured using luminol-enhanced 
chemiluminescence assay, and the results revealed interesting consistency with the 
flow cytometry data, as well as striking similarity between neutrophils and the 
differentiated PLB-985 cells. Neutrophils express high and low chemiluminescence 
responses when stimulated by PMA and fMLP, respectively, whereas incubation with 
GM-CSF increased the fMLP- but not, the PMA- induced chemiluminescence. Again, 
this is not surprising, because fMLP binds to receptors normally on granule 
membranes and therefore, requires priming to mobilise the granules to the cell 
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surface. PMA being membrane permeable, readily enters the cell and activates PKC 
directly without the need for priming, though, neutrophil responses to PMA can be 
accelerated by priming (DeChatelet et al., 1976). Activation of the NADPH oxidase 
by PMA is independent of receptor binding or generation of second messages 
(Edwards, et al., 1990). The bacterial peptide fMLP activates neutrophils via the 
formyl peptide receptors (FPR) that may be present on the granules, and priming is 
required to mobilise these granules to the cell surface (Hallett & Lloyds, 1995). 
Normally, in vivo neutrophil activation occurs by receptor-coupled mechanisms, which 
is regulated by pre-exposure to priming agents, such as GM-CSF that enhance their 
functional responsiveness (Edwards et al., 1990).  
 
In contrast to blood neutrophils, differentiated PLB-985 cells did not produce any 
chemiluminescence in response to fMLP stimulation which may be another indication 
of receptor expression deficiency. On the other hand, differentiated PLB-985 cells 
stimulated with PMA showed a single peak response similar to that of blood 
neutrophils. Flow cytometry measures ROS generation by NADPH-oxidase activity 
only, whilst chemiluminescence assay measures both the oxidase activity and 
myeloperoxidase ROS activities. This may partly, explain why fMLP produced ROS 
with flow cytometry, but not with luminol-enhanced chemiluminescence assay. Non-
differentiated PLB-985 cells did not produce chemiluminescence in response to PMA 
or fMLP stimulation (see Figure 5.19).  
 
fMLP stimulation produced a bimodal chemiluminescence response peak (see Figure 
5.17), the first peak occurring within 2-3 min and was considered a result of 
extracellular oxidant generation, while the second peak occurs around 5-7 min after 
addition of stimulus and was considered a result of intracellular oxidants generation, 
probably due to entrance of luminol into the cells and its oxidation intracellularly 
(Briheim, et al., 1984). In contrast, PMA stimulation produces a single response peak 
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reaching maximum at around 5-7 min. Most of the PMA induced chemiluminescence 
was largely due to intracellular oxidants (Dahlgren, 1987). These observations further 
indicated that differentiation of PLB-985 cells was indeed, required for ROS 
production, measured by both techniques. 
 
Chapter 6 of this thesis focused on the expression of some cell surface receptors, 
chemotaxis and activation of intracellular signalling pathways in neutrophils and 
differentiated PLB-985 cells, some of which mediated the functional responses 
identified in Chapters 4 and 5. Many of the essential components of the cytotoxic 
machinery of neutrophils are present in the membranes of mobilizable intracellular 
granules which are recruited to the plasma membrane following stimulation and 
degranulation (Sengelov, et al., 1993).  
 
Results from this study indicate that both neutrophils and differentiated PLB-985 cells 
expressed high levels of CD11b, though expression levels on neutrophils were higher 
than on differentiated PLB-985 cells, and both increased following treatment with 
cytokines G-CSF and GM-CSF. CD11b is one of the most abundant β2-integrins on 
neutrophils and is essential for their adherence to the endothelium during chemotaxis, 
diapedesis and phagocytosis of opsonised particles (Futosi et al., 2013). CD11b 
receptors are stored intracellularly in neutrophil granules from where they are 
recruited to replenish the cell surface levels, following stimulation with inflammatory 
mediators or during phagocytosis (Edwards, 1994). The mobilization of intracellular 
stores of some proteins, such as the adhesion molecules, is one of the underlying 
mechanisms for the generation of a ‘primed’ cell phenotype, which enhances the 
readiness of neutrophils to respond to subsequent stimuli (Volk et al., 2011).  
 
The expression level of the cell surface receptor, CD14 was low in both neutrophils 
and differentiated PLB-985 cells. CD14 is known to be strongly expressed on 
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monocytes and macrophages, and present at lower expression levels on 
granulocytes (Simmons, et al., 1989). However, consistent with other reports (Fleck 
& Nahm, 2005; Wright et al., 1991), enhanced expression of CD14 was observed 
following priming with the cytokines G-CSF and GM-CSF. The level of CD14 
expression on neutrophils was higher than on differentiated PLB-985 cells, with and 
without cytokines. Surface CD14 recognises LPS-opsonised particles and LPS-
binding protein (LBP), and mediates the formation of the LPS-LBP complex, thereby 
facilitating the killing and clearance of Gram-negative bacteria (Vosbeck et al., 1990). 
In addition, CD14 binding of LPS leads to increased activity of the adhesion receptor 
CD11b/CD18, promoting the neutrophil response to bacterial endotoxin, LPS 
(Dahinden et al., 1983). CD14 has also been shown to interact with the surface of 
apoptotic cells, in a receptor-ligand manner, facilitating their safe elimination (Devitt 
et al., 1998).  
 
Expression levels of low affinity immunoglobulin G receptor, FcγRIIIb (CD16b) 
showed that it was strongly expressed on neutrophils, which was further increased 
following treatment with G-CSF or GM-CSF. On the contrary, differentiated PLB-985 
cells did not express appreciable amounts of surface CD16b, though incubation with 
G-CSF and GM-CSF caused an increase in its expression on these cells, the levels 
were nevertheless, very low compared to blood neutrophils. Stimulation of neutrophils 
with cytokines, such as GM-CSF triggers rapid shedding of CD16 from the surface 
and concurrent replenishment from internal pools (Bruhns, 2012; Perussia et al., 
1983). GM-CSF maintains the expression of cell surface CD16 through mobilisation 
of intracellular stores of the pre-formed receptor (Moulding, et al., 1999). 
 
A study  by Selmeczy et al., reported expression of CD16 on DMF-differentiated PLB-
985 cells by FACS analysis (Selmeczy et al., 2003), but in contrast, Pivot-pajot et al., 
reported a failure to detect CD16 expression on any of the PLB-985 cells 
294 
 
differentiated with DMSO, DMF or dbcAMP by western blot analysis (Pivot-Pajot, et 
al., 2010). Intracellular CD16 expression on differentiated PLB-985 cells was not 
detected, which could mean that there were little if any, internal stores of this receptor 
in the differentiated PLB-985 cells.  
 
Neutrophils and differentiated PLB-985 cells express directional chemotactic 
movement towards a variety of chemoattractants. Neutrophils express stronger 
chemotactic responses to fMLP and casein, compared to IL-8 and zymosan-activated 
serum. Conversely, differentiated PLB-985 cells express strong chemotactic 
response towards casein and zymosan-activated serum than fMLP and IL-8. The 
differences in these responses of neutrophils and differentiated PLB-985 cells 
towards fMLP and IL-8 could be explained by the same reason as the difference 
observed in chemiluminescence and oxidative burst responses, described in Chapter 
5, i.e., the absence or low expression of receptors by the differentiated PLB-985 cells, 
as these molecules function via their receptors (Futosi, et al., 2013, Bruhns, 2012, 
Migeotte et al., 2006). The directional transmigration of a cell towards a chemotactic 
attractant gradient, requires interaction of the attractant with the cell surface receptors 
(Van Epps et al., 1977). 
 
Previous reports on chemotaxis of differentiated cells are inconsistent. For example, 
Sirak et al., reported that fMLP failed to induce chemotactic migration, but stimulated 
the production of hydrogen peroxide in dbcAMP differentiated HL-60 cells (Sirak, et 
al., 1990), while Fontana et al., reported that fMLP induced chemotaxis in DMF 
differentiated HL-60 cells (Fontana, et al., 1980). In addition, Hauert et al., reported 
that IL-8 was less effective in stimulating chemotaxis of differentiated HL-60 as 
compared to neutrophils (Hauert et al., 2002). Under my experimental conditions, 
differentiated PLB-985 cells expressed chemotactic responses towards both fMLP 
and IL-8, but fewer cells transmigrated compared to blood neutrophils. Therefore, my 
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findings agree with some reports and disagree with others. Nevertheless, these 
differences might be accounted for by the differences in culture conditions and assay 
procedures. Overall, the results of Chapter 6 confirm that differentiated PLB-985 cells 
express various cell surface receptors and underwent chemotactic transmigration, in 
response to a variety of chemoattractants, in a similar manner to blood neutrophils. 
 
My study finally investigated the effects of low molecular weight JAK inhibitors, 
baricitinib and tofacitinib on the proliferation, differentiation capacity and viability of 
differentiated PLB-985 cells, as well as on the response of the differentiated cells to 
the cytokines G-CSF and GM-CSF. The results showed that growth rate, percent 
differentiation and viability of differentiated PLB-985 cells were suppressed and 
progression into apoptosis enhanced considerably, by the two JAK inhibitors. 
However, tofacitinib had more inhibitory effects on the differentiated PLB-985 cells 
than baricitinib. These effects were observed in the absence or presence of cytokines 
G-CSF and GM-CSF, known to promote proliferation, differentiation, maturation, and 
survival of granulocytes (Derouet et al., 2004; Shimoda et al., 1997; Edwards et al., 
1989). 
 
JAK-STAT signalling enhances the expression of many inflammatory cytokines and 
chemokines. The four members of Janus associated tyrosine kinases; JAK1, JAK2, 
JAK3 and TYK2 are activated differentially, in response to various cytokines. JAK1 is 
essential for G-CSF mediated tyrosine receptor phosphorylation, and can be 
activated along with TYK2 in response to G-CSF (Shimoda et al., 1997). JAK2 is the 
predominant JAK activated in response to GM-CSF and a wide array of cytokines 
including IL-3, IL-5 (Quintas-Cardama & Verstovsek, 2013; Meyer et al., 2010). JAK3 
associates specifically with the common gamma chain (γc) subunit of six cytokine 
receptors (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) that are required for lymphocyte 
proliferation and functions (Vijayakrishnan et al., 2011; Parganas et al., 1998). 
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Therefore, JAK inhibitors may inhibit production of cytokines and chemokines (Hu & 
Ivashkiv, 2009), and may have anti-inflammatory effects, which partly explains their 
efficacy in the treatment of inflammatory diseases (Yarilina et al., 2012). JAK 
inhibitors are amongst the successful therapeutic agents that have reached clinical 
application (Passamonti et al., 2012). Baricitinib and tofacitinib are among the several 
JAK inhibitors in advanced stages of clinical trials, for the treatment of haematopoietic 
disorders as well as autoimmune and inflammatory diseases (Miossec, 2013; Meyer 
et al., 2010).  
 
Baricitinib, a potent and selective inhibitor of JAK1 and JAK2 enzymes, has been 
shown to be effective in the treatment of arthritis without suppression of humoral 
immunity or adverse hematologic effects (Shi et al., 2014; Fridman et al., 2010). 
Tofacitinib, a novel and specific inhibitor of JAK3 and JAK1, associates exclusively 
with the common gamma chain (γc)  subunit to block signalling by JAK3-dependent 
cytokine receptors or other cytokine receptors signalling through JAK1 (Yarilina et al., 
2012; Ghoreschi et al., 2011). The findings of the JAK inhibition study in Chapter 7, 
indicated that both baricitinib and tofacitinib can suppress the proliferation, 
differentiation and viability of the differentiated PLB-985 cells, facilitate their 
progression into apoptosis, and down-regulate the responses of the differentiated 
PLB-985 cells to G-CSF and GM-CSF signalling. Therefore, they may inhibit in vitro 
granulopoiesis, and have anti-inflammatory activity. 
 
In conclusion, my study has confirmed, and extended the findings of previous 
research on PLB-985 cells differentiation into mature neutrophil-like phenotypes. The 
differentiated PLB-985 cells generated in this thesis resembled blood neutrophils 
morphologically and functionally, and may therefore, provide an excellent model 
system of neutrophil differentiation and function. Although the differentiated cells are 
asynchronous and had some limitations, the functional consequences of my findings 
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are far reaching; for example, the differentiated PLB-985 cells proved effective in 
studying the neutrophil properties and functions, such as apoptosis, chemotaxis, 
phagocytosis, oxidative burst activity and expression of cell surface receptors. Hence, 
these cells can be modified genetically in transfection studies to study targeted genes, 
and effects of their modulation on functions, in combination with primary blood 
neutrophils. This could facilitate understanding of neutrophil functions in health and 
diseases, such as apoptosis regulation in autoimmune and inflammatory diseases, 
as well as in neutropenia associated with bone marrow transplantation, and/or in 
cancers. 
 
 
Future directions 
 
While the results shown in this thesis have advanced the usefulness of the PLB-985 
cell line as a model for mature neutrophils, further work is necessary to fully define 
the properties of the differentiated cells, and also to resolve some of the unexpected 
findings of the data obtained in this study. For example, a fuller characterisation of 
the properties of differentiated PLB-985 cells and comparison of these with mature 
blood neutrophils is necessary to confirm the molecular similarities and identify any 
components/processes that are different. This could be achieved in several ways, for 
example by extending the range of functions measured in the differentiated PLB-985 
cells, and one key set of parameters would be identification of the intracellular 
signalling pathways that control blood neutrophil function. These would include 
measurement of expression/activation of pathways such as STAT3, STAT5, Akt, Erk 
and p38-MAPK in the differentiated PLB-985 cells. These signalling pathways are 
known to play key roles in the regulation of key neutrophil functions such as 
chemotaxis, respiratory burst activation and apoptosis.  
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One unexpected result in this thesis that would need to be explored further is the fact 
that while the differentiated PLB-985 cells expressed a number of surface receptors 
normally expressed on mature neutrophils, they only expressed very low levels of 
CD16b (normally expressed on neutrophils at very high levels) and they did not 
generate reactive oxidants or undergo chemotaxis after stimulation by fMLP. It is 
unknown why these receptors were not expressed. Therefore, future experiments 
should focus on modification of the differentiation protocol to determine if expression 
of these archetypical receptors can be stimulated. Additionally, it would be of great 
interest to compare the transcriptomes of differentiated PLB-985 cells and human 
neutrophils, perhaps by qPCR, a technique in routine use in this laboratory. This 
approach would identify and quantify the primary transcripts (mRNA), and would be 
a powerful way to “fingerprint” the similarities and differences between the two cell 
types, if these transcripts were expressed but not translated into functional proteins, 
then this would indicate that the differentiation programme had been correctly 
triggered, but other signals were required to translate the transcripts.  
 
Furthermore, transfection studies involving genetic manipulations to knock out or 
knock in specific genes using plasmids or other vectors, such as by RNA interface ( 
Brazas & Hagstrom, 2005) (RNAi) to introduce small inhibitory RNA (siRNA) that can 
disrupt key genes (e.g. MCL-1 and BCL-XL) and identify changes in the expression of 
the Mcl-1 and Bcl-XL proteins in the differentiated PLB-985 cells would help in gaining 
further insights into the neutrophil signalling pathways during apoptosis. This would 
also help in the validation of the differentiated PLB-985 cells as neutrophil models, as 
transfection of primary blood neutrophils is currently not feasible. 
 
 
In addition, further studies would benefit from experimental approaches that could 
synchronise the differentiation of PLB-985 cells into mature neutrophil-like cells, to 
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generate a uniform population of cells for functional analysis. This can be achieved 
by changing the culture conditions to temporarily stop cell growth, such as by 
inhibition of growth with an inhibitor of DNA replication (e.g. thymidine, hydroxyurea 
or aphidicolin) and removing it later (Darzynkiewicz et al., 2011), or by removing 
essential nutrient(s) from the culture and re-introducing it later. In either case, cell 
growth can be stopped and upon release from these blockades, cells would start to 
re-grow and differentiate at the same stage of the cell cycle. The synchronously 
differentiated cells may be kept ‘viable’ for longer periods when using the cytokines 
G-CSF or GM-CSF, as described in this thesis.  
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